Liver-specific Wnt signal enhancing molecule and use thereof

JP2023549854A5Pending Publication Date: 2024-11-15SURROZEN OPERATING INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023528657
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-09-24
Filing Date
2021-11-16
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

Current therapies for modulating Wnt signaling lack liver-specificity, leading to non-specific effects due to the widespread expression of Wnt ligands and receptors across various tissues, necessitating the development of liver-specific Wnt signal-enhancing molecules to treat and prevent diseases.

Method used

Development of liver-specific Wnt signal-enhancing molecules, such as fusion proteins or antibodies, that bind to ZNRF3/RNF43 E3 ubiquitin ligases and liver-specific cell surface receptors, mediating the internalization or sequestration of these ligases to enhance Wnt signaling in a liver-specific manner.

Benefits of technology

The molecules effectively enhance Wnt signaling in liver tissues, providing therapeutic benefits for various liver diseases and disorders by stabilizing Wnt receptors, thereby improving treatment outcomes.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2022104280000001
    Figure 2022104280000001
  • Figure 2022104280000002
    Figure 2022104280000002
  • Figure 2022104280000003
    Figure 2022104280000003
Patent Text Reader

Abstract

The present disclosure provides liver-specific Wnt signal enhancing molecules, and provides related methods of using these molecules to increase Wnt signaling in liver tissue and treat liver diseases and disorders.In one embodiment, the present invention provides a liver-specific Wnt signal enhancing molecule or its pharmaceutically acceptable salt, which comprises a first domain that specifically binds to one or more transmembrane E3 ubiquitin ligases selected from ZNRF3 and RNF43, and a second domain that specifically binds to liver-specific cell surface molecules, and increases Wnt signaling in tissue.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] Cross-references to related applications This application claims priority to U.S. Provisional Application No. 63 / 114,457 filed November 16, 2020, U.S. Provisional Application No. 63 / 182,106 filed April 30, 2021, and U.S. Provisional Application No. 63 / 248,157 filed September 24, 2021, each of which is incorporated herein by reference in whole for all purposes.

[0002] Statement regarding sequence listings The sequence listing relating to this application is provided in text format instead of a paper copy and is incorporated herein by reference. The name of the text file containing the sequence listing is SRZN_019_03WO_ST25.txt. This text file is 100KB in size, was created on November 11, 2021, and submitted electronically via EFS-Web.

[0003] Field of Invention This disclosure relates to liver-specific Wnt signaling-enhancing molecules, such as fusion proteins, comprising a domain that binds to an E3 ubiquitin ligase, ZNRF3, or RNF43, and a liver-specific cell surface receptor-binding domain, as well as related methods of using liver-specific Wnt signaling-enhancing molecules to mediate liver-specific internalization or sequestration of E3 ligase, ZNRF3 / RNF43, and consequently, stabilization of Wnt receptors and enhancement of Wnt signaling in a liver-specific manner, and to treat and prevent various diseases and disorders. [Background technology]

[0004] Background of the Invention Wnt ("Wingless-associated integration site," "Wingless and Int-1," or "Wingless-Int") ligands and their signaling play crucial roles in regulating development, homeostasis, and regeneration in many vital organs and tissues, including bone, liver, skin, stomach, intestines, kidneys, central nervous system, mammary glands, oral mucosa, taste buds, ovaries, cochlea, and many other tissues (as outlined, e.g., by Clevers, Loh, and Nusse, 2014; 346:1248012). Modulation of the Wnt signaling pathway has potential for treating degenerative diseases and tissue injury. To achieve this objective, it is desirable to develop strategies for modulating Wnt signaling activity in a liver-specific or cell-type-specific manner to avoid undesirable effects. One challenge for Wnt signaling modulation as a therapeutic agent is the presence of multiple Wnt ligands and Wnt receptors, Frizzled 1-10 (Fzd1-10), and the fact that many tissues express multiple overlapping Fzds. In addition to Fzd, low-density lipoprotein (LDL) receptor-related protein 5 (LRP5) or low-density lipoprotein (LDL) receptor-related protein 6 (LRP6) are also involved in the canonical Wnt signaling pathway as co-receptors that are widely expressed in various tissues.

[0005] R-spongins 1-4 are a family of ligands that amplify Wnt signaling. Each R-spongin functions via a receptor complex containing zinc and ring finger 3 (ZNRF3) or ring finger protein 43 (RNF43) at one end and leucine-rich repeat-containing G protein-coupled receptors 4-6 (LGR4-6) at the other (as outlined, e.g., by Knight and Hankenson 2014, Matrix Biology; 37: 157-161). R-spongins may also function through further mechanisms of action. ZNRF3 and RNF43 are two membrane-bound E3 ligases that specifically target Wnt receptors (Fzd1-10 and LRP5 or LRP6) for degradation. The binding of R-spondin to ZNRF3 / RNF43 and LGR4-6 induces clearance or sequestration of the ternary complex, thereby removing E3 ligase from the Wnt receptor, stabilizing the Wnt receptor, and consequently enhancing Wnt signaling. Each R-spondin contains two furin domains (1 and 2), with furin domain 1 binding to ZNRF3 / RNF43 and furin domain 2 binding to LGR4-6. Fragments of R-spondin containing furin domains 1 and 2 are sufficient to amplify Wnt signaling. Although the R-spondin effect is dependent on Wnt signaling, the effect of R-spondin is not tissue-specific because both LGR4-6 and ZNRF3 / RNF43 are widely expressed in various tissues. There is a clear need in the field for liver-specific Wnt signaling-enhancing molecules for the treatment and prevention of certain diseases and disorders. This invention addresses this need by providing compositions and methods useful for enhancing Wnt activity in a liver-specific manner. [Prior art documents] [Non-patent literature]

[0006] [Non-Patent Document 1] Knight and Hankenson 2014, Matrix Biology; 37: 157-161 Summary of the Invention Means for Solving the Problems

[0007] Summary of the Invention The present invention relates to liver-specific Wnt signal enhancing molecules and their use, for example, increasing Wnt signaling in a target tissue and their use in treating diseases and conditions that would benefit from an increase in Wnt signaling. In certain embodiments, the tissue is the liver.

[0008] In one embodiment, the present invention provides a liver-specific Wnt signal enhancing molecule, or a pharmaceutically acceptable salt thereof, comprising a first domain that specifically binds to one or more transmembrane E3 ubiquitin ligases selected from ZNRF3 and RNF43, and a second domain that specifically binds to a liver-specific cell surface molecule, and that increases Wnt signaling in a tissue. In certain embodiments, the second domain specifically binds to a liver-specific cell surface molecule and increases Wnt signaling in the liver or liver cells. In various embodiments, either or both of the first domain and the second domain are a polypeptide, an antibody, a small molecule, a natural ligand, a non-natural ligand, or a variant thereof.

[0009] In certain embodiments of the Wnt signal enhancing molecule, the first domain comprises a first polypeptide sequence and / or the second domain comprises a second polypeptide sequence. In certain embodiments, the molecule comprises a fusion protein comprising the first polypeptide sequence and the second polypeptide sequence.

[0010] In certain embodiments, the first polypeptide sequence comprises an R-spongin sequence or a fragment or variant thereof. In certain embodiments, the R-spongin is R-spongin-1, R-spongin-2, R-spongin-3, or R-spongin-4, e.g., human R-spongin-1 to 4. In certain embodiments, the first polypeptide sequence comprises an R-spongin furin domain 1 or a fragment or variant thereof. In certain embodiments, the first polypeptide sequence is a sequence derived from wild-type R-spongin or a modified sequence. In addition, the first polypeptide sequence may have increased, similar, or reduced binding to LGR4 to 6 compared to the corresponding native full-length R-spongin. In some embodiments, the R-spongin or R-spongin furin domain 1 has at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or at least 95% identity to any of the R-spongin or R-spongin furin 1 domains present in SEQ ID NOs. 29 to 32 or 47 to 50. In certain embodiments, the first polypeptide is an antibody or its antigen-binding fragment that specifically binds to ZNRF3 and / or RNF43. In certain embodiments, the first polypeptide is an antibody or its antigen-binding fragment comprising a) the CDRH1, CDRH2 and CDRH3 sequences shown herein, and / or b) the CDRL1, CDRL2 and CDRL3 sequences shown herein, or a variant of the antibody or its antigen-binding fragment comprising one or more amino acid modifications, wherein the variant comprises fewer than eight amino acid substitutions in the CDR sequence. In certain embodiments, the first polypeptide is an antibody or its antigen-binding fragment comprising a nanobody, a VH or VL sequence shown herein, or a fragment or variant thereof.

[0011] In certain embodiments, the second polypeptide sequence is a polypeptide, an antibody or a fragment or variant thereof, or a ligand or a fragment or variant thereof. In certain embodiments, the second polypeptide is an antibody or an antigen-binding fragment thereof that specifically binds to ASGR1 and / or ASGR2. In certain embodiments, the second polypeptide is an antibody or an antigen-binding fragment thereof comprising a) the CDRH1, CDRH2 and CDRH3 sequences shown herein, and / or b) the CDRL1, CDRL2 and CDRL3 sequences shown herein, or a variant of the antibody or an antigen-binding fragment thereof comprising one or more amino acid modifications, wherein the variant comprises fewer than eight amino acid substitutions in the CDR sequence. In certain embodiments, the first polypeptide is an antibody or an antigen-binding fragment thereof comprising a nanobody, a VH or VL sequence shown herein, or a fragment or variant thereof.

[0012] In certain exemplary embodiments of the liver-specific Wnt signaling-enhancing molecules disclosed herein, the tissue is liver tissue, and the cell surface receptor is asialoglycoprotein receptor 1 (ASGR1), asialoglycoprotein receptor 2 (ASGR2), transferrin receptor 2 (TFR2), or solute carrier family 10 member 1 (SLC10A1).

[0013] In certain embodiments of the liver-specific Wnt signal-enhancing molecules described herein, the first and second domains are joined by a linker moiety. In certain embodiments, the linker moiety is a peptidyl linker sequence. In certain embodiments, the peptidyl linker sequence comprises one or more amino acids selected from the group consisting of glycine, asparagine, serine, threonine, and alanine.

[0014] In certain embodiments, the liver-specific Wnt signal-enhancing molecule described herein comprises a single polypeptide, e.g., a fusion protein comprising a first domain and a second domain. In certain embodiments, the liver-specific Wnt signal-enhancing molecule described herein comprises a dimer or polymer comprising two or more polypeptides, e.g., two or more fusion proteins each comprising a first domain and a second domain, wherein the two or more polypeptides are linked, e.g., via a linker moiety or by linkages between amino acid residues in each of the two or more polypeptides, e.g., by intermolecular disulfide bonds between cysteine ​​residues. In certain embodiments, the liver-specific Wnt signal-enhancing molecule described herein comprises two or more polypeptide sequences. For example, a liver-specific Wnt signal-enhancing molecule may comprise an antibody heavy chain and light chain (or its antigen-binding fragment) constituting either a first or second domain, the other domain (i.e., the second or first domain) being linked to the antibody heavy chain or light chain either as a fusion protein (e.g., directly or via a peptide linker) or via a linker moiety. In certain embodiments, the other domain is linked to the N-terminus of the heavy chain, the C-terminus of the heavy chain, the N-terminus of the light chain, or the C-terminus of the light chain. Such a structure may be referred to herein as an appended IgG scaffold or format.

[0015] In related embodiments, the Disclosure provides a liver-specific Wnt ("Wingless-associated integration site", "Wingless and Int-1", or "Wingless-Int") signal-enhancing molecule or a pharmaceutically acceptable salt thereof comprising a first domain that specifically binds to one or more transmembrane E3 ubiquitin ligases selected from zinc and ring finger 3 (ZNRF3) and ring finger protein 43 (RNF43), and a second domain that specifically binds to asialoglycoprotein receptor 1 (ASGR1), wherein (a) the first domain comprises a modified R-spongin polypeptide, or a fragment or variant thereof, and (b) the second domain comprises a modified antibody, or an antigen-binding fragment thereof, comprising CDRH1, CDRH2 and CDRH3 sequences and CDRL1, CDRL2 and CDRL3 sequences. In certain embodiments, the R-spongin polypeptide, or a fragment or variant thereof, comprises a furin domain 1 sequence and, optionally, a wild-type or mutant furin domain 2 sequence, or a fragment or variant thereof, wherein the R-spongin polypeptide, or a fragment or variant thereof, has reduced binding to leucine-rich repeat-containing G protein-coupled receptors 4-6 (LGR4-6) compared to the full-length, wild-type R-spongin polypeptide. In certain embodiments, the R-spongin polypeptide, or a fragment or variant thereof, comprises amino acid substitutions at positions corresponding to amino acids 105 and 109 of human R-spongin 2. In certain embodiments, the amino acid substitutions are (a) F105R, F105A, or F105E, and (b) F109A or F109E. In certain embodiments, the two amino acid substitutions are (a) F105R and F109A, (b) F105A and F109A, (c) F105E and F109A, or (d) F105E and F109E.In certain embodiments, the combinations of the CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, and CDRL3 sequences are as follows: (a) SYAMS (SEQ ID NO: 34), AISGSGGSTYYEDSVKG (SEQ ID NO: 35), DFSSRRWYLEY (SEQ ID NO: 36), QGESLRSYYAS (SEQ ID NO: 37), YGKSNRPS (SEQ ID NO: 38), and CTSLERIGYLSYV (SEQ ID NO: 39), respectively; (b) SYAMS (SEQ ID NO: 34), AISGSGGSTYYEDSVKG (SEQ ID NO: 35), DFSSRWYLEY (SEQ ID NO: 36), QGESLRSYYAS (SEQ ID NO: 37), YGKANRPS (SEQ ID NO: 40), and CTSLERIGYLSYV (SEQ ID NO: 39), or (c) selected from RISENIYSNLA (SEQ ID NO: 41), AAINLAE (SEQ ID NO: 42), QHFWGTPFT (SEQ ID NO: 43), AYGIN (SEQ ID NO: 44), EIFPRDSTFYNEKFKG (SEQ ID NO: 45), and KGREYGTSHYFDY (SEQ ID NO: 46), respectively. In certain embodiments, the second domain comprises an antibody light chain polypeptide and an antibody heavy chain polypeptide, and the first domain is fused to the N-terminus of the antibody heavy chain polypeptide, optionally via a linker moiety. In certain embodiments, the linker moiety is a peptidyl linker sequence. In certain embodiments, the linker sequence comprises one or more amino acids selected from the group consisting of glycine, asparagine, serine, threonine, and alanine. In a particular embodiment, the Wnt signal-enhancing molecule comprises two antibody light chain polypeptides and two fusion polypeptides, each fusion polypeptide comprising a modified R-spongin polypeptide or a fragment or variant thereof fused to the N-terminus of an antibody heavy chain polypeptide via a linker moiety, optionally a peptidyl linker sequence, the two fusion polypeptides linked to each other, and the two antibody light chain polypeptides each linked to a different heavy chain polypeptide of the fusion polypeptide.In certain embodiments, the molecule (i) two antibody light chain polypeptides each contain a variable region sequence having at least 95% identity to one of SEQ ID NOs: 1, 3, 5, 7, 9, 11, 14, 17, 18, 19, 21, 23, 25, or 27 or a variable region sequence in its variable region, and / or (ii) two antibody heavy chain polypeptides each contain a variable region sequence having at least 95% identity to one of SEQ ID NOs: 2, 4, 6, 8, 10, 12, 13, 15, 16, 20, 22, 24, 26, 28, 33, or 51 or a variable region sequence in its variable region. In certain embodiments, each of the two fusion polypeptides contains a sequence having at least 95% identity to one of SEQ ID NOs: 2, 4, 6, 8, 10, 12, 13, 14, 15, 16, 20, 22, 24, 26, 28, 33, or 51 or a variable region sequence. In a particular embodiment, the two antibody light chain polypeptides include a sequence having at least 95% identity with SEQ ID NO: 7 or its variable region, and each of the two fusion polypeptides includes a sequence having at least 95% identity with SEQ ID NO: 8 or its variable region. In a particular embodiment, the two antibody light chain polypeptides include a sequence having at least 95% identity with SEQ ID NO: 25 or its variable region, and each of the two fusion polypeptides includes a sequence having at least 95% identity with SEQ ID NO: 26 or its variable region.

[0016] In another related embodiment, the present disclosure relates to a polypeptide comprising a sequence having at least 95% identity to any one of SEQ ID NOs: 1-28, 33, or 51 or its variable region, and optionally comprising the following set of CDRs: (a) SYAMS (SEQ ID NO: 34), AISGSGGSTYYEDSVKG (SEQ ID NO: 35), and DFSSRWYLEY (SEQ ID NO: 36); (b) QGESLRSYYAS (SEQ ID NO: 37), YGKSNRPS (SEQ ID NO: 38), and CTSLERIGYLSYV The present invention provides polypeptides comprising (SEQ ID NO: 39); (c) QGESLRSYYAS (SEQ ID NO: 37), YGKANRPS (SEQ ID NO: 40), and CTSLERIGYLSYV (SEQ ID NO: 39); (d) RISENIYSNLA (SEQ ID NO: 41), AAINLAE (SEQ ID NO: 42), and QHFWGTPFT (SEQ ID NO: 43); or (e) AYGIN (SEQ ID NO: 44), EIFPRDSTFYNEKFKG (SEQ ID NO: 45), and KGREYGTSHYFDY (SEQ ID NO: 46). In certain embodiments, the polypeptide is a fusion protein comprising a modified R-spongin polypeptide or a fragment or variant fused to the N-terminus of an antibody heavy chain polypeptide via a linker moiety, optionally a peptidyl linker sequence, wherein the R-spongin polypeptide or a fragment or variant comprises two amino acid substitutions at positions corresponding to amino acids 105 and 109 of human R-spongin 2. In certain embodiments, the two amino acid substitutions are (a) F105R, F105A, or F105E, and (b) F109A or F109E. In certain embodiments, the two amino acid substitutions are (a) F105R and F109A, (b) F105A and F109A, (c) F105E and F109A, or (d) F105E and F109E.In certain embodiments, the antibody heavy chain polypeptide comprises: (a) each of SYAMS (SEQ ID NO: 34), AISGSGGSTYYEDSVKG (SEQ ID NO: 35), DFSSRRWYLEY (SEQ ID NO: 36), or (b) each of combinations of CDRH1, CDRH2, and CDRH3 sequences selected from RISENIYSNLA (SEQ ID NO: 41), AAINLAE (SEQ ID NO: 42), and QHFWGTPFT (SEQ ID NO: 43). In certain embodiments, it comprises a modified antibody light chain polypeptide. In certain embodiments, the modified antibody light chain polypeptide comprises: (a) QGESLRSYYAS (SEQ ID NO: 37), YGKSNRPS (SEQ ID NO: 38), and CTSLERIGYLSYV (SEQ ID NO: 39), respectively; (b) QGESLRSYYAS (SEQ ID NO: 37), YGKANRPS (SEQ ID NO: 40), and CTSLERIGYLSYV (SEQ ID NO: 39), respectively; or (c) AYGIN (SEQ ID NO: 44), EIFPRDSTFYNEKFKG (SEQ ID NO: 45), and KGREYGTSHYFDY (SEQ ID NO: 46), respectively, a combination of CDRL1, CDRL2, and CDRL3 sequences.

[0017] In another related embodiment, the Disclosure provides nucleic acid sequences encoding any of the polypeptides disclosed herein, for example, antibody light chain polypeptides or fusion polypeptides disclosed herein, or polypeptides having at least 95% identity to any one of SEQ ID NOs: 1-33 or 51 or their variable region. In certain embodiments, the nucleic acid sequence is DNA or mRNA.

[0018] In another embodiment, the Disclosure provides a vector comprising a nucleic acid sequence disclosed herein. In a particular embodiment, it is an expression vector comprising a promoter sequence operably ligated to the nucleic acid sequence. In a particular embodiment, it is a virus comprising a promoter sequence operably ligated to the nucleic acid sequence.

[0019] In related embodiments, the disclosure provides host cells comprising a vector disclosed herein. In further related embodiments, the disclosure provides a process for producing an antibody light chain polypeptide or fusion polypeptide disclosed herein, comprising the step of culturing host cells under conditions in which the polypeptide is expressed by an expression vector. In certain embodiments, the method comprises the step of isolating the produced fusion polypeptide.

[0020] In related embodiments, the Disclosure provides a pharmaceutical composition comprising a) a molecule disclosed herein, a nucleic acid sequence disclosed herein, a vector disclosed herein, or a host cell disclosed herein, and b) a pharmaceutically acceptable diluent, adjuvant, or carrier.

[0021] In another embodiment, the present invention provides a pharmaceutical composition comprising a liver-specific Wnt signaling-enhancing molecule described herein or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable diluent, adjuvant, or carrier.

[0022] In another embodiment, the present invention provides a pharmaceutical composition comprising a polynucleotide containing a nucleic acid sequence encoding a liver-specific Wnt signaling-enhancing molecule described herein or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable diluent, adjuvant, or carrier. In certain embodiments, the nucleic acid sequence includes DNA or mRNA, and optionally, modified mRNA.

[0023] In another embodiment, the present invention provides a pharmaceutical composition comprising a vector containing a nucleic acid sequence encoding a liver-specific Wnt signaling-enhancing molecule or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable diluent, adjuvant, or carrier. In a particular embodiment, the vector comprises a promoter operably ligated to the nucleic acid sequence, which drives the expression of the liver-specific Wnt signaling-enhancing molecule. In a particular embodiment, the vector is an expression vector or a viral vector.

[0024] In another embodiment, the Disclosure provides a method for increasing Wnt ("Wingless-associated integration site" or "Wingless and Int-1" or "Wingless-Int") signaling in liver tissue, comprising the steps of contacting liver tissue with a) a Wnt signaling-enhancing molecule disclosed herein, b) a nucleic acid disclosed herein, c) a vector disclosed herein, d) a host cell disclosed herein, or e) a pharmaceutical composition disclosed herein, wherein the molecule binds to the liver tissue and sequesters one or more transmembrane E3 ubiquitin ligases selected from zinc and ring finger 3 (ZNRF3) and ring finger protein 43 (RNF43) in the liver tissue, or increases the endocytosis of transmembrane E3 ubiquitin ligases.

[0025] In related embodiments, the present disclosure provides a method for treating or preventing liver disease or liver injury in a subject that requires treatment or prevention of liver disease or liver injury, wherein the liver disease or liver injury is associated with reduced Wnt ("Wingless-associated integration site" or "Wingless and Int-1" or "Wingless-Int") signaling, or would benefit from increased Wnt signaling, the method comprising the step of administering to the subject an effective amount of a) a molecule disclosed herein, b) a nucleic acid disclosed herein, c) a vector disclosed herein, d) a host cell disclosed herein, or e) a pharmaceutical composition disclosed herein. In certain embodiments, liver disease or liver injury includes acute liver failure of any cause, drug-induced acute liver failure, acute exacerbation of chronic liver failure (ACLF), acute liver decompensation, ascites due to cirrhosis, hyponatremia in patients with cirrhosis, hepatorenal syndrome - acute kidney injury (HRS-AKI), hepatic encephalopathy, alcoholic liver disease, chronic liver failure of any cause, decompensated liver failure, late compensated liver failure, cirrhosis, hepatic fibrosis of any cause, portal hypertension, chronic liver dysfunction of any cause, end-stage liver disease (ESLD), non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD) (fatty liver), alcoholic hepatitis, acute alcoholic hepatitis (AAH) or severe alcoholic hepatitis, chronic alcoholic hepatitis, alcoholic liver disease (ALD) (alcohol-related liver disease (ARLD)). Selected from the group consisting of hepatitis C virus (HCV)-induced liver disease, hepatitis B virus (HBV)-induced liver disease, other viral hepatitis (e.g., hepatitis A virus (HAV)-induced liver disease and hepatitis D virus (HDV)-induced liver disease), primary biliary cirrhosis, autoimmune hepatitis, liver surgery, liver injury, veno-occlusive disease (VOD), sinusoidal obstructive syndrome (SOS), primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), liver transplantation, liver surgery and "undergraft" syndrome in transplantation, congenital liver disease and impairment, hepatic failure due to APAP (acetaminophen) overdose, acetaminophen-induced liver injury, and any other liver disease or impairment resulting from genetic disorders, degeneration, aging, drugs or injury.

[0026] In certain embodiments, the liver disease or liver injury is selected from acute alcoholic hepatitis, acute liver failure (including, but not limited to, acute liver failure (ALF) resulting from acetaminophen (APAP) overdose), acute exacerbation of chronic liver failure (ACLF), acute liver decompensation, ascites due to cirrhosis, hyponatremia in patients with cirrhosis, hepatorenal syndrome-acute kidney injury (HRS-AKI), hepatic encephalopathy, or cirrhosis. In certain embodiments, the liver disease is alcoholic hepatitis, e.g., acute alcoholic hepatitis or severe alcoholic hepatitis. In certain embodiments, the molecule, nucleic acid, vector, host cell, or pharmaceutical composition is administered parenterally, orally, intramuscularly, or topically to the liver. In certain embodiments, the subject is a mammal, and optionally, a human.

[0027] In related embodiments, the Disclosure provides a method for generating, culturing, or maintaining liver cells, liver tissue, or liver organoids, comprising the step of contacting the cells, tissue, or organoids with a) a molecule disclosed herein, b) a nucleic acid disclosed herein, c) a vector disclosed herein, d) a host cell disclosed herein, or e) a pharmaceutical composition disclosed herein. In some embodiments, the method is for maintaining the viability of liver tissue ex vivo, comprising the step of contacting liver tissue obtained from a donor with a composition containing molecules, optionally by perfusing the liver tissue ex vivo. In some embodiments, the method is for maintaining the viability of liver tissue, optionally by contacting donor liver tissue with a composition containing molecules in vivo. In some embodiments, the method is for generating or maintaining liver organoid cultures, comprising the step of contacting the liver organoid cultures with a culture medium containing molecules, optionally by culturing the liver organoid cultures in a culture medium containing molecules.

[0028] In further embodiments, the present invention provides a method for increasing Wnt signaling in a target tissue, comprising the step of contacting the target tissue with a liver-specific Wnt signaling-enhancing molecule described herein, wherein a second domain specifically binds to a cell-specific surface molecule on the target tissue, and the liver-specific Wnt signaling-enhancing molecule binds to the target tissue and sequesters one or more transmembrane E3 ubiquitin ligases selected from ZNRF3 and RNF43 in the target tissue, or increases the endocytosis of such transmembrane E3 ubiquitin ligases.

[0029] In certain embodiments, the target tissue or cells are brought into contact with a polynucleotide containing a nucleic acid sequence encoding a liver-specific Wnt signaling-enhancing molecule, or with a vector containing a nucleic acid sequence encoding a liver-specific Wnt signaling-enhancing molecule, such as an expression vector or a viral vector.

[0030] In yet another related embodiment, the present invention relates to a method for treating or preventing a disease or condition in a subject that requires treatment or prevention of the disease or condition, wherein the disease or condition is related to reduced Wnt signaling or would benefit from increased Wnt signaling, and the method includes the step of providing to the subject an effective amount of a pharmaceutical composition comprising either a liver-specific Wnt signaling-enhancing molecule or a pharmaceutically acceptable salt thereof, either alone or in combination with Wnt, Norrin, or a Wnt-activating / mimetic molecule. In a particular embodiment, the method is carried out using a pharmaceutical composition comprising a polynucleotide comprising a nucleic acid sequence encoding a liver-specific Wnt signaling-enhancing molecule (e.g., DNA or mRNA), or a vector comprising a nucleic acid sequence encoding a liver-specific Wnt signaling-enhancing molecule (e.g., an expression vector or a viral vector).

[0031] In any particular embodiment of the treatment methods described herein, the disease or disorder is acute liver failure of any cause, drug-induced acute liver failure, acute exacerbation of chronic liver failure (ACLF), acute hepatic decompensation, ascites due to cirrhosis, hyponatremia in patients with cirrhosis, hepatorenal syndrome - acute kidney injury (HRS-AKI), hepatic encephalopathy, alcoholic liver disease, chronic liver failure of any cause, decompensated liver failure, late compensated liver failure, cirrhosis, hepatic fibrosis of any cause, portal hypertension, chronic hepatic dysfunction of any cause, end-stage liver disease (ESLD), non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD) (fatty liver), alcoholic hepatitis, acute alcoholic hepatitis (AAH), chronic alcoholic hepatitis, alcoholic liver disease (ALD) (alcohol-related liver disease) Liver disease or impairment of tissue selected from the group consisting of hepatitis C virus (HCV)-induced liver disease, hepatitis B virus (HBV)-induced liver disease, other viral hepatitis (e.g., hepatitis A virus (HAV)-induced liver disease and hepatitis D virus (HDV)-induced liver disease), primary biliary cirrhosis, autoimmune hepatitis, liver surgery, liver injury, veno-occlusive disease (VOD), sinusoidal obstructive syndrome (SOS), primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), liver transplantation, liver surgery and "undergraft" syndrome in transplantation, congenital liver disease and impairment, hepatic failure due to APAP (acetaminophen) overdose, and any other liver disease or impairment resulting from genetic disorders, degeneration, aging, drugs or injury. In certain embodiments, liver disease is alcoholic hepatitis, e.g., acute alcoholic hepatitis or severe alcoholic hepatitis. In certain embodiments of any treatment or preventive method described herein, the pharmaceutical composition is administered systemically, parenterally, orally, intramuscularly, topically, or externally. In certain embodiments, the subject is a mammal, and optionally, a human.

[0032] In certain embodiments, the antibody or its antigen-binding fragment includes a heavy chain variable region or a light chain variable region, or a heavy chain or a light chain, which includes an amino acid sequence having at least 90% identity with the amino acid sequences disclosed herein, for example, SEQ ID NOs: 1-28, 33, or 51, or a fragment or variant thereof, for example, a variable domain of the sequence.

[0033] The features of this disclosure are specifically described in the appended claims. A better understanding of the features and advantages of the present invention can be obtained by referring to the subsequent detailed description illustrating exemplary embodiments in which the principles of the present invention are used, and by referring to the appended drawings. [Brief explanation of the drawing]

[0034] [Figure 1] Figure 1 shows the light chain variable domain sequence and the fusion polypeptide heavy chain variable domain-RSPO2 sequence for the initial αASGR1-RSPO2 Wnt signaling enhancer molecule. CDRs are underlined, and deamidation or isomerization risks are in bold. Various amino acid substitutions made to eliminate the risks are shown at each position.

[0035] [Figure 2] Figure 2 provides SEC profile graphs of variants of the first αASGR1-RSPO2 Wnt signaling enhancer molecule having various amino acid substitutions at the D62 position of CDR H2.

[0036] [Figure 3] Figure 3 provides SEC profile graphs of variants of the first αASGR1-RSPO2 Wnt signaling enhancer molecule having various amino acid substitutions at the D25 position of CDR L1.

[0037] [Figure 4] Figure 4 provides SEC profile graphs of variants of the first αASGR1-RSPO2 Wnt signaling enhancer molecule having various amino acid substitutions at the N51 position of CDR L2.

[0038] [Figure 5] Figure 5 provides SEC profile graphs of variants of the first αASGR1-RSPO2 Wnt signaling enhancer molecule having various amino acid substitutions at the N88 position of CDR L3.

[0039] [Figure 6] Figure 6 shows SDS-PAGE gel analysis of the expression and folding of Wnt signaling enhancers, including point mutations, compared to the original αASGR1-RSPO2 Wnt signaling enhancer molecule, under non-reducing (left panel) or reducing (right panel) conditions.

[0040] [Figure 7] Figure 7 shows SDS-PAGE gel analysis of expression and folding of Wnt signaling enhancer molecules, including combinations showing point mutations compared to the initial αASGR1-RSPO2 Wnt signaling enhancer molecule (left panel: lane 1 = marker, lanes 2-8 = EESY, EEAL, EEAE, EEAH, EEAT, EEAY, EEAR, non-reduced, and lanes 9-15 = EESY, EEAL, EEAE, EEAH, EEAT, EEAY, EEAR, reduced; right panel: lane 1 = marker, lanes 2-9 = EESN, EEAN, EESL, EESE, EESH, EEST, EESR, EESK).

[0041] [Figure 8] Figure 8 is a table summarizing the assay results shown for Wnt signaling enhancer molecules, including combinations showing point mutations compared to the initial αASGR1-RSPO2 Wnt signaling enhancer molecule (wild type).

[0042] [Figure 9]Figure 9 is a table summarizing the ASGR1 binding assay results for Wnt signaling enhancer molecules, including combinations showing point mutations compared to the initial αASGR1-RSPO2 Wnt signaling enhancer molecule (wild type).

[0043] [Figure 10] Figure 10 provides a graph showing the results of the STF assay for Wnt signaling enhancer molecules, including combinations of point mutations, in Huh-7 (left panel) and Hek-203 (right panel) cells.

[0044] [Figure 11] Figure 11 provides a graph showing Axin2 / ActB expression in vehicles or animals treated with the indicated Wnt signaling enhancer molecules. Data are presented with or without values ​​for injured animals treated daily with Rimadyl (left panel) or (right panel).

[0045] [Figure 12] Figure 12 is a graph (from left to right by tissue) showing increased Axin2 expression in various tissues isolated from animals treated with anti-bgal, anti-GFP-mutRSPO, the EEST-EE Wnt signaling enhancer molecule (1R34-EEST-EE), or Rspo2.

[0046] [Figure 13] Figure 13 provides a graph showing the increased expression in the liver of the indicated Wnt target genes in animals treated with the indicated Wnt signaling enhancer molecules (from left to right) at the indicated time.

[0047] [Figure 14A]Figure 14A shows the increased expression of the growth marker Ki67 in the livers of animals treated with αGFP-IgG, αASGR1-RSPO2-EEST-EE, or αASGR1-RSPO2-EEST-RA (from left to right) at the indicated time points.

[0048] [Figure 14B] Figure 14B shows increased expression of the growth marker Ki67 in the livers of animals treated with the indicated doses of αASGR1-RSPO2-EEST-EE or control.

[0049] [Figure 15] Figure 15 provides pharmacokinetic profiles of EEST-EE Wnt signaling-enhancing molecules in mice after either IV administration at 3, 10, 30, or 100 mg / kg, or ip administration at 10 or 30 mg / kg.

[0050] [Figure 16] Figure 16 shows a mouse model of chronic thioacetamide-induced liver fibrosis and various Wnt signaling-enhancing molecules that were tested.

[0051] [Figure 17] Figures 17A–17C show INR (Figure 17A), Axin2 (Figure 17B), and CYP2e1 mRNA (Figure 17C) after administration of the indicated amounts of Wnt signaling-enhancing molecules, EEST-EE or EEST-RA.

[0052] [Figure 18] Figure 18 shows Ki67 expression in the livers of animals treated with TAA in or without, control (anti-bgal), EEST-EE, or Rspo2.

[0053] [Figure 19] Figure 19 shows INR (left), Axin2 (center), and CYP2e1 mRNA (right) after administration of the indicated amounts of the Wnt signaling-enhancing molecule, EEST-EE or EEST-RA.

[0054] [Figure 20] Figure 20 shows Ki67 expression in the livers of animals treated with or without CCl4, control (anti-bgal), EEAT-EE (αASGR1-RSPO2-EEAT-EE or 1R34-EEAT / EE), or Rspo2.

[0055] [Figure 21] Figure 21 is a graph showing the expression of the growth marker Ki67 in the livers of animals treated with either control or αASGR1-RSPO2-EEST-EE.

[0056] [Figure 22] Figure 22 is a graph showing the expression of the growth marker Ki67 in the small intestine of animals treated with either control or αASGR1-RSPO2-EEST-EE.

[0057] [Figure 23] Figure 23 is a graph showing the fibrosis area in animals treated with CCl4 followed by control (anti-GFP), Rspo2, or αASGR1-RSPO2-EEAT-EE.

[0058] [Figure 24] Figure 24 is a graph showing ALP expression after treatment with vehicle, EEST-RA, EEST-EE, 8M24-EASE-RA, or 8M24-EASE-EE.

[0059] [Figure 25] Figure 25 provides sequences of the variable domains of the 8M24 antibody heavy and light chains, as well as various humanized versions thereof.

[0060] [Figure 26A] Figure 26A provides the sequences of the VH and VL domains of the 8M24 antibody. The CDR is underlined, and modified amino acids are shown in bold.

[0061] [Figure 26B] Figure 26B shows the various amino acid substitutions made at each of the indicated positions within the 8M24 CDR.

[0062] [Figure 27] Figure 27 is a graph showing the results of an STF assay for the 8M24 Wnt signaling enhancer molecule containing the indicated point mutation at N57.

[0063] [Figure 28] Figure 28 is a table summarizing the characteristics of various 8M24 Wnt signaling enhancer molecules, including combinations showing point mutations.

[0064] [Figure 29] Figure 29 provides a graph showing the expression of Axin2, Ccnd, and Ki67 in animals treated with the first 8M24-RA Wnt signaling enhancer or the EEST-EE IgG2-type Wnt signaling enhancer (1R34-EEST / EE IgG2) at various doses.

[0065] [Figure 30] Figure 30 provides graphs showing the expression of Axin2, Ccnd, and Ki67 in animals treated with the 8M24-EASE-RA Wnt signaling enhancer or the EEST-EE IgG2-type Wnt signaling enhancer (1R34-EEST / EE IgG2) at various doses.

[0066] [Figure 31] Figure 31 shows the pharmacokinetic profiles of the Wnt signaling-enhancing molecules EEST-RA (1R34-EEST / RA), EEST-EE (1R34-EEST / EE), 8M24-EASE-RA, or 8M24-EASE-EE in mice.

[0067] [Figure 32]Figure 32 shows the percentage ratio of liver to body weight at slaughter. Statistical analysis: One-way ANOVA (GraphPad Prism), *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, Error bars: mean and SEM.

[0068] [Figure 33-1] Figures 33A and 33B show serum ALP (Figure 33A) and albumin (Figure 33B) on days 7 and 14 after the start of administration of the test substance. [Figure 33-2] Figures 33A and 33B show serum ALP (Figure 33A) and albumin (Figure 33B) on days 7 and 14 after the start of administration of the test substance.

[0069] [Figure 34-1] Figure 34 shows the liver RNA expression analysis of the Axin2, Ccnd1, and Mki67 genes as measured by qPCR. [Figure 34-2] Figure 34 shows the liver RNA expression analysis of the Axin2, Ccnd1, and Mki67 genes as measured by qPCR.

[0070] [Figure 35] Figure 35 shows immunofluorescence staining of liver sections from mice treated with SZN-043.v2, RSPO2, and anti-GFP after CCl4 treatment, or control sections from mice injected with olive oil alone. Staining with the proliferation marker anti-Ki67 nuclear antigen (green), staining with the hepatocyte-specific marker anti-HNF4α (red), and DNA staining with DAPI (blue).

[0071] [Figure 36-1] Figures 36A and 36B show the percentage of fibrosis area measured by picrosilius red staining (Figure 36A), followed by quantification using Image J (Figure 36B). [Figure 36-2] Figures 36A and 36B show the percentage of fibrosis area measured by picrosilius red staining (Figure 36A), followed by quantification using Image J (Figure 36B).

[0072] [Figure 37A] Figure 37A shows the overall structure of the HuASGR1-CBD:8M24 complex. The molecular surface of HuASGR1-CBD is shown as a light gray transparent surface. The heavy and light chains of 8M24 are colored in darker and lighter shades of black, respectively. The three structural calcium ions are shown as dark spheres.

[0073] [Figure 37B] Figure 37B shows a magnified view of the HuASGR1-CBD:8M24 boundary, indicating the location of the CDR loop, the heavy chains H1, H2, and H3, and the light chains L1, L2, and L3.

[0074] [Figure 38] Figure 38 shows the alignments of all four human R-spongin proteins (Rspo1 (SEQ ID NO: 47), Rspo2 (SEQ ID NO: 48), Rspo3 (SEQ ID NO: 49), and Rspo4 (SEQ ID NO: 50)), with furin domains 1 (Fu1) and 2 (Fu2) indicated by light and dark shading, respectively. The Fu1 domain generally corresponds to approximately amino acid residues 38-94 of SEQ ID NO: 47, approximately amino acid residues 37-93 of SEQ ID NO: 48, approximately amino acid residues 39-95 of SEQ ID NO: 49, and approximately amino acid residues 32-88 of SEQ ID NO: 50. The Fu2 domain generally corresponds to approximately amino acid residues 97-144 of SEQ ID NO: 47, approximately amino acid residues 96-143 of SEQ ID NO: 48, approximately amino acid residues 98-144 of SEQ ID NO: 49, and approximately amino acid residues 91-137 of SEQ ID NO: 50.

[0075] [Figure 39-1]Figures 39A–C show the binding of various Wnt signal-enhancing molecules, including combinations showing point mutations compared to the initial αASGR1-RSPO2 Wnt signaling enhancer molecule (NG or "wild-type"). Figure 39A is a table showing the kinetic fir parameters from the data in Figures 39B and 39C. The data were fitted using a divalent analyte model in ForteBIO Data Analysis Software. Figures 39B–39C provide data from serial dilutions of various Wnt signal-enhancing molecules tested for binding using biotinylated ASGR1 captured with a streptavidin sensor using Octet Red96e. [Figure 39-2] Figures 39A–C show the binding of various Wnt signal-enhancing molecules, including combinations showing point mutations compared to the initial αASGR1-RSPO2 Wnt signaling enhancer molecule (NG or "wild-type"). Figure 39A is a table showing the kinetic fir parameters from the data in Figures 39B and 39C. The data were fitted using a divalent analyte model in ForteBIO Data Analysis Software. Figures 39B–39C provide data from serial dilutions of various Wnt signal-enhancing molecules tested for binding using biotinylated ASGR1 captured with a streptavidin sensor using Octet Red96e. [Figure 39-3]Figures 39A–C show the binding of various Wnt signal-enhancing molecules, including combinations showing point mutations compared to the initial αASGR1-RSPO2 Wnt signaling enhancer molecule (NG or "wild-type"). Figure 39A is a table showing the kinetic fir parameters from the data in Figures 39B and 39C. The data were fitted using a divalent analyte model in ForteBIO Data Analysis Software. Figures 39B–39C provide data from serial dilutions of various Wnt signal-enhancing molecules tested for binding using biotinylated ASGR1 captured with a streptavidin sensor using Octet Red96e.

[0076] [Figure 40-1] Figures 40A–40D show the STF activity of various combinations of mutations in Huh-7 (Figures 40A and 40C) and Hek-293 (Figures 40B and 40D) cells. [Figure 40-2] Figures 40A–40D show the STF activity of various combinations of mutations in Huh-7 (Figures 40A and 40C) and Hek-293 (Figures 40B and 40D) cells.

[0077] [Figure 41] Figure 41 shows the stability of constructs with the indicated combinations of amino acid substitutions.

[0078] [Figure 42] Figure 42 shows the STF activity of constructs with the indicated amino acid substitution combinations.

[0079] [Figure 43]Figure 43 provides a graph showing the expression levels of indicated Wnt target genes and cytochrome P450 (CYP) metabolic enzymes in the livers of uninjured animals or APAP-injured animals treated with αGFP-IgG, Nac, or αASGR1-RSPO2-EEAT-EE Wnt signaling enhancer molecules (from left to right) at the indicated time.

[0080] [Figure 44] Figure 44 provides a micrograph showing Ki67 and HNF4a expression in hepatocytes of a liver treated with the indicated drugs after acetaminophen-induced liver injury.

[0081] [Figure 45] Figure 45 provides a micrograph showing Ki67 and CYP2F2 expression in hepatocytes of a liver treated with the indicated drugs after acetaminophen-induced liver injury.

[0082] [Figure 46] Figure 46 provides a micrograph showing a histological image of a liver treated as indicated. Necrotic areas after anti-GFP or Nac treatment are shown.

[0083] [Figure 47] Figure 47 provides a graph showing ALT, AAST, ALP, and AMMN levels at the indicated time in the livers of uninjured animals or in the livers injured by APAP treated with αGFP-IgG, Nac, or αASGR1-RSPO2-EEAT-EE Wnt signaling enhancer molecules (from left to right).

[0084] [Figure 48] Figure 48 shows a study of the effects of 1R34-EEST-EE on liver function and tissue repair in an animal model of chronic-binge ethanol-induced liver injury.

[0085] [Figure 49] Figure 49 provides a graph showing the expression of the indicated Wnt target gene on day 0, day 3, or day 7 after treatment. The bars on day 0, from left to right, correspond to paired feed and EtOH, while the bars on day 3 and on days 3 and 7, from left to right, correspond to treatment with anti-GFP or 1R43-EEST-EE.

[0086] [Figure 50] Figure 50 provides a graph showing the expression of the indicated liver growth markers on day 0, day 3, or day 7 after treatment. The bars on day 0, from left to right, correspond to paired feed and EtOH, while the bars on day 3 and on days 3 and 7, from left to right, correspond to treatment with anti-GFP or 1R43-EEST-EE.

[0087] [Figure 51] Figure 51 provides a micrograph showing immunofluorescence staining of Ki67 or HNF4A.

[0088] [Figure 52] Figure 52 provides a graph showing the expression of the indicated molecules on day 0, day 3, or day 7 after treatment. The bars on day 0, from left to right, correspond to paired feed and EtOH, while the bars on day 3 and on days 3 and 7, from left to right, correspond to treatment with anti-GFP or 1R43-EEST-EE.

[0089] [Figure 53] Figure 53 is a graph showing Lect2 and angiogenin expression on day 0, day 3, or day 7 after treatment. The bars on day 0, from left to right, correspond to paired feed and EtOH, while the bars on day 3 and on days 3 and 7, from left to right, correspond to treatment with anti-GFP or 1R43-EEST-EE.

[0090] [Figure 54]Figure 54 provides a graph showing the expression of inflammatory markers, interleukins IL1b and IL6, on day 0, day 3, or day 7 after treatment. The bars on day 0, from left to right, correspond to paired feed and EtOH, while the bars on day 3 and on days 3 and 7, from left to right, correspond to treatment with anti-GFP or 1R43-EEST-EE. [Modes for carrying out the invention]

[0091] Detailed description of the invention This disclosure provides liver-specific Wnt signaling-enhancing molecules that, in certain embodiments, 1) selectively bind to liver-specific cell surface receptors, 2) mediate the internalization or sequestration of ZNRF3 / RNF43 in targeted liver tissue or cells, and / or 3) enhance Wnt signaling in a liver-specific manner. In certain embodiments, the molecule is a fusion protein. In certain embodiments, the molecule is an antibody having an appended binding domain. Also provided are pharmaceutical compositions and methods for using any of the molecules and compositions disclosed herein to enhance, i.e., increase, Wnt signaling in liver tissue or hepatocytes, for example, for the treatment or prevention of liver disease or impairment. These and other objects, advantages and features of the present invention will become apparent to those skilled in the art by reading the details of the compositions and methods which are further described below. definition

[0092] As used herein, “vector” refers to a macromolecule or aggregate of macromolecules that contains or associates with polynucleotides and can be used to mediate the delivery of polynucleotides to cells. Exemplary vectors include, for example, plasmids, viral vectors, liposomes, and other gene delivery vehicles.

[0093] The term “polynucleotide” refers to a nucleotide in a multimeric form of any length, including either a deoxyribonucleotide or a ribonucleotide, or an analog thereof. Polynucleotides may include modified nucleotides, such as methylated nucleotides and nucleotide analogs, and non-nucleotide components may be interposed in the polynucleotide. Where present, modifications to the nucleotide structure may be made before or after the assembly of the polymer. As used herein, the term polynucleotide refers to mutually interchangeable double-stranded and single-stranded molecules. Unless otherwise specified or required, any embodiment of the invention disclosed herein that is a polynucleotide encompasses both the double-stranded form and each of two complementary single-stranded forms that are known to or are expected to constitute the double-stranded form.

[0094] A polynucleotide or polypeptide (the sequence of interest) has a certain percentage of “sequence identity” with respect to another polynucleotide or polypeptide (the reference sequence). “Sequence identity” means that when the two sequences are aligned and then compared, the percentage of bases or amino acids are the same. As understood in the art, sequence identity refers to the percentage of identity obtained when the sequences are aligned to the maximum match over a comparison region (e.g., each specified region of the sequence), which can be calculated by one of the algorithms described herein using default parameters, which, when applied to similar sequences, are expected to produce the same alignment in most cases. Identity is calculated over the entire length of the reference sequence unless otherwise specified. Thus, the sequence of interest “shares at least x% identity” with the reference sequence if, when the sequence of interest is aligned with the reference sequence, at least x% (rounded down) of the residues in the sequence of interest are aligned as a perfect match to the corresponding residues in the reference sequence. Gaps may be introduced into the target sequence and / or reference sequence to maximize the match across the comparison domain.

[0095] Sequence similarity (i.e., identity) can be determined in several different ways. To determine sequence identity, sequences can be aligned using methods and computer programs, including BLASTP or BLASTN, which are publicly available from the National Center for Biotechnology Information (NCBI), for example, at ncbi.nlm.nih.gov / BLAST / on the worldwide web (e.g., the BLAST and BLAST 2.0 algorithms described in Altschul et al. (1990) J. Mol. Biol. 215: 403-410 and Altschul et al. (1997) Nucleic acids Res. 25: 3389-3402, respectively). For example, sequence identity can be determined by using a standalone executable BLAST engine program (bl2seq) with default parameters to BLAST two sequences that can be imported from the NCBI ftp site (Tatusova and Madden, FEMS Microbiol Lett. 1999, 174, 247-250). Another alignment algorithm is FASTA, available from Genetics Computing Group (GCG), a wholly owned subsidiary of Oxford Molecular Group, Inc., in Madison, Wis., USA. Other techniques for alignment are described in Methods in Enzymology, vol. 266: Computer Methods for Macromolecular Sequence Analysis (1996), ed. Doolittle, Academic Press, Inc., a division of Harcourt Brace & Co., San Diego, Calif., USA. Alignment programs that allow gaps in sequences are particularly intended. Smith-Waterman is a type of algorithm that allows for gaps during array alignment.See Meth. Mol. Biol. 70: 173-187 (1997). Additionally, a GAP program using the Needleman and Wunsch alignment method may be used to align sequences. See J. Mol. Biol. 48: 443-453 (1970). The BestFit program, which uses the local homology algorithm of Smith and Waterman (Advances in Applied Mathematics 2: 482-489 (1981)) to determine sequence identity, is intended. The gap generation penalty is generally in the range of 1–5, usually 2–4, but in many embodiments it is 3. The gap expansion penalty is generally in the range of approximately 0.01–0.20, but in many examples it is 0.10. The program has default parameters determined by the input sequences being compared. Sequence identity can be determined using the default parameters determined by the program. This program is also available from the Genetics Computing Group (GCG) package, Madison, Wis., USA. Another program of interest is the FastDB algorithm. FastDB is described in Current Methods in Sequence Comparison and Analysis, Macromolecule Sequencing and Synthesis, Selected Methods and Applications, pp. 127-149, 1988, Alan R. Liss, Inc. Percent sequence identity is calculated by FastDB based on the following parameters: mismatch penalty: 1.00; gap penalty: 1.00; gap size penalty: 0.33; and joining penalty: 30.0. Another program of interest is CLUSTAL from uniprot.org, available at https: / / www.ebi.ac.uk / Tools / msa / clustalo / . Unless otherwise indicated, sequence identity is determined using the BLAST algorithm (e.g., bl2seq) with default parameters.

[0096] When applied to polynucleotides, "recombinant" means that the polynucleotide is the product of a diverse combination of cloning, restriction, or ligation steps and other procedures that result in a construct distinct from naturally occurring polynucleotides.

[0097] A “regulatory element” or “regulatory sequence” is a nucleotide sequence involved in molecular interactions that contribute to the regulation of polynucleotide function, including replication, duplication, transcription, splicing, translation, or degradation. This regulation may affect the frequency, rate, or specificity of a process and may be either enhancing or inhibiting. Regulatory elements known in the art include, for example, transcriptional regulatory sequences, such as promoters and enhancers. A promoter is a DNA region that, under certain conditions, can bind to RNA polymerase and initiate transcription of a coding region typically located downstream (3' direction) of the promoter.

[0098] "Operationally linked" or "operationally linked" refers to the juxtaposition of gene elements, where these elements are related in a way that allows them to function in the expected manner. For example, if a promoter helps initiate transcription of a coding sequence, the promoter is operationally linked to the coding region. There may be intervening residues between the promoter and the coding region, as long as this functional relationship is maintained.

[0099] An "expression vector" is a vector containing a region that codes for a target gene product and is used to induce the expression of that gene product in intended target cells. Expression vectors also include regulatory elements that are operably ligated to the coding region to enhance the expression of the gene product in the target. The combination of regulatory elements and the gene(s) to which they are operably ligated for expression is sometimes called an "expression cassette," and many of these can be readily constructed from components that are known, available, or available in the art.

[0100] As used herein, the terms “polypeptide,” “peptide,” and “protein” refer to polymers of amino acids of any length. These terms also encompass amino acid polymers that have been modified, for example, to involve disulfide bond formation, glycosylation, lipidation, phosphorylation, or conjugation with a labeling component.

[0101] As used herein, the term “antibody” means an isolated or recombinant conjugate containing a variable region sequence necessary for specific binding to an antigen epitope. Therefore, an antibody is any form of antibody or fragment thereof that exhibits a desired biological activity, e.g., binding to a specific target antigen. Hence, the term “antibody” is used in its broadest sense, specifically covering monoclonal antibodies (including full-length monoclonal antibodies), polyclonal antibodies, human antibodies, humanized antibodies, chimeric antibodies, nanobodies, diabodies, multispecific antibodies (e.g., bispecific antibodies), and antibody fragments, including but not limited to scFv, Fab, and Fab2, if they exhibit the desired biological activity.

[0102] An "antibody fragment" is a portion of an intact antibody, such as the antigen-binding region or variable region of an intact antibody. Examples of antibody fragments include Fab, Fab', F(ab')2, and Fv fragments; diabodies; linear antibodies (e.g., Zapata et al., Protein Eng. 8(10): 1057-1062 (1995)); single-chain antibody molecules (e.g., scFv); and polyspecific antibodies formed from antibody fragments. Papain digestion of an antibody produces two identical antigen-binding fragments, called "Fab" fragments, each having a single antigen-binding site, and the remaining "Fc" fragment (a designation reflecting its ability to easily crystallize). Pepsin treatment produces an F(ab')2 fragment, which has two antigen-binding sites and can still crosslink antigens.

[0103] "Includes" means that the listed elements are required for, for example, a composition, method, kit, etc., but other elements may be included, for example, to form a composition, method, kit, etc. within the scope of the claims. For example, an expression cassette "including" a gene encoding a therapeutic polypeptide operably linked to a promoter is an expression cassette that may include other elements in addition to the gene and promoter, such as polyadenylated sequences, enhancer elements, other genes, linker domains, etc.

[0104] "Essentially derived from" means that the scope of the described, for example, composition, method, kit, etc., is limited to specified materials or steps that do not substantially affect the basic and novel features(s) of the composition, method, kit, etc. For example, an expression cassette "essentially derived from" a gene encoding a therapeutic polypeptide operably linked to a promoter and a polyadenylation sequence may include further sequences, such as linker sequences, provided that they do not substantially affect the transcription or translation of the gene. As another example, a variant, or mutant, polypeptide fragment "essentially derived from" an enumerated sequence has approximately 10 amino acid residues plus or minus the amino acid sequence of the enumerated sequence at the boundary of the sequence based on the full-length naive polypeptide from which it is derived, for example, 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 residue less than the enumerated binding amino acid residues, or 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 residues more than the enumerated binding amino acid residues.

[0105] "Consists of" means that any element, step, or component not explicitly stated in the claim is excluded from the composition, method, or kit. For example, a polypeptide or polypeptide domain "consists of" the listed sequences contains only the listed sequences.

[0106] When used herein, “expression vector” refers to a vector containing a polynucleotide encoding a gene product of interest, such as a plasmid, minicircle, viral vector, liposome, etc., as discussed herein or known in the art, used to induce the expression of the gene product in intended target cells. An expression vector also includes regulatory elements operably ligated to the coding region to facilitate the expression of the gene product in the target. The combination of regulatory elements, such as promoters, enhancers, UTRs, miRNA targeting sequences, etc., and the gene(s) operably ligated for expression is sometimes called an “expression cassette.” Many such regulatory elements are known, available, or readily constructed from components available in the art.

[0107] When used herein, “promoter” encompasses a DNA sequence, i.e., the smallest sequence sufficient to direct transcription, that directs the binding of RNA polymerase and thereby promotes RNA synthesis. Promoter and corresponding protein or polypeptide expression may be universal, meaning strongly active in a wide range of cells, tissues, and species, or the promoter and expression may be cell type specific, liver specific, or species specific. Promoter may be “constitutive,” meaning continuously active, or promoter may be “inducible,” meaning that the promoter can be activated or inactivated by the presence or absence of biofactors or non-biological factors. Enhancer sequences, which may or may not be contiguous with promoter sequences, are also included in the nucleic acid constructs or vectors of the present invention. Enhancer sequences may affect promoter-dependent gene expression and may be located in the 5' or 3' region of the native gene.

[0108] The terms “native” or “wild-type,” as used herein, refer to a nucleotide sequence, e.g., a gene or gene product, e.g., RNA or protein, present in wild-type cells, tissues, organs, or organisms. The term “variant,” as used herein, refers to a variant of a reference polynucleotide or polypeptide sequence, e.g., a native polynucleotide or polypeptide sequence, i.e., a variant having less than 100% sequence identity with the reference polynucleotide or polypeptide sequence. In other words, a variant contains at least one amino acid difference (e.g., an amino acid substitution, an amino acid insertion, or an amino acid deletion) compared to the reference polynucleotide sequence, e.g., a native polynucleotide or polypeptide sequence. For example, a variant may be a polynucleotide having 50% or more, 60% or more, or 70% or more sequence identity with the full-length native polynucleotide sequence, e.g., 75% or 80% or more, e.g., 85%, 90% or 95% or more identity with the full-length native polynucleotide sequence, e.g., 98% or 99% identity. In another example, a variant may be a polypeptide having 70% or more sequence identity with the full-length native polypeptide sequence, e.g., 75% or 80% or more identity with the full-length native polypeptide sequence, e.g., 85%, 90%, or 95% or more identity, e.g., 98% or 99% identity. A variant may also include a variant fragment of a reference, e.g., the native sequence, that shares 70% or more sequence identity with a reference, e.g., the native sequence fragment, e.g., 75% or 80% or more identity with the native sequence, e.g., 85%, 90%, or 95% or more identity, e.g., 98% or 99% identity.

[0109] As used herein, the terms “bioactive” and “biologically active” refer to activity attributable to a particular biological element within a cell. For example, the “bioactive” of R-spongin, or a fragment or variant thereof, refers to its ability to enhance Wnt signaling. As another example, the bioactive of a polypeptide or a functional fragment or variant thereof refers to the ability of the polypeptide or a functional fragment or variant thereof to perform its native function, such as binding or enzymatic activity. As a third example, the bioactive of a gene regulatory element, such as a promoter, enhancer, or Kozak sequence, refers to the ability of the regulatory element or a functional fragment or variant thereof to regulate the expression of the gene to which it is operably linked, i.e., to promote, enhance, or activate the translation of that gene, respectively.

[0110] The terms “administer,” “introduce,” or “deliver,” as used herein, refer to the delivery of a composition to cells, to cells, tissues and / or organs of interest, or to the subject. Such administering or introducing steps may be carried out in vivo, in vitro, or ex vivo.

[0111] The terms “treatment,” “to treat,” etc., are used herein to generally mean obtaining a desired pharmacological and / or physiological effect. This effect may be preventive in terms of completely or partially preventing a disease or its symptoms, e.g., reducing the likelihood of the disease or its symptoms occurring in the subject, and / or therapeutic in terms of the partial or complete cure of the disease and / or adverse effects resulting from the disease. “Treatment,” as used herein, covers any treatment of a disease in a mammal and includes: (a) inhibiting the disease, i.e., partially or completely halting its development; or (b) mitigating the disease, i.e., causing regression of the disease. Therapeutic agents may be administered before, during, or after the onset of a disease or injury. Treatment of an ongoing disease is particularly targeted, where the treatment stabilizes or reduces undesirable clinical symptoms in the patient. Such treatment is preferably carried out before the complete loss of function in the affected tissue. Targeted therapies are preferably administered during the symptomatic stage of the disease, and in some cases, after the symptomatic stage of the disease.

[0112] The terms “individual,” “host,” “subject,” and “patient” are used interchangeably herein and refer to mammals, including but not limited to human and non-human primates, including monkeys and humans; mammalian sports animals (e.g., horses); mammalian farm animals (e.g., sheep, goats, etc.); mammalian pets (e.g., dogs, cats, etc.); and rodents (e.g., mice, rats, etc.).

[0113] A variety of compositions and methods of the present invention are described below. While specific compositions and methods are illustrated herein, it is understood that any of several alternative compositions and methods may be applicable and preferred for use in carrying out the present invention. It is also understood that the expression constructs and methods of the present invention can be evaluated using standard procedures in the art.

[0114] Unless otherwise indicated, the implementation of this invention will involve conventional techniques of cell biology, molecular biology (including recombinant techniques), microbiology, biochemistry, and immunology, which are within the scope of those skilled in the art. Such techniques are described in “Molecular Cloning: A Laboratory Manual”, second edition (Sambrook et al., 1989); “Oligonucleotide Synthesis” (MJ Gait, ed., 1984); “Animal Cell Culture” (RI Freshney, ed., 1987); “Methods in Enzymology” (Academic Press, Inc.); “Handbook of Experimental Immunology” (DM Weir & CC Blackwell, eds.); “Gene Transfer Vectors for Mammalian Cells” (JM Miller & MP Calos, eds., 1987); “Current Protocols in Molecular Biology” (FM Ausubel et al., eds., 1987); “PCR: The Polymerase Chain Reaction”, (Mullis et al., eds., 1994); and “Current Protocols in Immunology“ (JE Coligan et al., eds., This is adequately explained in literature such as 1991, and each of these documents is explicitly incorporated herein by reference.

[0115] Some aspects of the present invention are described below in relation to examples of applications for illustrative purposes. It should be understood that a number of specific details, relationships, and methods are shown to give a full understanding of the present invention. However, it will be readily apparent to those skilled in the art that the present invention can be carried out without using one or more of these specific details, or by other methods. The present invention is not limited by the order of the exemplary actions or events, for some actions may be carried out in a different order and / or in combination with other actions or events. Furthermore, not all exemplary actions or events are necessarily required to carry out the methodology according to the present invention.

[0116] The terminology used herein is intended solely to describe specific embodiments and is not intended to limit the invention. Where used herein, the singular forms “a,” “an,” and “the” are intended to include the plural unless otherwise explicitly indicated by the context. Furthermore, where the terms “including,” “includes,” “having,” “has,” “accompany,” or their variants are used in either the detailed description and / or the claims, such terms are intended to be inclusive, as is the term “comprising.”

[0117] The terms “about” or “approximately” mean a range of acceptable error for a particular value, as determined by those skilled in the art, and this range of acceptable error depends in part on the limitations of the method or determination of the value, i.e., the measurement system. For example, “about” could mean a range of up to 20%, up to 10%, up to 5%, or up to 1% of a given value. Alternatively, particularly with respect to biological systems or processes, the term could mean within one order of magnitude of the value, for example, within five times, or within two times. Where a particular value is described in this application and claims, unless otherwise stated, the term “about” should be assumed to mean a range of acceptable error for that particular value.

[0118] All publications referenced herein are incorporated herein by reference to disclose and describe methods and / or materials relating to those publications cited. In the event of any conflict, this disclosure shall prevail over any disclosure in the incorporated publications.

[0119] It should be further noted that claims may be conceived to exclude elements as needed. Therefore, this statement is intended to serve as a basis prior to the use of exclusive terminology such as “exclusively,” “simply,” or “negative” limitations in relation to the description of elements of the claims.

[0120] Unless otherwise indicated, all terms used herein have the same meaning as those to the art, and the implementation of the present invention will utilize conventional techniques of microbiology and recombinant DNA technology that are within the scope of knowledge of those skilled in the art. array

[0121] The following table (Table A) is a list of representative sequences and associated sequence identification numbers. CDRs are underlined in plain font. For each heavy chain and light chain sequence, the CDRs are sequentially CDR1, CDR2, and CDR3. Linker sequences are shown in bold plain font, and RSPO2 sequences are shown in italics. Thus, heavy chain and light chain sequences, as well as their variable domains, can be easily determined based on the provided sequences. The heavy chain constant domain is shaded in gray. In certain embodiments, the sequence is a polypeptide sequence present within the liver-specific Wnt signal-enhancing molecule shown. In certain embodiments, the Wnt signal-enhancing molecule contains two of the heavy chain fusion protein sequences and two of the light chain sequences in antibody form, for example, with two heavy chain fusion protein sequences linked to each other and each of the two light chain sequences linked to a different heavy chain fusion protein sequence. In certain embodiments, the Wnt signal-enhancing molecule comprises two heavy chain fusion protein sequences, each containing a CDR present in one of these sequences, and two light chain sequences present in one of these sequences, for example, in antibody form, where the two heavy chain fusion protein sequences are linked to each other and each of the two light chain sequences is bound to a different heavy chain fusion protein sequence. In certain embodiments, each of the two heavy chain fusion protein sequences and / or each of the two light chain sequences has at least 90%, at least 95%, at least 98%, or at least 99% identity to any of the disclosed sequences, and in certain embodiments, amino acid modifications, such as insertions, deletions, or substitutions, are not present within the CDR.In certain embodiments, amino acid modifications are not made in (a) F105R, F105A, or F105E, and / or (b) F109A or F109E. Table A. Sequences of representative liver-specific Wnt signal-enhancing molecules containing two of the light chain sequences and two of the heavy chain fusion sequences shown in antibody form, such as 1R34-DDNN / RA, 8M24-v1, 1R34-EEST / EE, 1R34-EEST / RA, 1R34-EEAT / EE, 8M24 Humanized 1, 8M24 Humanized 2, 8M24-EASE-RA, 8M24-EASE-EE, 1R34-DDNN / RA, for example, a bispecific molecule containing or consisting of (a) (i) one Rspo2 domain fused to each heavy chain of IgG, (ii) each arm of IgG bound to a liver-specific cell surface receptor-binding domain (e.g., ASGR1), and (b) the binding of such IgG arms activates downstream signaling. [Table A-1] [Table A-2] [Table A-3] [Table A-4] [Table A-5] [Table A-6] [Table A-7] [Table A-8]

[0122] In certain embodiments, the sequence is a polypeptide sequence present in the liver-specific Wnt signal-enhancing molecule, comprising one or more polypeptides or variants thereof, or any combination thereof, as shown in Table A. In certain embodiments, the Wnt signal-enhancing molecule comprises two heavy chain fusion protein sequences and two light chain sequences in antibody form, for example, the two heavy chain fusion protein sequences are linked to each other and each of the two light chain sequences is linked to a different heavy chain fusion protein sequence. In certain embodiments, the Wnt signal-enhancing molecule comprises two heavy chain fusion protein sequences, each containing a CDR present in one of these sequences and two light chain sequences present in one of these sequences, in antibody form, for example, the two heavy chain fusion protein sequences are linked to each other and each of the two light chain sequences is linked to a different heavy chain fusion protein sequence. In certain embodiments, the Wnt signal-enhancing molecule comprises, for example, two heavy chain fusion protein sequences, each containing a CDR present in either of these sequences, and two light chain sequences, each containing a CDR present in either of these sequences, in antibody form, such that the two heavy chain fusion protein sequences are linked to each other and each of the two light chain sequences is linked to a different heavy chain fusion protein sequence. In certain embodiments, each of the two heavy chain fusion protein sequences and / or each of the two light chain sequences is a variant of any of the disclosed sequences and has at least 90%, at least 95%, at least 98%, or at least 99% identity to any of the disclosed sequences, and in certain embodiments, no amino acid modifications, such as insertions, deletions, or substitutions, are present in the CDR. In certain embodiments, no amino acid modifications are made in (a) F105R, F105A, or F105E, and / or (b) F109A or F109E. In certain embodiments, the heavy chain variant includes N297G. In certain embodiments, the RPOS2 sequence present in the variant includes F105R and F109A substitutions.In certain embodiments, the RPOS2 sequence present in the variant includes F105E and F109E substitutions. In certain embodiments, the molecule includes amino acid substitutions compared to the parent or wild type for any of the following constructs: EEST / EE, EEST / RA, EEAT / EE, EESN / RA, EEAN / RA, 8M24-EAASE-0RA, or 8M24-EASE-EE. Liver-specific Wnt signaling-enhancing molecules

[0123] In certain embodiments, the disclosure provides a liver-specific Wnt signaling-enhancing molecule capable of enhancing Wnt activity in a liver-specific manner. In certain embodiments, the liver-specific Wnt signaling-enhancing molecule is a bifunctional molecule comprising a first domain that binds to one or more ZNRF3 and / or RNF43 ligases and a second domain that binds to liver tissue and / or hepatocytes. Each of the first and second domains may be any portion that can bind to a ligase complex or a targeted tissue or cell, respectively. For example, each of the first and second domains may be, but are not limited to, a polypeptide (e.g., an antibody or its antigen-binding fragment, or a peptide or polypeptide different from an antibody), a small molecule, and a native ligand or its variant, fragment, or derivative. In certain embodiments, the native ligand may be a polypeptide, a small molecule, an ion, an amino acid, a lipid, or a sugar molecule. The first and second domains may be of the same type as each other, or they may be of different types. In certain embodiments, the liver-specific Wnt signaling-enhancing molecule binds to a liver-specific cell surface receptor. In certain embodiments, liver-specific Wnt signaling-enhancing molecules increase or enhance Wnt signaling in liver tissue or hepatocytes by, for example, at least 50%, at least 2x, at least 3x, at least 5x, at least 10x, at least 20x, at least 30x, at least 40x, or at least 50x compared to a negative control.

[0124] Liver-specific Wnt signal-enhancing molecules can take different forms. In certain embodiments, the liver-specific Wnt signal-enhancing molecule is a fusion protein comprising a first polypeptide sequence that binds to ZNRF3 / RNF43 and a second polypeptide sequence that binds to liver tissue or hepatocytes. In certain embodiments, the two polypeptide sequences may be directly fused or fused via a linker. In certain embodiments, the liver-specific Wnt signal-enhancing molecule comprises a dimer or polymer comprising two or more polypeptides, e.g., two or more fusion proteins each containing a first domain and a second domain, where the two or more polypeptides are linked, e.g., via a linker moiety or by linkages between amino acid residues in each of the two or more polypeptides, e.g., by intermolecular disulfide bonds between cysteine ​​residues.

[0125] In certain embodiments, the liver-specific Wnt signal-enhancing molecule is an antibody (or its antigen-binding fragment) comprising an antibody heavy chain and a light chain, constituting either a first or second domain, wherein the other domain (i.e., the second or first domain) is fused to the antibody heavy chain or light chain either as a fusion protein or via a linker moiety. In certain embodiments, the other domain is fused to the N-terminus of the heavy chain, the C-terminus of the heavy chain, the N-terminus of the light chain, or the C-terminus of the light chain. Such a structure may be referred to herein as an additional IgG scaffold. For example, the liver-specific Wnt signal-enhancing molecule may be an antibody that binds to a liver-specific cell surface receptor, and a binding domain that binds to ZNRF3 / RNF43 is fused to or added to either the heavy chain or light chain of an antibody that binds to a tissue-specific or cell-specific receptor. In certain embodiments, the liver-specific Wnt signal-enhancing molecule is an antibody or its antigen-binding fragment that binds to ASGR1 or ASGR2, and the binding domain that binds to ZNRF3 / RNF43 is fused to or added to either the heavy or light chain of the antibody or its antigen-binding fragment. In certain embodiments, the binding domain that binds to ZNRF3 / RNF43 is derived from an Rspo polypeptide, and in some embodiments, it comprises Fu1 and Fu2 domains, which optionally include one or more amino acid modifications, including any of those disclosed herein, e.g., F105R, F105E, F109A, or F109E.

[0126] In certain embodiments, the liver-specific Wnt signaling-enhancing molecule comprises a first domain ("action module") that binds to ZNRF3 / RNF43, and a second domain ("targeting module") that binds to the liver-specific receptor, for example, with high affinity. In certain embodiments, each of these two domains has substantially reduced activity or is inactive in itself to enhance Wnt signaling. However, when the liver-specific Wnt signaling-enhancing molecule engages with liver tissue or cells expressing the liver-specific receptor, the E3 ligase ZNRF3 / RNF43 is recruited to a ternary complex with the liver-specific receptor, thereby being sequestered and / or cleared from the cell surface by receptor-mediated endocytosis. The final result is enhancement of Wnt signaling in a liver-specific manner.

[0127] In certain embodiments, the action module is a binding factor to the ZNRF3 / RNF43 E3 ligase, and the action module can be designed based on R-spongins, including but not limited to human R-spongins-1 to 4. In certain embodiments, the action module is an R-spongin, for example, wild-type R-spongins-1 to 4, optionally human R-spongins-1 to 4, or a variant or fragment thereof. In certain embodiments, it is a variant of any of R-spongins-1 to 4 having at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% sequence identity with respect to the corresponding wild-type R-spongins-1 to 4 sequences. In certain embodiments, the action module includes or comprises a furin domain 1 of an R-spongin, for example, any of R-spongins-1 to 4, that binds to ZNRF3 / RNF43. Extended versions of furin domain 1 (including, but not limited to, those having mutant furin domain 2 that no longer bind to LGR4-6 or have reduced binding to LGR4-6), or engineered antibodies, or any other derivatives, or any engineered polypeptide other than an antibody that can specifically bind to ZNRF3 / RNF43, can also be used. In certain embodiments, the action module comprises one or more furin domains 1 of R-sponge. In certain embodiments, it does not comprise furin domain 2 of R-sponge, or it comprises a modified or variant furin domain 2 of R-sponge, e.g., furin domain 2 having reduced activity compared to wild-type furin domain 2. In certain embodiments, the action module comprises furin domain 1 of R-sponge but does not comprise furin domain 2. In certain embodiments, the action module comprises two or more furin domains 1, or a polymer of furin domain 1. The action domain may comprise one or more wild-type furin domains 1 of R-sponge.In certain embodiments, the action module comprises a modified or variant furin domain 1 of R-spongin having increased activity compared to wild-type furin domain 1, e.g., binding to ZNRF3 / RNF43. Variants having increased binding to ZNRF3 / RNF43 can be identified, for example, by screening a phage or yeast display library containing variants of R-spongin furin domain 1. Peptides or polypeptides having binding to ZNRF3 / RNF43 but unrelated to R-spongin furin domain 1 can also be identified by screening. The action module may further include additional partial or polypeptide sequences, e.g., additional amino acid residues, to stabilize the structure of the action module or liver-specific Wnt signal-enhancing molecule in which it exists.

[0128] R-spongin can amplify the Wnt signal. The smallest functional unit of R-spongin consists of two furin domains: furin domain 1, which binds to the ZNRF3 / RNF43 E3 ligase, and furin domain 2, which binds to LGR4-6. These furin domains form a ternary complex of R-spongin, LGR, and E3 ligase. As a result, the entire complex is internalized, preventing ZNRF3 / RNF43 from becoming a target for disruption. Furin domain 1 alone is not fully functional, but it can bind to both ZNRF3 and RNF43.

[0129] The action module of the liver-specific Wnt signaling-enhancing molecules described herein may be, but are not limited to, any functional portion that can bind to the ZNRF3 / RNF43 ligase, such as a polypeptide or an organic chemical. In certain embodiments, the action module, either alone or together with the targeting module, such as a polypeptide containing the furin domain 1 of R-sponge, is substantially inactive in untargeted tissue and thus minimizes potential off-target effects. With respect to liver-specific Wnt signaling-enhancing molecules, the action module is fused to or bound to the targeting module, and when the liver-specific Wnt signaling-enhancing molecule associates with target tissue expressing a liver-specific receptor, the E3 ligase ZNRF3 / RNF43 is recruited to a ternary complex with the liver-specific receptor, thereby resulting in relocation to, sequestration of, and / or removal from the cell surface.

[0130] In certain embodiments, the action module comprises a fragment or variant of the R-sponge polypeptide (e.g., any of R-sponge 1-4), or a functional fragment or variant thereof. In certain embodiments, the action module comprises a fragment of wild-type R-sponge, and in other embodiments, the action module comprises a fragment of R-sponge containing one or more amino acid modifications. R-sponge can be any R-sponge known in the art, or its homolog, including R-sponge from any animal species, including but not limited to mammalian species such as human R-sponge. R-sponge has been identified and described, and their polypeptides and encoding polynucleotide sequences are known and available in the art. In certain embodiments, the R-sponge polypeptide is human R-sponge, or a homolog found in other vertebrates or nonvertebrates, e.g., mouse R-sponge. The amino acid sequences of human R-sponge 1, human R-sponge 2, human R-sponge 3, and human R-sponge 4, and their furin domain 1, are provided in Figure 38 and SEQ ID NOs: 47-50, respectively. These homologs and variants are available from general database searches, such as https: / / www.dot.ncbi.dot.nlm.dot.nih.dot.gov / protein / . The present invention includes (but is not limited to) action modules comprising or consisting of fragments and variants of any of these or other R-spongins. In various embodiments, variants and fragments of any of the R-spongin polypeptides comprise one or more amino acid modifications, e.g., deletions, additions, or substitutions, compared to the wild-type R-spongin polypeptide. The modifications may be present in any region of the R-spongin variant or fragment, comprising but not limited to furin domain 1 and / or furin domain 2.It is understood that amino acid modifications other than furin domain 1 or furin domain 2 may alter the resulting variant so that it has reduced LGR4-6 binding activity compared to wild-type R-spongin or its fragments.

[0131] In certain embodiments, the action module includes or comprises an R-spongin sequence, e.g., full-length or wild-type R-spongin-1, -2, -3, or -4, optionally human R-spongin-1, -2, -3, or -4, or a variant or fragment thereof. In certain embodiments, it is a variant of any of R-spongin-1 to 4 having at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% sequence identity with the corresponding wild-type R-spongin-1 to 4 sequences. In certain embodiments, the action module includes or comprises a full-length R-spongin (e.g., any of R-spongin-1 to 4) containing one or more amino acid modifications, including but not limited to any of those disclosed herein. In certain embodiments, the action module includes or comprises a fragment of wild-type or modified R-spongin (e.g., any of R-spongin-1 to 4). In certain embodiments, the fragment can bind to ZNRF3 and / or RNF43. In certain embodiments, the action module includes furin domain 1 of the R-spondin protein, or a fragment or variant of the R-spondin protein. In certain embodiments, the action module includes or comprises one or more (e.g., one, two, three or more) furin domains 1 of the R-spondin protein (e.g., R-spondin-1 to 4), or a variant thereof having at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% sequence identity to the R-spondin furin domain 1. In certain embodiments, the action module includes the R-spondin furin 1 domain or a variant or fragment thereof, and the R-spondin furin 2 domain or a variant or fragment thereof. In certain embodiments, the action module includes an antibody or antigen-binding fragment thereof that binds to ZNRF3 and / or RNF43. In certain embodiments, the action module specifically binds to either ZNRF3 or RNF43.

[0132] In certain embodiments, the action module includes one or more furin domains 1 of R-spongin, e.g., human R-spongin 1 or human R-spongin 2, or a variant thereof. In certain embodiments, the action module includes one or more furin domains 1 of R-spongin, but does not include furin domain 2 of R-spongin. In certain embodiments, the action module includes one or more furin domains 1 of R-spongin, and the action module includes a modified or variant furin domain 2 of R-spongin, e.g., a furin domain 2 having reduced activity compared to wild-type furin domain 2. In certain embodiments, the action module includes an R-spongin protein having a modified or variant furin domain 2 of R-spongin, e.g., a furin domain 2 having reduced activity compared to wild-type furin domain 2. In certain embodiments, the action module includes two or more furin domains 1, or variants thereof, or a polymer of furin domain 1 or its variants. In certain embodiments, the action module includes a variant R-spongin furin 1 domain containing one or more point mutations in amino acid residues corresponding to, for example, K58, H76, S77, R86, and / or N91 of human R-spongin 2. In certain embodiments, the action module includes a variant R-spongin furin 2 domain containing one or more point mutations in amino acid residues corresponding to, for example, F105, F109, and / or K121 of human R-spongin 2. In certain embodiments, the action module includes a modified or variant furin domain 1 of R-spongin having increased activity compared to wild-type furin domain 1, for example, binding to ZNRF3 / RNF43. The action module may further include further partial or polypeptide sequences, for example, further amino acid residues, to stabilize the structure of the action module or liver-specific Wnt signal-enhancing molecule in which it exists.In certain embodiments, the action module comprises a peptide or polypeptide that does not have obvious / strong sequence homology to R-spondin but has a binding affinity to ZNRF3 / RNF43 that is comparable to or higher than the binding affinity of R-spondin to ZNRF3 / RNF43.

[0133] In certain embodiments, the action module comprises furin domain 1 of an R-spongin polypeptide (e.g., human R-spongin), or a functional fragment or variant thereof, and a modified or variant furin domain 2 of an R-spongin polypeptide (e.g., human R-spongin), wherein the modified furin domain 2 has a reduced binding affinity to LGR4-6 compared to the corresponding wild-type furin domain 2. In certain embodiments, furin domain 2 contains one or more point mutations in amino acid residues corresponding to, for example, F105 and / or F109 of human R-spongin 2. Those skilled in the art can easily determine the corresponding amino acid residues in other R-spongin polypeptides by comparing their amino acid sequences with those of human R-spongin 2. In certain embodiments, the action module comprises furin domain 1 or a variant thereof, and furin domain 2 or a variant thereof, wherein furin domain 1 and / or furin domain 2 contains one or more point mutations. One or more point mutations within the action module (compared to the corresponding wild-type R-spongin sequence) may be present on any amino acid residue within furin domain 1 and / or furin domain 2, including, but not limited to, amino acid residues K58, H76, S77, R86, N91, F105, F109, or K121, and other residues that can be modified to reduce binding affinity to LGR4-6. Regions of furin domain 1 and furin domain 2 of human R-spongin 1 that are important for its functional activity have been identified, and these include the conserved hydrophilic residues S48, N51, R66, R70, and Q71, as well as the less conserved hydrophobic residues L46, L54, I62, and L64, which are important for binding to the E3 ligase. In addition, in human R-spondin 1 furin domain 1, amino acid residues K59, S78, D85, R87, N88, and N92 form a hydrophilic interaction surface with LGR5, and the FSHNF amino acid sequence has been identified as an important loop for the hydrophobic surface.In certain embodiments, the action module comprising R-spondin furin domain 1 and / or furin domain 2 may contain one or more mutations in any of these regions, surfaces, or amino acid residues.

[0134] In certain embodiments, the action module comprising R-spondin furin domain 1 and / or furin domain 2 may include one or more mutations or other modifications other than those regions, surfaces, or amino acid residues that indirectly impair LGR4-6 binding by affecting the structure and / or stability of the binding surface.

[0135] In certain embodiments, the action module comprising R-spongin furin domain 1 and / or furin domain 2 may comprise one or more mutations at any amino acid residue, including but not limited to those shown in the appended examples. In certain embodiments, the action module comprises a modified furin domain 2 comprising amino acid substitutions at amino acid residues F105 and / or F109. In certain embodiments, the action module comprises a furin 1 domain and a modified furin domain 2 comprising amino acid substitutions at amino acid residues F105 and / or F109. In certain embodiments, the action module comprises a modified furin 1 domain and a modified furin 2 domain, wherein in certain embodiments, the modified furin 1 domain comprises one or more amino acid modifications at amino acids R65, R69 and / or Q70, and the modified furin domain comprises one or more amino acid modifications at amino acids F105 and / or F109. In certain embodiments, the modified R-spongin polypeptide or a fragment or variant thereof comprises amino acid substitutions at positions corresponding to amino acids F105 and F109 of human R-spongin 2. In certain embodiments, the two amino acid substitutions include (a) F105R, F105A, or F105E, and (b) F109A or F109E. In certain embodiments, the two amino acid substitutions are (a) F105R and F109A, (b) F105A and F109A, (c) F105E and F109A, or (d) F105E and F109E. In certain embodiments, the modified R-spongin polypeptide or a fragment or variant thereof has at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% sequence identity to any of SEQ ID NOs. 29-32.In certain embodiments, the modified R-spongin polypeptide or a fragment or variant thereof has at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% sequence identity to any of SEQ ID NOs. 29-32 and comprises one of the following combinations of amino acid substitutions: (a) F105R and F109A, (b) F105A and F109A, (c) F105E and F109A, or (d) F105E and F109E. In certain embodiments, the modified furin domain 2 has a binding affinity to LGR4-6 that is less than 80%, less than 50%, less than 20%, or less than 10% of the binding of the corresponding wild-type furin domain 2 with respect to the full-length R-spongin protein, for example.

[0136] In certain embodiments, the action module comprises a furin domain 1 of the R-sponge polypeptide (e.g., human R-sponge) or a functional fragment or variant thereof, and an unmodified furin domain 2 of the R-sponge polypeptide (e.g., human R-sponge). In certain embodiments, a modified furin domain 2 with lower binding affinity to LGR4-6 compared to the corresponding wild-type furin domain 2 is desirable to increase tissue targeting specificity; however, in certain embodiments, the unmodified furin domain 2 combined with the targeting module has improved tissue targeting than wild-type R-sponge without the targeting module and is useful in certain situations.

[0137] In certain embodiments, the action module includes, for example, a wild-type or modified R-spongin furin domain 1 from R-spongin-1, -2, -3, -4, and optionally from any of human R-spongin-1, -2, -3, or -4. In certain embodiments, the action module includes, for example, an R-spongin furin 1 domain and a wild-type or modified R-spongin furin 2 domain from R-spongin-1, -2, -3, -4, and optionally from any of human R-spongin-1, -2, -3, or -4. In certain embodiments, the action module includes, for example, a first R-spongin furin 1 domain and a second wild-type or modified R-spongin furin 1 domain from R-spongin-1, -2, -3, -4, and optionally from any of human R-spongin-1, -2, -3, or -4. In certain embodiments, the modified furin domain 2 has, for example, a binding affinity to LGR4-6 with respect to the full-length R-spongin protein that is comparable to the binding of the corresponding wild-type furin domain 2, or a binding affinity to LGR4-6 that is less than 80%, less than 50%, less than 20%, or less than 10% of the binding of the corresponding wild-type furin domain 2.

[0138] In certain embodiments, the action module includes an antibody or its antigen-binding fragment that specifically binds to ZNRF3 and / or RNF43. In certain embodiments, the action module includes an antibody or its antigen-binding fragment that binds to human RNF43 (hRNF43, NCBI reference sequence XP_011523257.1, residues 44-198) or human ZNRF3 (hZNRF3; NCBI reference sequence NP_001193927.1, residues 56-219). In certain embodiments, the action module is an antibody or its antigen-binding fragment that includes a nanobody, a VH or VL sequence, or a fragment or variant thereof.

[0139] In certain embodiments, the targeting module specifically binds to a liver-specific surface molecule, such as a liver-specific surface receptor, which may be, for example, a native ligand, an antibody, or a synthetic chemical. In certain embodiments, the liver-specific surface molecule is preferentially expressed on the organ, tissue, and / or hepatocytes of the liver. In certain embodiments, the liver-specific surface molecule has increased or enhanced expression on liver tissue or hepatocytes compared to one or more other non-target organs, tissues, or cell types. In certain embodiments, the liver-specific surface molecule is preferentially expressed on the surface of the organ, tissue, or hepatocytes of the liver, respectively, compared to one or more other organs, tissues, or cell types. For example, in certain embodiments, a cell surface receptor is considered liver-specific or liver-specific cell surface molecule if it is expressed in the organs, tissues, or cells of the liver at a level at least 2 times, at least 5 times, at least 10 times, at least 20 times, at least 30 times, at least 40 times, at least 50 times, at least 100 times, at least 500 times, or at least 1000 times higher than it is expressed in one or more, five or more, all other organs, tissues, or cells, or at the average level of all other organs, tissues, or cells. In certain embodiments, the liver-specific or liver-specific cell surface molecule is a cell surface receptor, such as a polypeptide receptor, which includes a region located within the cell surface membrane and extracellular region to which a targeting module can bind. In various embodiments, the methods described herein may be carried out by specifically targeting cell surface molecules expressed only on liver tissue or a subset of tissues containing liver tissue, or by specifically targeting cell surface molecules that have a higher level of expression on liver tissue compared to all, most or a significant number of other tissues, for example, at least two, at least five, at least ten, or at least 20 other tissues.

[0140] Liver-specific cell surface receptors are well known in this field. Examples of liver-specific surface receptors include, but are not limited to, ASGR1, ASGR2, TFR2, and SLC10A1. Further receptors for delivery to the liver are described, for example, by Yan et al., Tumor Biology, 2015; 36:55-67.

[0141] In certain embodiments, the targeting module comprises an antibody or its antigen-binding fragment that specifically binds to ASGR1 and / or ASGR2. In certain embodiments, the targeting module comprises an antibody or its antigen-binding fragment comprising a) the CDRH1, CDRH2 and CDRH3 sequences shown herein, and / or b) the CDRL1, CDRL2 and CDRL3 sequences shown herein, or a variant of the antibody or its antigen-binding fragment comprising one or more amino acid modifications, wherein the variant comprises fewer than eight (e.g., fewer than seven, fewer than six, fewer than five, fewer than four, fewer than three, or fewer than two) amino acid substitutions in the CDR sequence. In certain embodiments, the targeting module comprises an antibody heavy chain variable domain comprising the CDRs of SEQ ID NOs. 34, 35 and 36, and an antibody light chain variable domain comprising the CDRs of SEQ ID NOs. 37, 38 and 39. In a particular embodiment, the targeting module includes antibody heavy chain variable domains containing CDRs of SEQ ID NOs. 34, 35, and 36, and antibody light chain variable domains containing CDRs of SEQ ID NOs. 37, 40, and 39. In a particular embodiment, the targeting module includes antibody light chain variable domains containing CDRs of SEQ ID NOs. 41, 42, and 43, and antibody heavy chain variable domains containing CDRs of SEQ ID NOs. 44, 45, and 46.

[0142] As used herein, a cell surface molecule is said to be liver-specific if a larger amount of the molecule is present on liver cells or liver tissue compared to one or more other cell or tissue types, or any other cell or tissue type. In certain embodiments, "larger amount" means at least twice, at least five times, at least ten times, at least twenty times, at least fifty times, or at least one hundred times, compared to the amount in one or more other cell or tissue types, or any other cell or tissue type. For example, in certain embodiments, a cell surface receptor is considered liver-specific or cell-specific cell surface molecule if it is expressed in a target organ, tissue, or cell at a level at least twice, at least five times, at least ten times, at least twenty times, at least thirty times, at least forty times, at least fifty times, at least one hundred times, at least five hundred times, or at least one thousand times higher than the level expressed in one or more, five or more, all other organs, tissues, or cells, or at the average level of all other organs, tissues, or cells. In certain embodiments, the liver-specific or cell-specific cell surface molecule is a cell surface receptor, such as a polypeptide receptor, which includes a region located within the cell surface membrane and extracellular region to which the targeting module can bind.

[0143] In certain embodiments, the targeting module binds to a liver-specific surface molecule. The targeting module that binds to each liver-specific surface molecule may be, but is not limited to, an antibody or its antigen-binding fragment, a peptide, a native ligand for a tissue or cell-specific receptor, or a derivative thereof, and a synthetic small molecule.

[0144] In certain embodiments, the liver-specific Wnt signaling-enhancing molecule binds to specific liver cell types, e.g., specific cell types associated with the target tissue. For example, within liver tissue, the targeting module may bind to hepatocytes, hepatocyte precursors and stem cells, cholangiocarcinomas, and / or endothelial or other vascular cells.

[0145] The asialoglycoprotein receptor (ASGPR) is composed of ASGR1 and ASGR2 (as outlined, e.g., Stockert, Morell and Ashwell, 1991, Targeted Diagnostics and Therapy 4: 41-64). This receptor is a transmembrane protein that plays a crucial role in serum glycoprotein homeostasis by mediating the endocytosis and lysosomal degradation of glycoproteins having exposed terminal galactose or N-acetylgalactosamine residues. Therefore, native and synthetic ligands for AGPR include, but are not limited to, galactosylated cholinesterases, galactose (Gal) and N-acetylgalactosamine (GalNAc), GalNAc-containing molecules, such as GalNAc-terminating glycoproteins, and monosaccharide, oligosaccharide, or polysaccharide-containing molecules or nanoparticles (as outlined, e.g., D'Souza and Devarajan 2015, Journal of Controlled Release, 203:126-139).

[0146] In various embodiments, the liver-specific surface molecules are liver-specific cell surface receptors. For the liver, these include, but are not limited to, ASGR1 and ASGR2. In certain embodiments, the targeting module binds to human ASGR1 (hASGR1; NCBI reference sequence NP_001662.1, residues 62-291), human ASGR2 (hASGR2; NCBI reference sequence NP_550436.1, residues 66-292), cynomolgus monkey ASGR1 (cynoASGR1, sequence ID XP_005582755.1, residues 62-291), or cynomolgus monkey ASGR2 (cynoASGR2).

[0147] In certain embodiments, the targeting module includes an antibody or an antigen-binding fragment thereof comprising the CDRH1, CDRH2, and CDRH3 sequences shown herein, and / or the CDRL1, CDRL2, and CDRL3 sequences shown herein, or a variant of the antibody or an antigen-binding fragment thereof comprising one or more amino acid modifications, wherein the variant comprises fewer than eight amino acid substitutions in the CDR sequence. In certain embodiments, the isolated antibody or its antigen-binding fragment comprises a heavy chain variable region, a light chain variable region, a nanobody, or an scFv sequence comprising an amino acid sequence having at least 90% or at least 95% identity to the sequence disclosed herein, for example, in any one of SEQ ID NOs: 1-24 or 29. In certain embodiments, the targeting module includes a variable heavy chain region having at least 90% or at least 95% identity to the variable heavy chain domain shown in any one of SEQ ID NOs: 2, 4, 6, 8, 10, 12, 13, 15, 16, 20, 22, 24, 26, 28, 33, or 51. In certain embodiments, the targeting module includes a variable light chain region having at least 90% or at least 95% identity to the variable light chain domain shown in any one of SEQ ID NOs: 1, 3, 5, 7, 9, 11, 14, 17, 18, 19, 21, 23, 25, or 27. In certain embodiments, the targeting module includes a heavy chain having at least 90% or at least 95% identity to the heavy chain shown in any one of SEQ ID NOs: 2, 6, 8, 10, 12, 22, 26, 33, or 51. In certain embodiments, the targeting module includes a light chain having at least 90% or at least 95% identity with the light chain shown in any one of sequence numbers 1, 5, 7, 9, 11, 21, or 25. In certain embodiments, the constant region of the light chain and / or heavy chain is IgG1 or IgG2.

[0148] In certain embodiments, the Wnt signal-enhancing molecule comprises a fusion protein, e.g., a fusion protein containing an antibody heavy or light chain of a targeting domain fused to an action domain. In certain embodiments, two regions of the fusion protein (e.g., a targeting domain region and an action domain) are fused via a linker moiety. In certain embodiments, the linker consists of amino acids linked to each other by peptide bonds. In certain embodiments, the linker comprises amino acids of length 1 to approximately 40 amino acid residues, 1 to approximately 20 amino acid residues, or 1 to approximately 10 amino acid residues. In certain embodiments, the amino acid residues in the linker are amino acid residues from among 20 standard amino acids, selected in certain embodiments from cysteine, glycine, alanine, proline, asparagine, glutamine, and / or serine. In certain embodiments, the linker comprises one or more non-natural amino acids. In some embodiments, the peptidyl linker consists of a majority of sterically unhinged amino acids, e.g., glycine, serine, and alanine linked by peptide bonds. Certain linkers include polyglycine, polyserine, and polyalanine, or combinations thereof. Some exemplary peptidyl linkers include poly(Gly) 1~8 In particular, (Gly)3, (Gly)4 (SEQ ID NO: 55), (Gly)5 (SEQ ID NO: 56), and (Gly)7 (SEQ ID NO: 57), as well as poly(Gly)4Ser (SEQ ID NO: 58), poly(Gly-Ala) 2~4 and poly(Ala) 1~8Other specific examples of peptidyl linkers include (Gly)5Lys (SEQ ID NO: 59) and (Gly)5LysArg (SEQ ID NO: 60). To illustrate the above nomenclature, for example, (Gly)3Lys(Gly)4 means Gly-Gly-Gly-Lys-Gly-Gly-Gly-Gly (SEQ ID NO: 61). Other combinations of Gly and Ala are also useful. In addition, peptidyl linkers may also include non-peptidyl segments, such as six-carbon aliphatic molecules of the formula --CH2--CH2--CH2--CH2--CH2--CH2--. By changing the peptidyl linker, derivatives described herein can be formed. In certain embodiments, the linker is one of those specified by SEQ ID NOs: 2, 4, 6, 8, 10, 12, 20, 22, 24, 26, or 28.

[0149] Examples of non-peptidyl linkers include alkyl linkers such as --NH--(CH2)s--C(O)-- (wherein s=2~20). These alkyl linkers may be further substituted with any non-sterically hindered group, such as lower alkyl (e.g., C1~C6), lower acyl, halogen (e.g., Cl, Br), CN, NH2, phenyl, etc. The non-peptide portion of the composition of the present invention, such as a non-peptidyl linker or a non-peptide half-life extension portion, can be synthesized by conventional organic chemical reactions. Examples of chemical groups used for linking the binding domains include carbamates, amides (amine plus carboxylic acid), esters (alcohol plus carboxylic acid), thioethers (haloalkane plus sulfhydryl; maleimide plus sulfhydryl), Schiff bases (amine plus aldehyde), urea (amine plus isocyanate), thiourea (amine plus isothiocyanate), sulfonamides (amine plus sulfonyl chloride), disulfides, hydrazones, and lipids, all of which are known in the art.

[0150] The linkage between domains may include a spacer, which may be linear or branched, usually a linear spacer such as an alkyl spacer, and may include one or more unsaturated bonds, which usually have from 1 to about 300 carbon atoms, more usually from about 1 to 25 carbon atoms, and may be from about 3 to 12 carbon atoms. This type of spacer may also include heteroatoms or functional groups such as amines, ethers, phosphodiesters, etc. Specific structures of interest include (CH2CH2O) n (where n is from 1 to about 12), (CH2CH2NH) n (where n is from 1 to about 12), [(CH2) n (C=O)NH(CH2) m z (where n and m are from 1 to about 6 and z is from 1 to about 10), [(CH2) n OPO3(CH2) m z (where n and m are from 1 to about 6 and z is from 1 to about 10). Such linkers may include polyethylene glycol, which may be linear or branched.

[0151] ​​In certain embodiments, a liver-specific Wnt signal-enhancing molecule, or a pharmaceutically acceptable salt thereof, comprises a first domain that specifically binds to one or more transmembrane E3 ubiquitin ligases selected from zinc and ring finger 3 (ZNRF3) and ring finger protein 43 (RNF43), and a second domain that specifically binds to asialoglycoprotein receptor 1 (ASGR1) and / or asialoglycoprotein receptor 2 (ASGR2), wherein (a) the first domain comprises an Rspo sequence or a fragment or variant thereof, and / or (b) the second domain comprises (i) the CDRH1, CDRH2 and CDRH3 sequences shown herein, and / or (ii) an antibody or antigen-binding fragment thereof comprising one or more amino acid modifications, the variant comprising fewer than eight amino acid substitutions in the CDR sequence. In particular embodiments, it comprises a polypeptide having at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% identity to any of SEQ ID NOs: 1-29. In particular embodiments, the polypeptide comprises a CDR sequence identified in any of SEQ ID NOs: 1-46 or 51, or any other sequence disclosed herein.

[0152] An action module or targeting module, such as an antibody or its antigen-binding fragment, is a module that "specifically binds to" or "is specific to" a particular cell surface polypeptide or receptor, and is such that it binds to that particular polypeptide or receptor without substantially binding to any other polypeptide or polypeptide epitope. In some embodiments, the action modules and targeting modules of the present disclosure have a dissociation constant (K) equal to or less than 1000 nM, equal to or less than 100 nM, equal to or less than 10 nM, equal to or less than 1 nM, equal to or less than 0.5 nM, equal to or less than 0.1 nM, equal to or less than 0.01 nM, equal to or less than 0.005 nM, or equal to or less than 0.0005 nM when measured at a temperature of about 4°C, 25°C, 37°C, or 42°C. d ) bind specifically to ZNRF3 / RNF43 or liver-specific cell surface molecules (e.g., receptors), respectively. The affinity of binding factors, such as antibodies, can be readily determined using conventional techniques, e.g., those described by Scatchard et al. (Ann. NY Acad. Sci. USA 51:660 (1949), ELISA assays, biolayer interferometry (BLI) assays, and surface plasmon resonance (SPR) assays). The binding properties of antibodies to antigens, their cells, or tissues can generally be determined and evaluated using immunodetection methods, which include immunofluorescence-based assays such as immunohistochemistry (IHC) and / or fluorescence-activated cell sorting (FACS).

[0153] In certain embodiments, the action module and / or targeting module of a liver-specific Wnt signaling-enhancing molecule are polypeptides, while in other embodiments, the action module and / or targeting module of a liver-specific Wnt signaling molecule are small organic molecules. In certain embodiments, both the action module and the targeting module are polypeptides, e.g., antibodies or their antigen-binding fragments. In certain embodiments, the action module and targeting module of a liver-specific Wnt signaling-enhancing molecule are covalently bonded to each other. In certain embodiments, the action module and targeting module of a liver-specific Wnt signaling-enhancing fusion molecule are non-covalently bonded to each other. In certain embodiments, the action module and targeting module of a liver-specific Wnt signaling-enhancing molecule reside within the same fusion protein. In other embodiments, the action module resides within a first polypeptide further comprising a first binding domain, and the targeting module resides within a second polypeptide further comprising a second binding domain, with the first and second binding domains bonded to each other. In some embodiments, the first and second binding domains are the same or variants thereof, e.g., Fc polypeptide. In some embodiments, the first and second binding domains are different from each other. In certain embodiments, the present invention includes the use of a fragment or variant of either the targeting module or the action module described herein, which includes a functional fragment or variant of the reference molecule.

[0154] In certain embodiments, the liver-specific Wnt signal-enhancing molecule (e.g., a fusion protein) has a formula selected from R1-L-R2 and R2-L-R1, where R1 is an action module that binds to ZNRF3 / RNF43, R2 is a targeting module that binds to a liver-specific cell surface receptor, and L is a linker, which may or may not be present. Each of R1 and R2 may be any of the diverse action modules and targeting modules described herein. Each of R1 and R2 may be any portion that can bind to one or more E3 ligases (ZNRF3 or RNF43) or targeted tissues or cells. For example, each of R1 and R2 may be, but is not limited to, a polypeptide (e.g., an antibody or its antigen-binding fragment, or a peptide or polypeptide different from an antibody), a small molecule, and a native ligand or its variant, fragment, or derivative. In certain embodiments, the native ligand may be a polypeptide, a small molecule, an ion, an amino acid, a lipid, or a sugar molecule. The action module and the targeting module (i.e., R1 and R2) may be of the same type or of different types. In certain embodiments, R2 is an antibody or its antigen-binding fragment, and in certain embodiments, R2 comprises an Fc protein or an analogue thereof.

[0155] In certain embodiments, the liver-specific Wnt signal-enhancing molecule comprises a single molecule (e.g., a polypeptide), while in other embodiments, the Wnt signal-enhancing fusion molecule comprises two or more molecules (e.g., polypeptides) that are linked to each other, for example, non-covalently. For example, in one embodiment, the liver-specific Wnt signal-enhancing fusion comprises two molecules having the formulas R3-L1 and R4-L2, respectively, where R3 is the action module, R4 is the targeting module, and the L1 and L2 groups are linked to each other to form, for example, a dimer. In various embodiments, the L1 and L2 groups may be the same or different from each other. Examples of L1 or L2 groups are Fc sequences, e.g., mouse Fc2b or human Fc1, each of which is known in the art. Each of R3 and R4 may be one of the various action modules and targeting modules described herein. Each of R3 and R4 may be any portion that can bind to one or more E3 ligases (ZNRF3 and / or RNF43) or to one or more targeted tissues or cells.

[0156] In certain embodiments, the liver-specific Wnt signal-enhancing molecule comprises an antibody or a binding fragment thereof that binds to one or more E3 ligases (ZNRF3 and / or RNF43), wherein the antibody heavy chain and / or antibody light chain include additional binding domains that bind to targeted tissue or cells.

[0157] In certain embodiments, the liver-specific Wnt signal-enhancing molecule comprises an antibody or one or more binding fragments thereof that bind to a targeted tissue or cell, wherein the antibody heavy chain and / or antibody light chain includes an additional binding domain that binds to one or more E3 ligases (ZNRF3 and / or RNF43). The additional binding domain may be directly fused to the N-terminus or C-terminus of the antibody, for example, as a heavy-chain or light-chain fusion protein, or it may be added to the heavy-chain or light chain, for example, at the N-terminus, C-terminus, or internal amino acids of the heavy-chain or light chain, via a linker moiety. In certain embodiments, the antibody is IgG, for example, IgG1 or IgG2. In certain embodiments, the liver-specific Wnt signal-enhancing molecule comprises four polypeptides, each containing two antibody light chains and two antibody heavy chains, wherein one or more of the antibody heavy chains and / or antibody light chains further include an additional binding domain that binds to one or more E3 ligases (ZNRF3 and / or RNF43), such as the Rspo2 variant disclosed herein. In certain embodiments, the additional binding domain is linked to one or both of the antibody heavy chain and / or antibody light chain (or its binding fragment) via a linker, for example, any of those disclosed herein. In certain embodiments, two antibody heavy chains are linked by one or more disulfide bonds, and each of the antibody light chains is linked to a different antibody heavy chain by one or more disulfide bonds. In certain embodiments, each of the light chains in the antibody-like Wnt signal-enhancing molecule is the same. In certain embodiments, each of the heavy chains in the antibody-like Wnt signal-enhancing molecule is the same. In certain embodiments, each of the light chains in the antibody-like Wnt signal-enhancing molecule is different. In certain embodiments, each of the heavy chains in the antibody-like Wnt signal-enhancing molecule is different. In certain embodiments, the Wnt signal-enhancing molecule comprises two different light chains and / or two different heavy chains, each binding to a different liver-specific cell surface molecule. In certain embodiments, the Wnt signal-enhancing molecule comprises two different light chains and / or two different heavy chains, each binding to a different E3 ligase. In various embodiments, the binding domain is added to either the heavy chain or the light chain.In certain embodiments, the liver-specific Wnt signal-enhancing molecule comprises two antibody light chains and two antibody heavy chains of an antibody that specifically binds to a liver-specific cell surface molecule, e.g., ASGR1 or ASGR2, with binding domains that bind to one or more E3 ligases (ZNRF3 and / or RNF43) added to the N-terminuses of the two antibody heavy chains. In certain embodiments, the binding domains that bind to one or more E3 ligases are Rspo or a fragment or variant thereof. In certain embodiments, Rspo has at least 90%, at least 95%, at least 98%, or at least 99% sequence identity to any one of SEQ ID NOs. 29-32 or SEQ ID NOs. 47-50 or a fragment thereof. In certain embodiments, the liver-specific Wnt signaling-enhancing molecule comprises two heavy-chain fusion proteins and two light-chain fusion proteins disclosed in Table A, for example, the liver-specific Wnt signaling-enhancing molecule is 1R34-DDNN / RA, 8M24-v1, 1R34-EEST / EE, 1R34-EEST / RA, 1R34-EEAT / EE, 8M24 Humanized 1, 8M24 Humanized 2, 8M24-EASE-RA, 8M24-EASE-EE, or 1R34-DDNN / RA.

[0158] In certain embodiments, a liver-specific Wnt signaling-enhancing molecule, or a pharmaceutically acceptable salt thereof, comprises a first domain that specifically binds to one or more transmembrane E3 ubiquitin ligases selected from zinc and ring finger 3 (ZNRF3) and ring finger protein 43 (RNF43), and a second domain that specifically binds to asial glycoprotein receptor 1 (ASGR1). (a) The first domain comprises a modified R-spongin polypeptide, or a fragment or variant thereof, (b) The second domain comprises a modified antibody or its antigen-binding fragment containing the CDRH1, CDRH2 and CDRH3 sequences and the CDRL1, CDRL2 and CDRL3 sequences.

[0159] In certain embodiments, the second domain comprises two modified antibody light chains and two modified antibody heavy chains, and the first domain is added to the N-terminus of each antibody heavy chain. Thus, in certain embodiments, the Wnt signal-enhancing molecule comprises two modified antibody light chains derived from an antibody that binds to ASGR1 and two fusion proteins, each fusion protein comprising a modified antibody heavy chain derived from an antibody that binds to ASGR1, with an R-spongin polypeptide (or a fragment thereof) fused to its N-terminus, optionally via a linker moiety. In certain embodiments, the R-spongin polypeptide is a modified R-spongin polypeptide, e.g., a modified Rspo-2 polypeptide comprising one or more amino acid modifications compared to wild-type human Rspo-2.

[0160] In certain embodiments, the modified R-spongin polypeptide or a fragment or variant thereof contains amino acid substitutions at positions corresponding to amino acids F105 and F109 of human R-spongin 2. In certain embodiments, the two amino acid substitutions include (a) F105R, F105A, or F105E, and (b) F109A or F109E. In certain embodiments, the two amino acid substitutions are (a) F105R and F109A, (b) F105A and F109A, (c) F105E and F109A, or (d) F105E and F109E. In certain embodiments, the modified R-spongin polypeptide or a fragment or variant thereof has at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% sequence identity to any of the following: [ka]

[0161] In certain embodiments, a modified antibody heavy chain derived from an antibody bound to ASGR1 is fused to a modified R-spongin polypeptide via a linker moiety comprising one of those disclosed herein. In certain embodiments, the linker moiety is a peptidyl linker comprising or having the following sequence: GGGGSGGGGSGGGGS (SEQ ID NO: 62).

[0162] In certain embodiments, the modified heavy chain variable region includes a sequence having at least 90% or at least 95% identity with any one of SEQ ID NOs: 2, 4, 6, 8, 10, 12, 13, 14, 15, 16, 20, 22, 24, 26, 28, 33, or 51. In certain embodiments, the modified light chain variable region includes a sequence having at least 90% or at least 95% identity with any one of SEQ ID NOs: 1, 3, 5, 7, 9, 11, 14, 17, 18, 19, 21, 23, 25, or 27. In certain embodiments, amino acid modifications, such as insertions, deletions, or substitutions, are not present in the CDR. In certain embodiments, amino acid modifications are not made in either (a) F105R, F105A, or F105E, and / or (b) F109A or F109E.

[0163] In certain embodiments, the modified heavy chain includes a sequence or fragment thereof that has at least 90% or at least 95% identity to any one of SEQ ID NOs: 2, 6, 8, 10, 12, 22, 26, or 33, including the heavy chain sequence or the heavy chain variable domain sequence (e.g., without RSPO2 and the linker sequence). In certain embodiments, the modified light chain includes a sequence that has at least 90% or at least 95% identity to any one of SEQ ID NOs: 1, 5, 7, 9, 11, 21, or 25. In certain embodiments, amino acid modifications, e.g., insertions, deletions, or substitutions, are not present in the CDR. In certain embodiments, amino acid modifications are not made in either (a) F105R, F105A, or F105E and / or (b) F109A or F109E. In certain embodiments, the heavy chain variant includes N297G. In certain embodiments, the RPOS2 sequence present in the variant includes F105R and F109A substitutions. In certain embodiments, the RPOS2 sequence present in the variant includes F105E and F109E substitutions. In certain embodiments, the molecule includes amino acid substitutions compared to the parent or wild type for any of the following constructs: EEST / EE, EEST / RA, EEAT / EE, EESN / RA, EEAN / RA, 8M24-EAASE-RA, or 8M24-EASE-EE.

[0164] In certain embodiments, each of the two fusion polypeptides contains a sequence having at least 95% identity with any one of sequence numbers 2, 4, 6, 8, 10, 12, 13, 14, 15, 16, 20, 22, 24, 26, 28, 33, or 51.

[0165] In certain embodiments, the modified heavy chain and light chain sequences are derived from an anti-ASGR1 antibody containing the following heavy chain and light chain sequences, or have at least 90%, at least 95%, at least 98%, or at least 99% identity to the following heavy chain and light chain sequences (indicated by underlining in the CDR): Light chain: [ka] and Heavy chain: [ka]

[0166] In certain embodiments, the light chain includes amino acid substitutions at one or more amino acid positions selected from D25, N51, and N88 (shown in bold above). In certain embodiments, all three positions are substituted. In certain embodiments, D25 is substituted with E. In certain embodiments, N51 is substituted with S or A. In certain embodiments, N88 is substituted with T. In one embodiment, D25 is substituted with E, N51 is substituted with S, and N88 is substituted with T (EST). In one embodiment, D25 is substituted with E, N51 is substituted with A, and N88 is substituted with T (EAT). In certain embodiments, any of the Wnt signal-enhancing molecules disclosed herein includes a light chain variable domain having at least 90%, at least 95%, at least 98%, or at least 99% identity with respect to the variable domain of SEQ ID NO: 1, and optionally further comprising an amino acid substitution at one or more amino acid positions selected from D25, N51, and N88, which includes any of the substitutions disclosed above.

[0167] In certain embodiments, the heavy chain includes an amino acid substitution at D62 (shown in bold above). In certain embodiments, D62 is substituted with E (E). In certain embodiments, any of the Wnt signal-enhancing molecules disclosed herein includes a heavy chain variable domain having at least 90%, at least 95%, at least 98%, or at least 99% identity with the variable domain of SEQ ID NO: 33, and optionally further including an amino acid substitution at D62, which includes any of the substitutions disclosed above.

[0168] In certain embodiments, the modified antibody moiety of the molecule (or its variable domain) includes the following combination of amino acid substitutions: (a) in the heavy chain, D62 is substituted with E; and (b) in the light chain, D25 is substituted with E, N51 is substituted with S, and N88 is substituted with T (EEST). In certain embodiments, the modified antibody moiety of the molecule (or its variable domain) includes the following combination of amino acid substitutions: (a) in the heavy chain, D62 is substituted with E; and (b) in the light chain, D25 is substituted with E, N51 is substituted with A, and N88 is substituted with T (EEAT).

[0169] Therefore, in a particular embodiment, the modified anti-ASGR1 antibody portion of the molecule includes one of the following combinations of CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, and CDRL3 sequences: (a) SYAMS (SEQ ID NO: 34), AISGSGGSTYYEDSVKG (SEQ ID NO: 35), DFSSRRWYLEY (SEQ ID NO: 36), QGESLRSYYAS (SEQ ID NO: 37), YGKSNRPS (SEQ ID NO: 38), and CTSLERIGYLSYV (SEQ ID NO: 39); or (b) SYAMS (SEQ ID NO: 34), AISGSGGSTYYEDSVKG (SEQ ID NO: 35), DFSSRRWYLEY (SEQ ID NO: 36), QGESLRSYYAS (SEQ ID NO: 37), YGKANRPS (SEQ ID NO: 40), and CTSLERIGYLSYV (SEQ ID NO: 39), respectively.

[0170] In certain embodiments, the modified anti-ASGR1 antibody moiety of the molecule includes VH and VL domains containing any of these combinations of CDRs in relation to the parent sequence, or variants thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% identity to the VH or VL domain. In certain embodiments, none of the variants disclosed herein include any further amino acid modifications (other than those described herein) to their CDR sequences.

[0171] In certain embodiments, the two antibody light chain polypeptides include sequences having at least 95% identity with respect to one of SEQ ID NOs: 1, 5, 7, 9, 11, 21, or 25 or their variable region.

[0172] In a particular embodiment, the two antibody light chain polypeptides include sequences having at least 95% identity with SEQ ID NO: 1 or its variable region, and each of the two fusion polypeptides includes sequences having at least 95% identity with SEQ ID NO: 2 or its variable region.

[0173] In a particular embodiment, the two antibody light chain polypeptides include sequences having at least 95% identity with SEQ ID NO: 7 or its variable region, and each of the two fusion polypeptides includes sequences having at least 95% identity with SEQ ID NO: 8 or its variable region.

[0174] In a particular embodiment, the two antibody light chain polypeptides include sequences having at least 95% identity with SEQ ID NO: 7 or its variable region, and each of the two fusion polypeptides includes sequences having at least 95% identity with SEQ ID NO: 10 or its variable region.

[0175] In a particular embodiment, the two antibody light chain polypeptides include sequences having at least 95% identity with SEQ ID NO: 11 or its variable region, and each of the two fusion polypeptides includes sequences having at least 95% identity with SEQ ID NO: 12 or its variable region.

[0176] In certain embodiments, each of the two fusion polypeptides contains a sequence having at least 95% identity with respect to one of sequence numbers 2, 4, 6, 8, 10, 12, 13, 14, 15, 16, 20, 22, 24, 26, 28, 33, or 51 or its variable region.

[0177] In certain embodiments, the modified heavy chain and light chain sequences are derived from the 8M24 anti-ASGR1 antibody containing the following heavy chain and light chain sequences, or have at least 90%, at least 95%, at least 98%, or at least 99% identity to the following heavy chain and light chain sequences (indicated by underlining in the CDR): Light chain: [ka] Heavy chain: [ka]

[0178] In certain embodiments, the light chain includes an amino acid substitution at amino acid position D56 (shown in bold above). In certain embodiments, D56 is substituted with E, S, or A. In certain embodiments, D56 is substituted with E (E). In certain embodiments, any of the Wnt signal-enhancing molecules disclosed herein includes a light chain variable domain having at least 90%, at least 95%, at least 98%, or at least 99% identity with the variable domain of SEQ ID NO: 5, and optionally further including an amino acid substitution at D56, including any of the substitutions disclosed above.

[0179] In certain embodiments, the heavy chain includes amino acid substitutions at one or more amino acid positions selected from N31, N57, or D102 (shown in bold above). In certain embodiments, all three positions are substituted. In certain embodiments, N31 is substituted with A or Q. In certain embodiments, N57 is substituted with S, A, or N. In certain embodiments, D102 is substituted with E, S, or A. In one embodiment, N31 is substituted with A, N57 is substituted with S, and D102 is substituted with E (ASE). In certain embodiments, N31 is substituted with A, N57 is substituted with S, D102 is substituted with E, and D110 is not substituted (ASED). In certain embodiments, any of the Wnt signal-enhancing molecules disclosed herein includes a heavy chain variable domain having at least 90%, at least 95%, at least 98%, or at least 99% identity with respect to any one of SEQ ID NOs: 20, 22, or 51, and optionally further comprising an amino acid substitution at one or more amino acid positions selected from N31, N57, or D102, which includes any of the substitutions disclosed above.

[0180] In certain embodiments, the modified antibody moiety of the molecule includes the following combination of amino acid substitutions: (a) in the light chain, D56 is substituted with E; and (b) in the heavy chain, N31 is substituted with A, N57 is substituted with S, D102 is substituted with E, and D110 is left unsubstituted (EASE).

[0181] Therefore, in a particular embodiment, the modified anti-ASGR1 antibody portion of the molecule includes the following combinations of CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, and CDRL3 sequences: (c) RISENIYSNLA (SEQ ID NO: 41), AAINLAE (SEQ ID NO: 42), QHFWGTPFT (SEQ ID NO: 43), AYGIN (SEQ ID NO: 44), EIFPRSDSTFYNEKFKG (SEQ ID NO: 45), and KGREYGTSHYFDY (SEQ ID NO: 46), respectively.

[0182] In certain embodiments, the modified anti-ASGR1 antibody moiety of the molecule includes VH and VL domains containing any of these combinations of CDRs in relation to the parent sequence, or variants thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% identity to the VH or VL domain. In certain embodiments, none of the variants contain any further amino acid modifications (other than those described herein) to their CDR sequences.

[0183] In certain embodiments, two antibody light chain polypeptides or their variable domains include a sequence having at least 90% or at least 95% identity with one of SEQ ID NOs: 3, 5, 14, 17, 18, 19, 21, or 25 or its variable region. In certain embodiments, each of two fusion polypeptides or antibody heavy chain polypeptides or their variable domains includes a sequence having at least 90% or at least 95% identity with one of SEQ ID NOs: 4, 6, 13, 15, 16, 20, 22, or 26 or its variable region. In certain embodiments, each of the two antibody light chain polypeptides includes a sequence having at least 95% identity with SEQ ID NO: 25 or its variable region, and each of the two fusion polypeptides includes a sequence having at least 95% identity with SEQ ID NO: 26 or its variable region.

[0184] In a particular embodiment, the light chain polypeptide is arranged as follows: [ka] Here, the CDR sequence is underlined), and in a particular embodiment, the heavy chain fusion polypeptide includes the sequence: [ka] (Here, the Rspo2 domain is italicized, the linker is in bold, and the CDR sequence is underlined.) In related embodiments, the R and A shown in bold are replaced with E and E.

[0185] It is understood that Wnt signal-enhancing molecules may include diverse combinations of action modules and targeting modules. Therefore, any variant anti-ASGR1 antibody sequence (or fragment thereof) may be combined with a variety of other action modules, including but not limited to those disclosed herein.

[0186] This disclosure further provides polypeptides comprising any of the light chains or fusion polypeptides disclosed herein, polypeptides comprising sequences having at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% sequence identity to any of the light chains or fusion polypeptides disclosed herein, and functional or binding fragments thereof, such as VH or VL domains. Those skilled in the art can readily determine the light chain regions of any of the polypeptides disclosed herein based on the information provided in this sequence listing and by comparing these sequences with other sequences disclosed herein.

[0187] In certain embodiments, a liver-specific Wnt signaling-enhancing molecule (e.g., a fusion protein) increases Wnt signaling in liver tissue or hepatocytes that come into contact with the fusion protein. In certain embodiments, Wnt signaling in liver tissue or hepatocytes is increased by at least 50%, at least 2-fold, at least 3-fold, at least 4-fold, at least 5-fold, or at least 10-fold.

[0188] Liver-specific Wnt signal-enhancing molecules can be produced by standard methods of organic synthesis and molecular biology known and available in the art. For example, liver-specific Wnt signal-enhancing fusion proteins can be generated by fusing a target module (e.g., an antibody or its antigen-binding fragment that binds to ASGR1 or ASGR2) to an action module (e.g., human R-spondin 2 furin domain 1 alone, corresponding to amino acid residues N37-R95, or human R-spondin 2 furin domain 1 followed by furin domain 2, in which case the interaction of furin domain 2 with the LGR protein is disabled or impaired individually or jointly by point mutations, e.g., F105A and F109A). In certain embodiments, the targeting module and the action module are fused by a linker, e.g., a glycine-serine linker, with either domain located at the N-terminus of the liver-specific Wnt signal-enhancing molecule. In certain embodiments, the targeting module and the action module are fused by a protein linker (e.g., albumin). Further methods for "fusing" the targeting module with the action module include, for example, "knob-in-hole" or leucine zipper-mediated dimerization. The DNA sequences encoding the targeting module, the action module (and optionally the linker) can be genetically engineered to encode the desired fusion protein.

[0189] For liver-specific Wnt signal-enhancing molecules and their domains (e.g., fusion molecules, antibody heavy chains, and light chains), DNA sequences encoding different portions of the fusion protein can be inserted into bacterial or eukaryotic expression vectors using standard molecular cloning techniques and expressed in suitable host cells. The expressed proteins can be uniformly purified using standard protein science techniques such as affinity, ion exchange, and size exclusion chromatography. This disclosure also includes functional fragments or variants of any of the polypeptide action modules, targeting modules, and fusion proteins described herein, including variants having at least 50%, at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% polypeptide sequence identity to any of the action modules, targeting modules, or fusion proteins described herein. Such variants may include one or more amino acid modifications, e.g., one or more amino acid deletions, insertions, or substitutions, compared to any of the sequences disclosed herein. In certain embodiments, functional fragments and variants of liver-specific Wnt signal-enhancing fusion proteins have at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 100%, or higher Wnt signal-enhancing activity compared to the liver-specific Wnt signal-enhancing fusion proteins from which they are derived. In certain embodiments, functional fragments and variants of polypeptide action modules have at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 100%, or higher Wnt signal-enhancing activity (when measured against the entire liver-specific Wnt signal-enhancing molecule) compared to the action modules from which they are derived.In certain embodiments, functional fragments and variants of the targeting module have at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 100%, or higher binding activity compared to the targeting module from which they are derived.

[0190] This disclosure also includes polynucleotides or nucleic acid sequences encoding one or more liver-specific Wnt signal-enhancing molecules or their components, such as proteins, fusion proteins, or variants thereof, as well as vectors containing these polynucleotides, including expression vectors, and cells containing these vectors. In certain embodiments, the polynucleotide or nucleic acid sequence is DNA or RNA. In certain embodiments, the RNA is messenger RNA (mRNA). In certain embodiments, the RNA is modified mRNA comprising one or more modified nucleosides. Modified mRNA comprising one or more modified nucleosides is described to have advantages over unmodified mRNA, including increased stability, higher expression levels, and reduced immunogenicity. Non-limiting examples of modified mRNA that may be used in accordance with the present invention include, for example, PCT Patent Application Publication Nos. WO2011 / 130624, WO2012 / 138453, WO2013052523, WO2013151666, WO2013 / 071047, WO2013 / 078199, WO2012045075, WO2014081507, WO2014093924, WO2014164253, and U.S. Patent No. 8,278,036 (Pseudo-Uridogen). The following are described in U.S. Patent No. 8,691,966 (which describes modified mRNA containing pseudouridine and / or N1-methylpsoiduridine), U.S. Patent No. 8,835,108 (which describes modified mRNA containing 5-methylcytidine), and U.S. Patent No. 8,748,089 (which describes modified mRNA containing pseudouridine or 1-methylpsoiduridine). In certain embodiments, the modified mRNA sequence encoding the liver-specific Wnt signal-enhancing polypeptide contains at least one modification compared to the unmodified A, G, U, or C ribonucleoside. In certain embodiments, at least one modified nucleoside contains N1-methylpsoiduridine and / or 5-methylcytidine.In certain embodiments, the modified mRNA includes a 5' terminal cap sequence, followed by a sequence encoding a liver-specific Wnt signal-enhancing polypeptide, followed by a 3' tailing sequence, such as a poly-A or poly-AG sequence.

[0191] In certain embodiments, the polynucleotide is a vector, e.g., an expression vector, which comprises a polynucleotide sequence encoding a liver-specific Wnt signal-enhancing fusion molecule described herein (e.g., a fusion protein, or one or both strands of an appended antibody) operably linked to a promoter sequence, e.g., a promoter sequence that drives the expression of the polynucleotide in a cell. In certain embodiments, the vector is a viral vector, e.g., a virus comprising a polynucleotide comprising an expression cassette containing a promoter operably linked to a DNA or RNA sequence encoding a liver-specific Wnt signal-enhancing polypeptide. In certain embodiments, the expression cassette comprises a 5' and / or 3' cell or viral UTR, or a derivative thereof.

[0192] This disclosure also includes functional fragments and variants of the polynucleotides described herein, including variants having at least 50%, at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% polynucleotide sequence identity with respect to the polynucleotides described herein. Such variants may include one or more nucleotide or nucleoside modifications compared to any of the sequences disclosed herein, e.g., one or more nucleotide deletions, insertions, or substitutions. In certain embodiments, the polynucleotides described herein are codon-optimized, for example, to enhance the expression of the encoded polypeptide in a host cell. In certain embodiments, the polynucleotide variant includes one or more modified nucleotides or nucleosides.

[0193] This disclosure also includes cells containing a liver-specific Wnt signal-enhancing molecule described herein, such as a fusion protein, or a polynucleotide or vector encoding a portion or domain thereof. In certain embodiments, the cell is a host cell, such as HEK293 cells which can be used to produce a liver-specific Wnt signal-enhancing fusion protein. Any host cell can be used when preparing the composition, including but not limited to mammalian cells (e.g., 293 cells), insect cells (e.g., SF9 cells), microorganisms, and yeast. In certain embodiments, the cell is heterologous or self-related to the subject to be treated with the liver-specific Wnt signal-enhancing polypeptide described herein. In certain embodiments, the cell is obtained from the subject and transduced with a viral vector described herein. In certain embodiments, the transduced cell is delivered to the subject for treatment.

[0194] The disclosure also includes pharmaceutical compositions comprising one or more liver-specific Wnt signaling-enhancing molecules (e.g., fusion proteins or antibody-based constructs), or one or more polynucleotides or vectors comprising a sequence or portion thereof encoding a liver-specific Wnt signaling-enhancing molecule.

[0195] Wnt signaling can be measured using techniques and assays known and available in the art. In certain embodiments, the increase in Wnt signaling is determined using a cell line corresponding to a target tissue or cell type. In certain embodiments, the cell line contains a reporter plasmid having a marker gene (e.g., a luciferase gene) under the control of a Wnt signal-responsive promoter. The enhanced reporter activity of cells in response to Wnt3a, Wnt3a-conditioned medium, a recombinant source of Wnt3a, or a Wnt-mimicking agonist can be determined by adding either furin domain 1 alone (or together with furin domain 2 having F105A and / or F109A point mutations) as a negative control, or functional R-spongin (full length or furin domains 1 and 2) as a positive control. Reporter activity in response to liver-specific Wnt signal-enhancing molecules can also be determined by contacting the reporter cell line with tissue-specific Wnt signal-enhancing molecules. Negative controls may be substantially, significantly, or completely negative for reporter activity, and liver-specific Wnt signaling-enhancing molecules and positive controls should show an increase in Wnt signaling response as an increase in reporter activity. Further controls may include anti-ASGR1 antibody alone (negative), a fusion protein in which an anti-GFP antibody is used instead of the anti-ASGR1 antibody (negative), and intact furin-domain 1-furin-domain 2 protein (positive). The tissue specificity of liver-specific Wnt signaling-enhancing molecules can be determined by similarly measuring reporter activity in response to treatment with liver-specific Wnt signaling-enhancing molecules in cell types or tissues other than the targeted ones. In certain embodiments, reporter activity is higher in targeted tissues bound with liver-specific Wnt signaling-enhancing molecules compared to untargeted tissues, e.g., at least 50%, at least 2x, at least 3x, at least 4x, at least 5x, or at least 10x higher.

[0196] In certain embodiments, the liver-specific Wnt signal-enhancing polypeptide comprises any combination of action modules and targeting modules, including any combination of either the action module or the targeting module described herein. In certain embodiments, they are joined by a linker, e.g., albumin (e.g., human serum albumin), a peptidyl linker, or a non-peptidyl linker, in which case the targeting and action modules are located on the N and C terminals of the linker, e.g., Fc or albumin, a peptidyl linker, or a non-peptidyl linker.

[0197] Liver-specific Wnt signaling-enhancing molecules can also be conjugated to parts known in the field to enhance their stability in vivo, such as polyethylene glycol (PEG), Fc, and albumin.

[0198] An example of a liver-specific Wnt signaling-enhancing molecule is a Wnt signaling-enhancing polypeptide comprising an action module containing a variant or fragment of R-spongin (e.g., human R-spongin 2) with reduced ability to enhance Wnt signaling, and a targeting module that specifically binds to ASGR1, ASGR2, TFR2, or SLC10A1. This tissue-specific Wnt signaling-enhancing polypeptide may be used to increase Wnt signaling in liver tissue and treat liver tissue diseases or conditions.

[0199] Exemplary, non-limiting examples of liver-specific Wnt signal-enhancing molecules include those described in the accompanying examples and sequences. In certain embodiments, the liver-specific Wnt signal-enhancing molecule comprises two or more polypeptide sequences disclosed herein, for example, in the form of additional IgG or antibody. Polypeptides disclosed herein include, but are not limited to, polypeptides comprising or comprising sequences having at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% identity to any of the sequences shown herein, as well as their fragments and variants. In certain embodiments, the polypeptide comprises an action module or a targeting module present within any of the sequences shown herein, as well as their fragments and variants. In certain embodiments, the polypeptide has activity as an action module and / or a targeting module.

[0200] Exemplary, non-limiting examples of polynucleotides disclosed herein include any of the polypeptides, variants, and fragments described herein, including those described above. In certain embodiments, the polynucleotide encodes a polypeptide having activity as a functional domain and / or a targeting module. Pharmaceutical composition

[0201] Also disclosed herein are pharmaceutical compositions comprising a liver-specific Wnt signal-enhancing molecule or antibody or an antigen-binding fragment thereof described herein, and one or more pharmaceutically acceptable diluents, carriers, or excipients. In certain embodiments, the Wnt signal-enhancing molecule is selected from any of those disclosed herein or comprises any of the polypeptide sequences disclosed herein, for example, a Wnt signal-enhancing molecule called EEST-EE, EEST-RA, EEAT-EE, or 8M24 EASE-EE or 8M24 EASE-RA.

[0202] In a further embodiment, a pharmaceutical composition is also disclosed that includes a polynucleotide comprising a nucleic acid sequence encoding a liver-specific Wnt signaling enhancing molecule or an antibody or an antigen-binding fragment thereof described herein, and one or more pharmaceutically acceptable diluents, carriers or excipients. In certain embodiments, the polynucleotide is DNA or mRNA, such as modified mRNA. In certain embodiments, the polynucleotide is modified mRNA that further comprises a 5' cap sequence and / or a 3' tailing sequence, such as a polyA tail. In other embodiments, the polynucleotide is an expression cassette comprising a promoter operably linked to the coding sequence.

[0203] In a further embodiment, a pharmaceutical composition is also disclosed that includes an expression vector, such as a viral vector, comprising a polynucleotide comprising a nucleic acid sequence encoding a liver-specific Wnt signaling enhancing molecule or an antibody or an antigen-binding fragment thereof described herein, and one or more pharmaceutically acceptable diluents, carriers or excipients.

[0204] The present invention also contemplates a pharmaceutical composition that includes a cell comprising an expression vector comprising a polynucleotide comprising a promoter operably linked to a nucleic acid encoding a liver-specific Wnt signaling enhancing molecule or an antibody or an antigen-binding fragment thereof described herein, and one or more pharmaceutically acceptable diluents, carriers or excipients. In certain embodiments, the cell is a heterologous cell or an autologous cell obtained from the subject to be treated. In certain embodiments, the cell is a stem cell, such as an adipose-derived stem cell or a hematopoietic stem cell.

[0205] The target molecules can be combined with pharmaceutically acceptable carriers, diluents, and reagents that are useful in preparing formulations containing excipients that are generally safe, non-toxic, and desirable, and permissible for use in mammals, such as humans or primates. Such excipients may be solids, liquids, semi-solids, or, in the case of aerosol compositions, gases. Examples of such carriers or diluents include, but are not limited to, water, saline solution, Ringer's solution, dextrose solution, and 5% human serum albumin. Complementary active compounds may also be incorporated into the formulations. The solutions or suspensions used in the formulation may include sterile diluents, such as water for injection, saline solution, non-volatile oils, polyethylene glycol, glycerin, propylene glycol, or other synthetic solvents; antibacterial compounds, such as benzyl alcohol or methylparaben; antioxidants, such as ascorbic acid or sodium bisulfite; chelate compounds, such as ethylenediaminetetraacetic acid (EDTA); buffers, such as acetic acid, citric acid, or phosphoric acid; detergents, such as Tween® 20 for preventing aggregation; and compounds for adjusting osmotic pressure, such as sodium chloride or dextrose. The pH may be adjusted with an acid or base, such as hydrochloric acid or sodium hydroxide. In certain embodiments, the pharmaceutical composition is sterile.

[0206] The pharmaceutical composition may further comprise a sterile aqueous solution or dispersion, and a sterile powder for the immediate preparation of a sterile injectable solution or dispersion. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water or phosphate buffered saline (PBS). In some cases, the composition must be fluid to the extent that easy syringability exists. In certain embodiments, this is stable under the conditions of manufacture and storage and is protected against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be, for example, a solvent or dispersion medium including water, ethanol, polyols (such as glycerol, propylene glycol and liquid polyethylene glycol, etc.), and suitable mixtures thereof. Suitable fluidity can be maintained, for example, by coating, such as the use of lecithin, by maintaining the required particle size in the case of a dispersion, and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, such as parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, etc. In many cases, it is preferable to include in the composition isotonic agents, such as sugars, polyalcohols, such as mannitol, sorbitol, sodium chloride. Prolonged absorption of the internal composition can be brought about by including in the composition agents that delay absorption, such as aluminum monostearate and gelatin.

[0207] The sterile solution can be prepared by incorporating the liver-specific Wnt signal enhancing molecule in the required amount in a suitable solvent together with one or a combination of the ingredients listed above, and then, if necessary, filtering and sterilizing it aseptically. Generally, the dispersion is prepared by incorporating the active compound in a sterile vehicle containing the basic dispersion medium and the other required ingredients from those listed above. In the case of a sterile powder for the preparation of a sterile injectable solution, the method of preparation is vacuum drying and lyophilization, which yields a powder of the active ingredient plus any further desired ingredients from its pre-sterile filtered solution.

[0208] In one embodiment, pharmaceutical compositions such as controlled-release formulations containing implants and microencapsulated delivery systems are prepared using a carrier that protects the fusion protein against rapid elimination from the body. Biodegradable, biocompatible polymers, such as ethylene vinyl acetate, polyacid anhydride, polyglycolic acid, collagen, polyorthoesters, and polylactic acid, may be used. Methods for preparing such formulations are apparent to those skilled in the art. These materials can also be commercially available. Liposome suspensions can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art.

[0209] For ease of administration and uniformity of dosage, it may be advantageous to formulate pharmaceutical compositions in dosage units. When used herein, a dosage unit refers to a physically distinct unit suitable as a unit dosage for the subject being treated; each unit contains a predetermined amount of the active compound calculated to produce the desired therapeutic effect in relation to the required pharmaceutical carrier. The specifications for the dosage unit forms of this invention are determined and directly depend on the unique characteristics of the active compound, the specific therapeutic effect to be achieved, and the inherent limitations in the field of creating such active compounds for the treatment of an individual.

[0210] The pharmaceutical composition may be contained in a container, pack, or dispenser, such as a syringe, such as a pre-filled syringe, along with instructions for administration.

[0211] The pharmaceutical compositions of the present invention include any pharmaceutically acceptable salts, esters, or salts of such esters, or any other compounds capable of providing (directly or indirectly) a biologically active liver-specific Wnt signaling-enhancing molecule when administered to animals, including humans.

[0212] The present invention comprises pharmaceutically acceptable salts of liver-specific Wnt signaling-enhancing molecules described herein. The term “pharmaceutically acceptable salt” means a physiologically and pharmaceutically acceptable salt of the compound of the present invention: i.e., a salt that retains the desired biological activity of the parent compound and does not impart any undesirable toxicological effects thereto. Various pharmaceutically acceptable salts are known in the art and are described, for example, in “Remington's Pharmaceutical Sciences,” 17th edition, Alfonso R. Gennaro (Ed.), Mark Publishing Company, Easton, PA, USA, 1985 (and more recent editions), “Encyclopaedia of Pharmaceutical Technology,” 3rd edition, James Swarbrick (Ed.), Informa Healthcare USA (Inc.), NY, USA, 2007, and J. Pharm. Sci. 66: 2 (1977). For an overview of appropriate salts, see "Handbook of Pharmaceutical Salts: Properties, Selection, and Use," Stahl and Wermuth (Wiley-VCH, 2002).

[0213] Pharmacopoecitable base addition salts are formed with metals or amines, such as alkali metals and alkaline earth metals or organic amines. Metals used as cations include sodium, potassium, magnesium, and calcium. Amines include N-N'-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, dicyclohexylamine, ethylenediamine, N-methylglucamine, and procaine (see, e.g., Berge et al., "Pharmaceutical Salts", J. Pharma Sci., 1977, 66, 119). Base addition salts of the above acidic compounds are prepared by contacting the free acid form with a sufficient amount of the desired base to produce a salt in the conventional manner. The free acid form can be regenerated by contacting the salt form with the acid and isolating the free acid in the conventional manner. The free acid forms differ somewhat from their respective salt forms in certain physical properties, such as solubility in polar solvents; however, in other respects, the salts are equivalent to their respective free acids for the purposes of this invention.

[0214] In some embodiments, the pharmaceutical compositions provided herein contain a therapeutically effective amount of the liver-specific Wnt signal-enhancing molecule described herein, in mixture with pharmaceutically acceptable carriers, diluents and / or excipients, such as saline, phosphate-buffered saline, phosphates and amino acids, polymers, polyols, sugars, buffers, preservatives and other proteins. Exemplary amino acids, polymers and sugars include octylphenoxypolyethoxyethanol compounds, polyethylene glycol monostearate compounds, polyoxyethylene sorbitan fatty acid esters, sucrose, fructose, dextrose, maltose, glucose, mannitol, dextran, sorbitol, inositol, galactitol, xylitol, lactose, trehalose, bovine or human serum albumin, citrate, acetate, Ringer's and Hanks' solutions, cysteine, arginine, carnitine, alanine, glycine, lysine, valine, leucine, polyvinylpyrrolidone, polyethylene and glycols. Preferably, this formulation is stable at 4°C for at least 6 months.

[0215] In some embodiments, the pharmaceutical compositions provided herein include buffers, such as phosphate-buffered saline (PBS) or sodium phosphate / sodium sulfate, Tris buffer, glycine buffer, sterile water, and other buffers known to those skilled in the art, such as those described by Good et al. (1966) Biochemistry 5:467. The pH of the buffer may be in the range of 6.5 to 7.75, preferably 7 to 7.5, and most preferably 7.2 to 7.4. Methods for increasing Wnt activity or Wnt receptor cell surface expression

[0216] Wnt signaling can be increased in liver tissue or hepatocytes using liver-specific Wnt signaling-enhancing molecules exemplified herein with respect to fusion proteins. In certain embodiments, the Wnt signaling is standard Wnt signaling. Accordingly, in certain embodiments, the present invention provides a method for increasing or enhancing Wnt signaling in liver tissue or hepatocytes, comprising the step of contacting liver tissue or cells with an effective amount of a liver-specific Wnt signaling-enhancing molecule disclosed herein, wherein the molecule includes a targeting module that binds to cell surface receptors on the target tissue or cell in a tissue-specific or cell-specific manner. In certain embodiments, the Wnt signaling-enhancing molecule is selected from any of those disclosed herein or includes any of the polypeptide sequences disclosed herein, for example, a Wnt signaling-enhancing molecule called EEST-EE, EEST-RA, EEAT-EE, or 8M24 EASE-EE or 8M24 EASE-RA. In certain embodiments, the Wnt signaling-enhancing molecule is EEST-EE. In certain embodiments, the Wnt signaling-enhancing molecule is 8M24 EASE-EE or 8M2 EASE-RA. In some embodiments, the contact step is performed in vitro, ex vivo, or in vivo, and, for example, a liver-specific Wnt signaling-enhancing molecule of the subject is administered to or provided to the subject. In certain embodiments, the cells are cultured cells, and the contact step is performed in vitro.

[0217] In related embodiments, the present invention provides a method for enhancing Wnt signaling in liver tissue or hepatocytes, comprising the step of contacting liver tissue or cells with an effective amount of one or more polynucleotides comprising a nucleic acid sequence encoding a liver-specific Wnt signaling-enhancing molecule disclosed herein, wherein the molecule comprises a targeting module that binds to a cell surface receptor on the target tissue or cell in a tissue-specific or cell-specific manner. In certain embodiments, the Wnt signaling-enhancing molecule is selected from any of those disclosed herein or comprises any of the polypeptide sequences disclosed herein, for example, a Wnt signaling-enhancing molecule called EEST-EE, EEST-RA, EEAT-EE, or 8M24 EASE-EE or 8M24 EASE-RA. In certain embodiments, the polynucleotide is DNA or mRNA, for example, modified mRNA. In certain embodiments, the Wnt signaling-enhancing molecule is EEST-EE. In certain embodiments, the Wnt signaling-enhancing molecule is 8M24 EASE-EE or 8M2 EASE-RA. In certain embodiments, the polynucleotide is a modified mRNA further comprising a 5' cap sequence and / or a 3' tailing sequence, e.g., a poly-A tail. In other embodiments, the polynucleotide is an expression cassette comprising a promoter operably ligated to the coding sequence.

[0218] In related embodiments, the present invention provides a method for increasing or enhancing Wnt signaling in liver tissue or cells, comprising the step of contacting target tissue or cells with an effective amount of one or more vectors comprising a nucleic acid sequence encoding a liver-specific Wnt signaling-enhancing molecule disclosed herein, wherein the molecule comprises a targeting module that binds to cell surface receptors on liver tissue or cells in a liver-specific manner. In certain embodiments, the Wnt signaling-enhancing molecule is selected from any of those disclosed herein or comprises any of the polypeptide sequences disclosed herein, for example, a Wnt signaling-enhancing molecule called EEST-EE, EEST-RA, EEAT-EE, or 8M24 EASE-EE or 8M24 EASE-RA. In certain embodiments, the Wnt signaling-enhancing molecule is EEST-EE. In certain embodiments, the Wnt signaling-enhancing molecule is 8M24 EASE-EE or 8M2 EASE-RA. In certain embodiments, the vector is an expression vector and may include a promoter operably ligated to the nucleic acid sequence. In certain embodiments, the vector is a viral vector.

[0219] In related embodiments, the present invention provides a method for increasing or enhancing Wnt signaling in liver tissue or cells, comprising the step of contacting target tissue with an effective amount of cells containing one or more nucleic acid sequences encoding the liver-specific Wnt signaling-enhancing molecules of the present invention, wherein the molecules include a targeting module that binds to cell surface receptors on liver tissue or cells in a liver-specific manner. In certain embodiments, the Wnt signaling-enhancing molecule is selected from any of those disclosed herein or includes any of the polypeptide sequences disclosed herein, for example, a Wnt signaling-enhancing molecule called EEST-EE, EEST-RA, EEAT-EE, or 8M24 EASE-EE or 8M24 EASE-RA. In certain embodiments, the Wnt signaling-enhancing molecule is EEST-EE. In certain embodiments, the Wnt signaling-enhancing molecule is 8M24 EASE-EE or 8M2 EASE-RA. In certain embodiments, cells are transduced with a vector containing an expression cassette encoding the liver-specific Wnt signaling-enhancing molecule. In certain embodiments, the cells are stem cells, for example, adipose-derived stem cells or hematopoietic stem cells.

[0220] The number of Frizzled (Fz) receptors on the surface of targeted cells, such as liver tissue cells, can also be increased using any of the methods described herein for increasing Wnt signaling. In certain embodiments, the number of Fz receptors on the surface of targeted cells is increased by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least twofold, at least fivefold, or at least tenfold. In certain embodiments, the Fz receptors include one or more of the human frizzled proteins Fz1, Fz2, Fz3, Fz4, Fz5, Fz6, Fz7, Fz8, Fz9, and Fz10. For example, the present disclosure provides a method for increasing Fz receptors on the surface of liver cells, comprising the step of contacting the liver cells with an effective amount of a liver-specific Wnt signaling-enhancing molecule disclosed herein, wherein the molecule includes a targeting module that binds to cell surface receptors on liver tissue or cells in a liver-specific manner. In certain embodiments, the targeting module is bound to ASGR1 or ASGR2. In certain embodiments, the targeting module comprises an antibody or its antigen-binding fragment disclosed herein. In certain embodiments, the Wnt signal-enhancing molecule is selected from any of those disclosed herein or comprises any of the polypeptide sequences disclosed herein, for example, a Wnt signal-enhancing molecule called EEST-EE, EEST-RA, EEAT-EE, or 8M24 EASE-EE or 8M24 EASE-RA. In certain embodiments, the Wnt signal-enhancing molecule is EEST-EE. In certain embodiments, the Wnt signal-enhancing molecule is 8M24 EASE-EE or 8M2 EASE-RA. In some embodiments, the contacting step is performed in vitro, ex vivo, or in vivo, for example, by administering or providing a liver-specific Wnt signal-enhancing molecule to a subject. In certain embodiments, the cells are cultured cells, and the contacting step is performed in vitro.In one particular embodiment, liver cells or tissue are first brought into direct contact with the Wnt signaling-enhancing molecule, while in other relevant embodiments, liver tissue or cells are first brought into contact with a polynucleotide encoding the Wnt signaling-enhancing molecule, for example, an expression vector, thereby causing the cells to take up the polynucleotide and express the Wnt signaling-enhancing molecule.

[0221] It is also possible to increase Ki-67 on liver tissue or hepatocytes using any of the methods described herein for increasing Wnt signaling. Methods for treating diseases and disorders

[0222] The liver-specific Wnt signaling-enhancing molecules exemplified herein with respect to fusion proteins may be used to treat diseases, disorders, or conditions by, for example, increasing Wnt signaling in targeted liver cells, tissues, or organs. Accordingly, in some embodiments, the present invention provides a method for treating a disease or condition, for example, a disease or disorder associated with reduced Wnt signaling, or a disease or disorder in which increased Wnt signaling provides a therapeutic benefit, in a subject requiring such treatment, the method comprising the step of contacting the subject with an effective amount of the composition of the present disclosure. In certain embodiments, the composition is a pharmaceutical composition comprising any of the following: a liver-specific Wnt signaling-enhancing molecule, for example, a small molecule or polypeptide; one or more polynucleotides containing a nucleic acid sequence encoding the liver-specific Wnt signaling-enhancing molecule, for example, DNA or mRNA, optionally modified mRNA; one or more vectors containing a nucleic acid sequence encoding the liver-specific Wnt signaling-enhancing molecule, for example, an expression vector or viral vector; or cells containing one or more nucleic acid sequences encoding the liver-specific Wnt signaling-enhancing molecule, for example, cells transduced with an expression vector or viral vector encoding the liver-specific Wnt signaling-enhancing molecule. In certain embodiments, the Wnt signal-enhancing molecule is selected from any of those disclosed herein or comprises any of the polypeptide sequences disclosed herein, for example, a Wnt signal-enhancing molecule called EEST-EE, EEST-RA, EEAT-EE, or 8M24 EASE-EE or 8M24 EASE-RA. In certain embodiments, the Wnt signal-enhancing molecule is EEST-EE. In certain embodiments, the Wnt signal-enhancing molecule is 8M24 EASE-EE or 8M2 EASE-RA. In certain embodiments, the disease or condition is a pathological disease or disorder, or an injury, for example, an injury resulting from a wound. In certain embodiments, the wound may be the result of another therapeutic treatment. In certain embodiments, the disease or condition includes or benefits from damaged tissue repair, healing, or regeneration.In some embodiments, the contact step is performed in vivo, i.e., the composition of interest is administered to the subject.

[0223] In related embodiments, the present invention provides a method for treating a disease or condition, for example, a disease or disorder associated with reduced Wnt signaling, or a disease or disorder in which increased Wnt signaling would provide a therapeutic benefit, comprising the steps of: administering a pharmaceutical composition containing an effective amount of the liver-specific Wnt signaling-enhancing molecule of the present invention to a subject requiring administration, or contacting a subject requiring contact with a pharmaceutical composition containing an effective amount of the liver-specific Wnt signaling-enhancing molecule of the present invention, wherein the molecule includes a targeting module that binds to cell surface receptors on target tissue or cells in a tissue-specific or cell-specific manner. In certain embodiments, the Wnt signaling-enhancing molecule is selected from any of those disclosed herein or includes any of the polypeptide sequences disclosed herein, for example, a Wnt signaling-enhancing molecule called EEST-EE, EEST-RA, EEAT-EE, or 8M24 EASE-EE or 8M24 EASE-RA. In certain embodiments, the Wnt signaling-enhancing molecule is EEST-EE. In certain embodiments, the Wnt signaling-enhancing molecule is 8M24 EASE-EE or 8M2 EASE-RA.

[0224] In related embodiments, the present invention provides a method for treating a disease or condition, for example, a disease or disorder associated with reduced Wnt signaling, or a disease or disorder in which increased Wnt signaling would provide a therapeutic benefit, comprising the steps of: administering to a subject requiring administration a pharmaceutical composition comprising an effective amount of one or more polynucleotides comprising a nucleic acid sequence encoding the liver-specific Wnt signaling-enhancing molecule of the present invention; or contacting a subject requiring contact with a pharmaceutical composition comprising an effective amount of the liver-specific Wnt signaling-enhancing molecule of the present invention, wherein the molecule comprises a targeting module that binds to cell surface receptors on a target tissue or cell in a tissue-specific or cell-specific manner. In particular embodiments, the Wnt signaling-enhancing molecule is selected from any of those disclosed herein or comprises any of the polypeptide sequences disclosed herein, for example, a Wnt signaling-enhancing molecule called EEST-EE, EEST-RA, EEAT-EE, or 8M24 EASE-EE or 8M24 EASE-RA. In particular embodiments, the Wnt signaling-enhancing molecule is EEST-EE. In certain embodiments, the Wnt signal-enhancing molecule is 8M24 EASE-EE or 8M2 EASE-RA.

[0225] In related embodiments, the present invention provides a method for treating a disease or condition, for example, a disease or disorder associated with reduced Wnt signaling, or a disease or disorder in which increased Wnt signaling would provide a therapeutic benefit, comprising the steps of contacting a subject with a pharmaceutical composition comprising an effective amount of one or more vectors comprising nucleic acid sequences encoding the liver-specific Wnt signaling enhancing molecule of the present invention, wherein the molecule comprises a targeting module that binds to cell surface receptors on target tissue or cells in a tissue-specific or cell-specific manner. In certain embodiments, the Wnt signaling enhancing molecule is selected from any of those disclosed herein or comprises any of the polypeptide sequences disclosed herein, for example, a Wnt signaling enhancing molecule called EEST-EE, EEST-RA, EEAT-EE, or 8M24 EASE-EE or 8M24 EASE-RA. In certain embodiments, the Wnt signaling enhancing molecule is EEST-EE. In certain embodiments, the Wnt signaling enhancing molecule is 8M24 EASE-EE or 8M2 EASE-RA.

[0226] In related aspects, the present invention provides a method for treating a disease or condition, such as a disease or disorder associated with reduced Wnt signaling, or a disease or disorder in which an increase in Wnt signaling would provide a therapeutic benefit, the method comprising contacting a subject in need of administration with a pharmaceutical composition comprising an effective amount of a cell comprising one or more nucleic acid sequences encoding a liver-specific Wnt signal enhancing molecule of the present invention, the method comprising contacting the subject in need of administration with a pharmaceutical composition comprising an effective amount of a liver-specific Wnt signal enhancing molecule of the present invention, the molecule comprising a targeting module that binds in a tissue-specific or cell-specific manner to a cell surface receptor on a target tissue or cell. In certain embodiments, the cell is a stem cell, such as an adipose-derived stem cell or a hematopoietic stem cell. In certain embodiments, the Wnt signal enhancing molecule is selected from any of those disclosed herein, or comprises any of the polypeptide sequences disclosed herein, such as a Wnt signal enhancing molecule designated EEST-EE, EEST-RA, EEAT-EE or 8M24 EASE-EE or 8M24 EASE-RA. In certain embodiments, the Wnt signal enhancing molecule is EEST-EE. In certain embodiments, the Wnt signal enhancing molecule is 8M24 EASE-EE or 8M2 EASE-RA.

[0227] Wnt signaling plays a crucial role in developmental processes and the maintenance of stem cells. Reactivation of Wnt signaling is associated with the regeneration and repair of most tissues after injury and disease. Liver-specific Wnt signaling-enhancing molecules may offer healing and tissue repair benefits in response to liver injury and disease. Causes of liver tissue damage and loss include, but are not limited to, aging, degeneration, genetic conditions, infection and inflammation, traumatic injury, toxin / metabolism-induced toxicity, or other pathological conditions. Wnt signaling and Wnt signaling enhancers have been shown to activate adult tissue-resident stem cells. In some embodiments, the compounds of the present invention are administered for use in treating affected or damaged liver tissue, for use in liver tissue regeneration, for use in liver cell growth and proliferation, and / or for use in liver tissue manipulation.

[0228] Human diseases associated with mutations in the Wnt pathway provide strong evidence for the enhancement of Wnt signaling in the treatment and prevention of these diseases. Preclinical in vivo and in vitro studies provide further evidence of the involvement of Wnt signaling in many disease conditions, further supporting the use of liver-specific Wnt signaling-enhancing molecules in various human diseases. For example, the compositions of the present invention may also be used in the enhanced regeneration of liver cells, e.g., liver regeneration, treatment of cirrhosis, enhancement of liver transplantation, treatment of acute liver failure, chronic liver disease due to or after hepatitis (type A, B, or C) virus infection or antiviral drug therapy, alcoholic liver disease, e.g., alcoholic hepatitis, e.g., acute or severe alcoholic hepatitis, non-alcoholic liver disease with steatohepatitis or fatty liver disease. The compositions of the present invention can treat diseases and disorders in which regenerative liver tissue or cell growth is desired, without limitation. In certain embodiments, the composition is used to treat, for example, acute exacerbation of chronic liver failure (ACLF), acute liver decompensation, ascites due to cirrhosis, hyponatremia in patients with cirrhosis, hepatorenal syndrome-acute kidney injury (HRS-AKI), or hepatic encephalopathy. In certain embodiments, the composition comprises a Wnt signaling-enhancing molecule, selected from any of those disclosed herein or any of the polypeptide sequences disclosed herein, for example, a Wnt signaling-enhancing molecule called EEST-EE, EEST-RA, EEAT-EE, or 8M24 EASE-EE or 8M24 EASE-RA. In certain embodiments, the Wnt signaling-enhancing molecule is EEST-EE. In certain embodiments, the Wnt signaling-enhancing molecule is 8M24 EASE-EE or 8M2 EASE-RA. In certain embodiments, the Wnt signaling-enhancing molecule is EEST-EE. In certain embodiments, the Wnt signaling-enhancing molecule is 8M24 EASE-EE or 8M2 EASE-RA. In certain embodiments, the method is used to treat alcoholic hepatitis, for example, acute alcoholic hepatitis or severe alcoholic hepatitis, and the Wnt signaling-enhancing molecule is EEST-EE, and in certain embodiments, the Wnt signaling-enhancing molecule is administered intravenously.In certain embodiments, the method is used to treat alcoholic hepatitis, for example, acute alcoholic hepatitis or severe alcoholic hepatitis, and the Wnt signaling-enhancing molecule is 8M24 EASE-EE or 8M2 EASE-RA, and in certain embodiments, the Wnt signaling-enhancing molecule is administered intravenously.

[0229] Certain populations of proliferative cells for homeostatic regeneration of hepatocytes, such as Axyn 2-positive cells in the pericentral region, have been identified through lineage follow-up studies. Lineage follow-up studies have also identified further potential hepatic progenitor cells, including but not limited to Lgr-positive cells. Self-regenerating hepatocytes, as well as other populations of potential progenitor cells, including Lgr5-positive and Axyn 2-positive cells, have been identified as capable of regenerating after injury in response to Wnt signaling and / or R-spondin. Numerous preclinical models of acute liver injury and hepatic failure, as well as chronic liver disease, have shown hepatocyte recovery and regeneration that benefit from enhancing Wnt signaling. In certain embodiments, the compositions of the present invention are, for example, used for acute liver failure of any cause, drug-induced acute liver failure, acute exacerbation of chronic liver failure (ACLF), acute liver decompensation, ascites due to cirrhosis, hyponatremia in patients with cirrhosis, hepatorenal syndrome - acute kidney injury (HRS-AKI), hepatic encephalopathy, alcoholic liver disease, chronic liver failure of any cause, decompensated liver failure, late compensated liver failure, cirrhosis, hepatic fibrosis of any cause, portal hypertension, chronic liver dysfunction of any cause, end-stage liver disease (ESLD), non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD) (fatty liver), alcoholic hepatitis, acute alcoholic hepatitis (AAH), chronic alcoholic hepatitis, alcoholic liver disease (ALD) (alcohol-related liver disease) It can be used to treat hepatitis C virus (HCV)-induced liver disease, hepatitis B virus (HBV)-induced liver disease, other viral hepatitis (e.g., hepatitis A virus (HAV)-induced liver disease and hepatitis D virus (HDV)-induced liver disease), primary biliary cirrhosis, autoimmune hepatitis, liver surgery, liver injury, veno-occlusive disease (VOD), sinusoidal obstructive syndrome (SOS), primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), liver transplantation, liver surgery and "undergraft" syndrome in transplantation, congenital liver disease and disorder, hepatic failure due to APAP (acetaminophen) overdose, and any other liver disease or disorder resulting from genetic disorders, degeneration, aging, drugs or injury. They can also be used to enhance hepatocyte regeneration in vivo or in vitro.In certain embodiments, the method results in increased hepatocyte regeneration, improved liver function, and / or decreased fibrosis. The method for regenerating liver tissue benefits from the administration of the compounds of the present invention, which may be systemic or localized. These include, but are not limited to, methods of systemic administration and methods of localized administration, such as by injection into liver tissue, by injection into veins or blood vessels leading to the liver, or by implantation of a sustained-release formulation. In certain embodiments, the composition comprises a Wnt signaling-enhancing molecule, selected from any of those disclosed herein or comprising any of the polypeptide sequences disclosed herein, for example, a Wnt signaling-enhancing molecule called EEST-EE, EEST-RA, EEAT-EE, or 8M24 EASE-EE or 8M24 EASE-RA. In certain embodiments, the Wnt signaling-enhancing molecule is EEST-EE. In certain embodiments, the Wnt signaling-enhancing molecule is 8M24 EASE-EE or 8M2 EASE-RA.

[0230] In certain embodiments, the liver-specific Wnt signaling-enhancing molecules disclosed herein are used to treat, inhibit, or prevent alcoholic hepatitis (AH), also known as acute alcoholic hepatitis (AAH), or severe alcoholic hepatitis (AAH), which is a severe form of alcohol-related liver disease with significant short-term mortality. Alcoholic hepatitis typically develops after more than 10 years of heavy, daily alcohol consumption, with one study showing an average consumption of 100 g / day (equivalent to 10 drinks per day). Typical patients present with a recent onset of jaundice, ascites, and proximal muscle weakness. Fever and leukocytosis are also common, but should prompt evaluation for infection, particularly spontaneous bacterial peritonitis. Liver biopsies of these patients show fatty liver, hypertrophied hepatocytes containing eosinophilic inclusions (Mallory bodies), and marked neutrophil inflammatory cell infiltration. Because the clinical diagnosis is accurate, biopsy is rarely necessary, and therefore, the diagnosis relies instead on the clinical and laboratory features. Acute alcoholic hepatitis (AH) is a severe form of acute decompensation of alcoholic liver disease (ALD) that develops in heavy drinkers and is characterized by jaundice, malaise, loss of appetite, hepatomegaly with tenderness, and the rapid onset of features of systemic inflammatory response syndrome (SIRS). Severe or acute alcoholic hepatitis (AH) is a fulminant form of disease with a very high 180-day mortality rate and generally requires hospitalization. It can present as an acute exacerbation of chronic liver failure, and the prognosis is worse if infection is present and the grade of liver disease severity is higher. Patients may have a recent history of heavy alcohol consumption within 3 months of the presentation of jaundice and a characteristic pattern of elevated liver enzymes, as well as other potential symptoms, such as itching and / or fever, associated with coagulation abnormalities, hepatic encephalopathy, variceal bleeding, and sepsis, leading to extrahepatic organ failure. In certain embodiments, the liver-specific Wnt signal-enhancing molecule is selected from any of those disclosed herein or includes any of the polypeptide sequences disclosed herein, for example, a Wnt signal-enhancing molecule called EEST-EE, EEST-RA, EEAT-EE, or 8M24 EASE-EE or 8M24 EASE-RA. In certain embodiments, the Wnt signal-enhancing molecule is EEST-EE.In certain embodiments, the Wnt signaling-enhancing molecule is 8M24 EASE-EE or 8M2 EASE-RA. In certain embodiments, it is administered intravenously. In certain embodiments, the method results in increased hepatocyte regeneration, improved liver function, and / or reduced fibrosis.

[0231] The compositions of the present invention may be used to treat end-stage liver disease (ESLD). ESLD, or chronic liver failure, is often a result of severe cirrhosis and the resulting hepatic fibrosis. ESLD manifests itself with the development of ascites, variceal bleeding, hepatic encephalopathy, and / or hepatic dysfunction (e.g., decompensated liver disease). Common diseases or disorders associated with ESLD include alcoholic hepatitis, chronic hepatitis C infection, chronic hepatitis B infection, chronic hepatitis D infection, non-alcoholic fatty liver disease (NAFLD) (including non-alcoholic steatoheptitis (NASH)), and genetic disorders such as cystic fibrosis, alpha-1 antitrypsin deficiency, hemochromatosis, Wilson's disease, galactosemia, and glycogen storage disease. Long-term exposure to drugs, toxic chemicals, parasitic infections, and frequent heart failure with hepatic congestion can also lead to ESLD. In certain embodiments, the composition comprises a Wnt signal-enhancing molecule, selected from any of those disclosed herein or any of the polypeptide sequences disclosed herein, for example, a Wnt signal-enhancing molecule called EEST-EE, EEST-RA, EEAT-EE, or 8M24 EASE-EE or 8M24 EASE-RA. In certain embodiments, the Wnt signal-enhancing molecule is EEST-EE. In certain embodiments, the Wnt signal-enhancing molecule is 8M24 EASE-EE or 8M2 EASE-RA. In certain embodiments, it is administered intravenously. In certain embodiments, the method results in increased hepatocyte regeneration, improved liver function, and / or reduced fibrosis.

[0232] In certain embodiments, the composition is administered parenterally, for example, intravenously, or orally, rectally, or by injection. In some embodiments, the pharmaceutical composition is administered topically, for example, externally or intramuscularly. In some embodiments, the composition is administered to a target tissue, for example, the liver. The methods of the present invention may be carried out in vivo or ex vivo. In some embodiments, the step of contacting target cells or tissue with a liver-specific Wnt signaling-enhancing molecule is carried out ex vivo, accompanied by subsequent implantation of cells or tissue, for example, activated stem cells or progenitor cells, into the subject. Those skilled in the art can determine the appropriate site and route of administration based on the disease or disorder being treated. Methods of administration include, but are not limited to, systemic administration methods and localized administration methods, such as by injection into liver tissue, by injection into a vein or blood vessel leading to the liver, or by implantation of a sustained-release formulation.

[0233] Dosage and dosage regimens may depend on various factors readily determined by the physician, such as the nature of the disease or disorder, the characteristics of the subject, and the subject's medical history. In certain embodiments, the amount of liver-specific Wnt signaling-enhancing molecule, e.g., fusion protein, administered or provided to the subject is in the range of about 0.01 mg to about 50 mg, 0.1 mg to about 500 mg, or about 0.1 mg to about 50 mg per kg of the subject's body weight.

[0234] In certain embodiments, the subject may be any mammal, such as humans, rodents (e.g., mice, rats, gerbils), rabbits, felines, canids, goats, sheep, pigs, equids, bovines, or primates.

[0235] In some embodiments, the method produces a therapeutic benefit, such as inhibiting or preventing the development of a disorder, halting the progression of liver disease or disorder, or reversing the progression of liver disease or disorder. In some embodiments, the method increases hepatocyte regeneration, enhances liver function, and / or reduces hepatic fibrosis. In some embodiments, the method includes a step of detecting that a therapeutic benefit has been achieved. Those skilled in the art will understand that such measures of therapeutic effectiveness are applicable to specific diseases or disorders being modified and will recognize appropriate detection methods to be used to measure therapeutic effectiveness.

[0236] In certain embodiments, the Disclosure provides a method for treating or preventing a disease or disorder associated with reduced Wnt signaling, such as any of the diseases or disorders disclosed herein that would benefit from liver regeneration, or a disease or disorder that would benefit from increased Wnt signaling activity in liver tissue, comprising the step of providing a subject in need of such treatment or prevention of a Wnt signaling-enhancing molecule comprising a targeted module that binds to liver tissue, for example, a targeted module that specifically binds to ASGR1, wherein the Wnt signaling-enhancing molecule increases or enhances Wnt signaling in the liver tissue of the subject. In certain embodiments, the composition comprises a Wnt signaling-enhancing molecule, selected from any of those disclosed herein or any of the polypeptide sequences disclosed herein, for example, a Wnt signaling-enhancing molecule called EEST-EE, EEST-RA, EEAT-EE, or 8M24 EASE-EE or 8M24 EASE-RA. In certain embodiments, the Wnt signaling-enhancing molecule is EEST-EE. In certain embodiments, the Wnt signaling-enhancing molecule is 8M24 EASE-EE or 8M2 EASE-RA. In certain embodiments, the pharmaceutical composition is administered orally or systemically, for example, parenterally. In certain embodiments, the Wnt signal-enhancing molecule comprises an action module comprising an R-spongin furin domain 1 or a fragment or variant thereof, and optionally a mutant furin domain 2 or a fragment or variant thereof. Methods for producing or maintaining liver cells, tissues, and organoids

[0237] Other embodiments relate in part to the use of molecules disclosed herein to promote or enhance the growth or proliferation of liver cells, liver tissue, and organoids by contacting liver cells, liver tissue, or liver organoids with one or more Wnt signaling-enhancing molecules disclosed herein, e.g., 1R34-EEST-EE, 8M24-EASE-EE, or 8M24-EASE-RA. In certain embodiments, the Wnt signaling-enhancing molecule is EEST-EE. In certain embodiments, the Wnt signaling-enhancing molecule is 8M24 EASE-EE or 8M2 EASE-RA. In certain embodiments, the method may be used to enhance the growth or proliferation of liver cells, liver tissue, or liver organoids, or to maintain or increase their viability. In certain embodiments, liver cells, liver tissue, or liver organoids are contacted ex vivo, in vitro, or in vivo. The method disclosed herein may be used, for example, to generate cells, tissues, or organoids for therapeutic use, which are transplanted or grafted into a subject. These can also be used to generate and / or maintain liver cells, tissues, or organoids for research use. Wnt signaling-enhancing molecules have broad applications in non-therapeutic methods, such as in vitro research methods.

[0238] In certain embodiments, liver tissue is brought into contact with a Wnt signaling-enhancing molecule to maintain the viability of the liver tissue. In certain embodiments, the liver tissue is donor liver tissue to be transplanted into a recipient requiring transplantation. In certain embodiments, the donor liver tissue is perfused in vivo with a solution containing the Wnt signaling-enhancing molecule disclosed herein, for example, before the liver tissue is removed from the donor. In certain embodiments, the donor liver tissue is perfused ex vivo with a solution containing the Wnt signaling-enhancing molecule disclosed herein, for example, during storage or during transport from the donor to the recipient. In certain embodiments, liver tissue brought into contact with the Wnt signaling-enhancing molecule remains viable for transplantation at least 10%, at least 20%, at least 50%, or at least 100% longer than if it were not brought into contact with the Wnt signaling-enhancing molecule.

[0239] In certain embodiments, liver organoid cultures are generated, grown, or maintained by contacting them with one or more Wnt signaling molecules disclosed herein. In certain embodiments, the Wnt signaling-enhancing molecules are present in the culture medium used to grow or maintain the liver organoid tissue.

[0240] All of the above-mentioned U.S. patents, U.S. patent application publications, U.S. patent applications, foreign patents, foreign patent applications, and non-patent publications mentioned herein and / or listed in the application data sheets are incorporated herein by reference in their entirety.

[0241] As stated above, specific embodiments of the present invention are described herein for illustrative purposes, but it will be understood that various modifications can be made without departing from the spirit and scope of the invention. Therefore, the present invention is not limited to those provided for by the appended claims. [Examples]

[0242] The following examples are provided to those skilled in the art to provide a complete disclosure and explanation of the methods of preparation and use of the present invention, and are not intended to limit the scope of what the inventors consider to be their invention, nor to indicate that the following experiments are all or only experiments to be performed. While efforts have been made to be accurate with respect to the numbers used (e.g., quantity, temperature, etc.), some experimental error and deviation should be taken into consideration. Unless otherwise indicated, parts are parts by weight, molecular weight is the weight-average molecular weight, temperature is the temperature in degrees Celsius, and pressure is atmospheric pressure or approximately atmospheric pressure.

[0243] Common methods in molecular biology, cell biology, and biochemistry are described in “Molecular Cloning: A Laboratory Manual, 3rd Ed.” (Sambrook et al., Harbor Laboratory Press 2001); “Short Protocols in Molecular Biology, 4th Ed.” (Ausubel et al. eds., John Wiley & Sons 1999); “Protein Methods” (Bollag et al., John Wiley & Sons 1996); “Nonviral Vectors for Gene Therapy” (Wagner et al. eds., Academic Press 1999); “Viral Vectors” (Kaplift & Loewy eds., Academic Press 1995); “Immunology Methods Manual” (I. Lefkovits ed., Academic Press 1997); and “Cell and Tissue Culture: Laboratory Procedures in Biotechnology” (Doyle & Griffiths, John Wiley & Sons These disclosures can be found in standard textbooks such as the 1998 edition, and these disclosures are incorporated herein by reference. The reagents, cloning vectors, and kits for genetic manipulation referred to herein are available from commercial suppliers, e.g., BioRad, Stratagene, Invitrogen, Sigma-Aldrich, and ClonTech.

[0244] The materials and methods used in the following examples include the following:

[0245] Protein Products: Unless otherwise specified, all recombinant proteins were produced in Expi293F cells (Thermo Fisher Scientific) by transient transfection. All IgG-based and Fc-containing constructs were purified using CaptivA Protein A affinity resin (Repligen) and eluted with 0.1M glycine pH 3.3. All proteins were further polished by size exclusion chromatography (SEC) using 1×HBS buffer (20mM HEPES pH 7.4, 150mM NaCl) or 2×HBS buffer (40mM HEPES pH 7.4, 300mM NaCl) on a Superdex 200 Increase 10 / 300 GL (GE Healthcare Life Sciences). Proteins were supplemented with glycerol up to 10% for long-term storage at -80°C. All tested proteins were examined by SDS-polyacrylamide electrophoresis and estimated to be at least 90% pure.

[0246] SuperTop Flash (STF) assay: Wnt signaling activity was measured using a cell line containing a luciferase gene regulated by a Wnt-responsive promoter, as reported (Janda et al., 2017; Nature 545:234). S uper T op F Lash Reporter Assay (STF). Briefly, cells were seeded at a density of 10,000 cells per well in 96-well plates 24 hours prior to treatment, and then treated overnight with either RSPO or a mimetic protein, either alone or together with 100 pM WNT3A surrogate, R2M3-26. Cells were lysed with Luciferase Cell Culture Lysis Reagent (Promega), and activity was measured using the supplier-suggested procedure with the Luciferase Assay System (Promega). Using Prism (GraphPad Software), data were plotted as mean- / + standard deviation of triplicate measurements and fitted by nonlinear regression.

[0247] Semi-quantitative PCR analysis of gene expression: RNA from mouse tissue (liver and small intestine samples) using MagMAX (商標) mirVana (商標) Extraction was performed using the Total RNA Isolation Kit (ThermoFisher, A27828). High-Capacity cDNA Reverse Transcription Kit (ThermoFisher, 43-688-14) or SuperScript. (商標) IV VILO (商標) cDNA was produced using Master Mix (ThermoFisher, catalog number 11756050). Mouse Axin2 and Ki67 mRNA expression was controlled using TaqMan. (登録商標) Fast Advanced Master Mix (ThermoFisher, 4444963) and Mm00443610_m1 Axin2, Mm01278617_m1 Ki67, Mm01300555_g1 wnt1, Mm00470018_m1 wnt2, Mm00437336_m1 wnt3, Mm01194003_m1 wnt4, Mm00437347_m1 wnt5a, Mm01183986_m1 wnt5b, Mm00437353_m1 wnt6, Mm00437356_m1 wnt7a, Mm01301717_m1 wnt7b, Mm01157914_g1 wnt8a, Mm00457102_m1 Measurements were taken using the wnt9b, Mm00442104_m1, wnt10b, Mm00437327_g1, wnt11, Mm00446420_m1, wnt16, Mm00507077_m1 rspo1, Mm00555790_m1 rspo2, Mm01188251_m1 rspo3, and Mm00615419_m1 rspo4 probes (ThermoFisher, 4331182). Values ​​were normalized to constitutive actin B gene expression using the Mm02619580_g1 probe (ThermoFisher, 4351368).

[0248] Multiple specificity assays: ELISA was used to investigate the binding of non-target antigens, including human insulin (Sigma 91077C-100MG), keyhole limpet hemocyanin (KLH) (Sigma H7017-50MG), lipopolysaccharide (LPS) from E. coli (Sigma L3012-10MG), double-stranded DNA (dsDNA) (Sigma D1626-5G), and heparin. Prior to use, dsDNA was sheared to 200–200 bp using sonication. (登録商標) 96-well EIA / RIA Easy Wash (商標) Clear Flat Bottom Polystyrene High Bind Microplates (Corning 3369) were coated overnight at 4°C with 50 μl of KLH, LPS, and dsDNA in PBS at 10 mg / ml. Insulin was coated at 5 mg / ml. Heparin-coated plates were purchased (Thermo Scientific C995X60). Coated plates were blocked at room temperature for 1 hour with 300 μl of 300 SuperBlock (Thermo 37516), and then probed at room temperature for 1 hour (or overnight at 4°C) with 100 μl of the target protein (antibody or fusion) at 1000, 250, 125, and 62.5 mg / ml. Anti-hFc-HRP (Jackson IR 109-035-098) was used for detection and chemiluminescent quantification.

[0249] Protein thermal stability assay: Protein thermal stability was measured using an Uncle instrument (Unchained Labs). The reaction was carried out by adding the protein sample in 1×HBS buffer to the unit, then sealing it with a silicone seal and sealing it in a frame. Fluorescence readings at UV266nm and Blue473nm were measured while increasing the temperature by 1°C per minute in the temperature range of 15°C to 95°C. Tm / Tagg was obtained using Uncle data analysis software.

[0250] Mouse Study: Six-week-old C57Bl / 6J male mice were obtained from Jackson Laboratories (Bar Harbor, ME, USA) and housed in groups. All animal experiments followed the standards of the "Guide for the Care and Use of Laboratory Animals" developed by the National Academy of Sciences. The animal experiment protocols were approved by the Surrozen Institutional Animal Care and Use Committee. Mice were acclimatized for a minimum of two days before the start of the experiment. Mice had access to purified laboratory-grade acidic water without restriction and were fed continuously (2018 Teklad global 18% protein rodent diet). Mice were housed in a 12 / 12-hour day-night cycle at 30%–70% humidity and room temperature ranging from 20°C to 26°C.

[0251] When humanizing mice for human ASGR gene expression, each mouse is given 1 × 10⁶ 11 A copy of the ssAAV8-CAG-hASGR1 genome (Vector Biolabs, Malvern, PA) was administered intravenously on day 0. On day 7, mice were intraperitoneally injected with αGFP, Fc-RSPO2-WT, αGFP-RSPO2-RA, or αASGR1-RSPO2-RA. At the indicated time after protein administration, mice were anesthetized with isoflurane and blood was collected by cardiac puncture. A portion of the left hepatic lobe and duodenum were collected for analysis.

[0252] Semi-quantitative PCR analysis of gene expression in CCl4 research: RNA from mouse tissue (liver sample) using MagMAX (商標) mirVana (商標)cDNA was extracted using the Total RNA Isolation Kit (ThermoFisher, A27828). cDNA was then extracted using the High-Capacity cDNA Reverse Transcription Kit (ThermoFisher, 43-688-14) or SuperScript. (商標) IV VILO (商標) Mouse mRNA expression was produced using Master Mix (ThermoFisher, catalog number 11756050). (登録商標) Measurements were performed using Fast Advanced Master Mix (ThermoFisher, 4444963) and Mm00443610_ml Axin2, Mm00432359_m1 Ccnd1, and Mm01278617_ml Mki67. Values ​​were normalized to constitutive actin B gene expression using the Mm02619580_gl probe (ThermoFisher, 4351368).

[0253] Serum Chemistry: Blood was collected from the tail end on day 7 and by cardiac puncture during sacrifice on day 14. Serum was separated by centrifugation at 10,000 RPM for 7 minutes in a serum separation tube containing gel (Fisher, 22030401). The supernatant was transferred to a new tube and kept at -20°C until analysis. Serum samples were analyzed using a VetAxcel clinical analyzer and alkaline phosphatase and albumin assay kits (404200-3, SA2002 and SA2001, Alfa-Wasserman Diagnostic Technologies, respectively).

[0254] Histological analysis and immunofluorescence testing: Sections were prepared from liver samples fixed in formalin and embedded in paraffin, and tested for anti-Ki-67 rabbit antibody (Fisher, 50245564), anti-HNF4a antibody (Abcam, ab199431), and goat anti-rat IgG H&L (Alexa Fluor). (登録商標) 488)(ab150157) and donkey anti-rabbit IgG H&L (Alexa Fluor (登録商標)The tissue was stained with 647)(ab150075). Entire liver tissue sections were stained with picrosilius red (PSR) using standard procedures and scanned into digital images. The percentage of sections stained with PSR was quantified using Image J. (Example 1) Development and characterization of liver-specific Wnt signaling-enhancing molecules

[0255] ASGR is a heterooligomer composed of two polypeptides, ASGR1 and ASGR2, which are preferentially expressed on hepatocytes and undergo rapid endocytosis. To create a liver-specific RSPO-like Wnt signaling enhancer molecule, we targeted the asialoglycoprotein receptor (ASGR).

[0256] We produced several IgG-like liver-specific Wnt signaling enhancer molecules, each containing two anti-ASGR1 antibody light chains and two anti-ASGR1 antibody heavy chains (αASGR1-RSPO2 constructs) in which a modified RSPO2 polypeptide is fused to their N-terminus via a linker sequence. In this design, the anti-ASGR1 antibody portion of the molecule acts as a "targeting module" providing liver specificity, while the RSPO2 portion of the molecule functions as an "action module" interacting with E3 ligases. Wnt signaling enhancer molecules contain an IgG1 backbone unless otherwise indicated.

[0257] The first αASGR1-RSPO2 Wnt signaling enhancer molecule we constructed contained an αASGR1-binding domain that binds to the stalk region of ASGR1. We call this 1R34-DDNN / RA. The light chain sequence of the 1R34-DDNA / RA molecule is provided below, with the CDR underlined: [ka] The heavy chain sequence fused with the RSPO2 sequence for the 1R34-DDNA / RA molecule is shown below, with the CDR underlined, the RSPO2 sequence italicized, and the linker sequence in bold: [ka] Two amino acid substitutions compared to the wild-type human RSPO2 sequence are shown in bold, italics, and underlined.

[0258] The subsequent αASGR1-RSPO2 Wnt signaling enhancer molecule, 8M24-v1, contained an αASGR1-binding domain that binds to the carbohydrate-binding domain of ASGR1. This molecule was derived from the 8M24 antibody. The sequence of the variable domain of the light chain of the 8M24-v1 molecule is provided below, underlined in the CDR: [ka] The light chain sequence of the 8M24-v1 molecule is provided below, with the CDR underlined: [ka] The sequence of the variable domain of the heavy chain fused with the RSPO2 sequence in the 8M24v1 molecule is shown below, with the CDR underlined, the RSPO2 sequence italicized, and the linker sequence in bold: [ka]

[0259] Two amino acid substitutions compared to the wild-type human RSPO2 sequence are shown in bold, italics, and underlined.

[0260] For testing purposes, we modified each of these two starting molecules and identified modified forms that possessed superior characteristics. 1R34-DDNA / RA molecular modification

[0261] We performed and tested various amino acid modifications of the initial αASGR1-RSPO2 Wnt signaling enhancer molecule, 1R34-DDNA / RA, to identify molecules with improved properties. Figure 1 provides the amino acid sequences of the light chain polypeptide and heavy chain-RSPO2 fusion polypeptide of the 1R34-DDNA / RA starting molecule, with modified amino acid residues in the variants shown in bold. All molecules contained an N297G substitution (NG) in the IgG1 backbone. In some molecules, point mutations were introduced at two highly conserved hydrophobic residues, F105 and F109, within the Fu2 domain of RSPO2, which have been reported to be critical to binding to LGR proteins, in order to invalidate LGR binding by the RSPO2 polypeptide. The 1R34-DDNA / RA heavy chain sequence shown in Figure 1 contains the F105R and F109A substitutions compared to the wild-type RSPO2 sequence, which are italicized and underlined.

[0262] Four Asn and Asp sites with a potential tendency towards deamidation or Asp isomerization are located in the CDR of the ASGR1-binding IgG portion of the 1R34-DDNA / RA Wnt signaling enhancer molecule (shown in bold in Figure 1). Various amino acid substitutions were performed at each of these positions. The molecules were manipulated using standard molecular biology techniques and expressed by transient transfection in Expi293 cells, followed by two-column purification (protein A, then SEC). The resulting molecules were tested for their potential to be introduced into the Wnt signaling enhancer molecule and eliminate the tendency towards deamidation or Asp isomerization.

[0263] Surprisingly, the D62 position in the heavy chain CDR2 showed limited freedom of substitution by other amino acids. As shown in Figure 2, D62 mutations to Ser or Ala resulted in substantial changes to the molecule's SEC profile. This suggests that these mutations disrupted molecular folding, while mutations to Glu maintained folding. These subsequent mutations also preserved STF activity (data not shown).

[0264] Similarly, as shown in Figure 3, replacing the D25 position in the CDR1 of the light chain with serine was not possible because it interfered with protein folding. However, substitution of D25 with Glu or Ala maintained protein folding and STF activity (Figure 3 and data not shown).

[0265] The N51 position in the light chain CDR2 had the freedom to be replaced by Gln, Ser, or Ala (Figure 4). Each of these substitutions maintained STF activity, although STF activity was somewhat reduced by the Gln mutation at position 51 (data not shown).

[0266] Modifications at position N88 in the light chain CDR3 did not affect the protein SEC profile when replaced with Gln, Ser, or Ala, as shown in Figure 5. Each of these substitutions maintained STF activity, although STF activity was somewhat reduced by the Gln mutation at position 88 (data not shown). However, SDS-PAGE analysis revealed that N88S and N88A mutants were well expressed, but the mutations to S or A resulted in poorly folded proteins, as shown in Figure 6. In combination with other mutants, LC N88Q impaired activity, and L88A impaired integrity. Further modifications of the N88 position in CD3 to His (EESH), Thr (EEST), Arg (EESR), or Lys (EESK) (and other amino acid residues) were performed against a background of heavy chain CDR2 D62E, light chain CDR1 D25E, and light chain CDR2 N51S substitutions and tested in Huh-7 and Hek-293 cells (Figure 50A-D). Mutant EESH and EESR had reduced STF activity, which may have been due to interference with the cell surface binding site. Mutant EEST, EESK, and EEAT had STF activity comparable to the wild type, but the following combinations of mutations had reduced activity: EESL, EESE, EESH, EESR, EESY, EEAL, EEAE, EEAH, EEAY, and EEAR. Protein folding of diverse combinations of mutants in which N88 was replaced with different amino acids was also investigated (Figure 41). Comparing combinations of sequences with similar activity, EEST had the highest Emax and lowest EC50 (Figure 42). Surprisingly, the N88 mutation to Thr maintained both STF activity and proper protein folding (Figure 41).

[0267] Preferred substitutions at various modification sites were selected based on activity. These are shown in Table 1, with preferred amino acid substitutions highlighted in bold (WT indicates the wild type). [Table 1]

[0268] Wnt signaling enhancer molecules containing various combinations of the preferred amino acid substitutions identified above were constructed and tested by STF assay, octect binding, and multispecificity assay. These molecules contained the following amino acids at positions 1-4 in Table 1: EESY, EEAL, EEAE, EEAH, EEAT, EEAY, EEAR, EESN, EEAN, EESL, EESE, EESH, EEST, EESR, and EESK. Protein folding was determined by SDS-PAGE analysis under non-reducing and reducing conditions (Figure 7: left panel: lane 1 = marker, lanes 2-8 = EESY, EEAL, EEAE, EEAH, EEAT, EEAY, EEAR, non-reducing, and lanes 9-15 = EESY, EEAL, EEAE, EEAH, EEAT, EEAY, EEAR, reduced; right panel: lane 1 = marker, lanes 2-9 = EESN, EEAN, EESL, EESE, EESH, EEST, EESR, EESK).

[0269] STF assays were performed to evaluate the ability of these molecules to modulate Wnt signaling in Huh-7 STF Wnt-responsive reporter cells in the presence of a supplying Wnt source. Only the mutants 1R34-EEST / RA ("EEST"), 1R34-EESA / RA ("EESA"), 1R34-EESN / RA ("EESN"), 1R34-EEAN / RA ("EEAN"), 1R34-EEAT / RA ("EEAT"), and 1R34-EESK / RA ("EESK") exhibited STF activity equivalent to that of the 1R34-DDNN / RA starting molecule ("NG") (Figure 8 and Figures 39A-C).

[0270] As summarized in Figure 8, the EEST, EESN, EEAN, and EEAT variants were all monodisperse and stable to freeze-thaw cycles, including three rounds of freeze-thaw cycles between liquid nitrogen freezing temperature and room temperature. Freeze-thaw stability was assayed by STF and SEC (data not shown). Binding to the ASGR1 antigen was also determined. As shown in Figures 8 and 9, these four variants and their parent molecules had similar binding affinity to the ASGR1 antigen. Multispecific binding to insulin, heparin, dsDNA, KLH, and LPS was also investigated. ELISA showed comparable interactions with heparin among the variants. At high concentrations, the variants also showed comparable weak binding to dsDNA, KLH, and LPS, but no binding to insulin. As a result, these constructs exhibited comparable activity and stability.

[0271] To neutralize LGR binding by the RSPO2 polypeptide, different point mutations were introduced in two highly conserved hydrophobic residues, F105 and F109, within the Fu2 domain of huRSPO2. Specifically, these residues were replaced with either F105R and F109A, or F105E and F109E. Table 2 shows the specific combinations of substitutions present in each of these variants. [Table 2]

[0272] The sequences of the light chain and heavy chain:RSPO2 fusion proteins present in each of these molecules are shown below.

[0273] The light chain sequence of the αASGR1-RSPO2-EEST-EE(1R34-EEST / EE) molecule is provided below, with the CDR underlined: [ka] The sequence of the heavy chain fused with the RSPO2 sequence for the αASGR1-RSPO2-EEST-EE molecule is shown below, with the CDR underlined, the RSPO2 sequence italicized, and the linker sequence in bold: [ka] Two amino acid substitutions compared to the wild-type human RSPO2 sequence are shown in bold, italics, and underlined.

[0274] The light chain sequence of the αASGR1-RSPO2-EEST-RA molecule is provided below, with the CDR underlined: [ka] The sequence of the heavy chain fused with the RSPO2 sequence for the αASGR1-RSPO2-EEST-RA molecule is shown below, with the CDR underlined, the RSPO2 sequence italicized, and the linker sequence in bold: [ka] Two amino acid substitutions compared to the wild-type human RSPO2 sequence are shown in bold, italics, and underlined.

[0275] The light chain sequence of the αASGR1-RSPO2-EEAT-EE molecule is provided below, with the CDR underlined: [ka] The sequence of the heavy chain fused with the RSPO2 sequence for the αASGR1-RSPO2-EEAT-EE molecule is shown below, with the CDR underlined, the RSPO2 sequence italicized, and the linker sequence in bold: [ka] Two amino acid substitutions compared to the wild-type human RSPO2 sequence are shown in bold, italics, and underlined.

[0276] As shown in Figure 10, the combination of mutants F105E and F109E (SWEETS-1_RSPO2EE_NG_EEST_G4S;1R34-EEST / EE) showed lower in vitro activity in the STF assay compared to the combination of mutants F105R and F109A (SWEETS-1_NG_EEST_G4S;1R34-EEST / RA), and in particular, the combination described below was almost six times more potent in Huh-7 cells. However, surprisingly, this greater in vitro activity did not translate to increased in vivo activity for the combination of mutants F105R and F109A. Instead, when Axin mRNA expression levels were analyzed in non-human primates treated with SWEETS-1_NG_EEST_G4S(1R34-EEST / RA) or SWEETS-1_RSPO2EE_NG_EEST_G4S(1R34-EEST / EE), the combination of mutants F105E and F109E showed an equal or greater increase in Axin2 expression compared to the combination of mutants F105R and F109A (Figure 11). This is the opposite of the efficacy observed in vitro. 8M24-v1 molecular modification

[0277] We performed various amino acid modifications on the αASGR1-RSPO2 Wnt signaling enhancer molecule (8M24-v1) based on 8M24, tested them, and identified molecules with improved properties.

[0278] First, the VH and VL domains of the starting 8M24 antibody sequence were humanized in two different ways (H1, H2, V1, and V2). The original VH and VL sequences, as well as the humanized VH and VL sequences, are shown in Figure 25 (SEQ ID NOs: 13-18). Various combinations of humanized VH and VL sequences were combined and tested for their binding affinity to human ASGR1 compared to the parent 8M24 VH and VL sequences in relation to the parent 8M24 IgG1 constant region. As shown in Table 3, combinations of L1 and H1 humanized VL and VH chains were selected based on their minimal impact on kinetic binding to human ASGR1. [Table 3]

[0279] Potential deamidation or Asp isomerization tendencies were identified in the CDR of 8M24 ASGR1, which binds to the IgG portion of the Wnt signaling enhancer molecule (shown in bold in Figure 26). Each of these amino acids was substituted with the various amino acids shown in Figure 26, and the αASGR1-RSPO2 Wnt signaling enhancer molecule based on the humanized 8M24 with L1H1 was tested using the STF assay as described above. The RSPO2 sequence contained the F105R and F109A substitutions described above. When tested for single mutations, the light chain D56E mutant was selected, and the heavy chain N31A mutant was selected as it was the most potent mutation at that position. The heavy chain N57Q, S, and A mutants all functioned almost equally well. The D102E mutant was also selected. All three mutations at D110 were less potent, so the wild-type D110 residue was selected (data not shown). The light chain containing the D56E mutation was tested in combination with the various heavy chain mutations identified above. This is shown in Figure 27. As shown in Figure 27, the mutant (EASE) containing heavy chain mutations at N31A, N57S, and D102E exhibited the best activity. Various combinations of mutants were tested using various other assays, including protein folding, HIC, multispecificity, Tm / Tagg, stability, and octet Kd. The results of these assays are summarized in Figure 28. The EASE mutant exhibited the best combination of activity and octet Kd. The sequence of its light chain variable domain polypeptide is shown below, underlined in CDR: [ka] The sequence of the heavy chain variable domain fused to the RSPO2 variant sequence is shown below, with the RSPO2 sequence in italics, the linker in bold, and the CDR underlined: [ka] The complete heavy chain also included the constant region sequence, as indicated by the ID number.

[0280] Based on the above research, we identified Wnt signaling enhancer molecules that possess specific combinations of mutations that could only be experimentally determined to provide superior properties. (Example 2) In vivo liver effects of liver-specific Wnt signaling-enhancing molecules

[0281] To demonstrate that the αASGR1-RSPO2 construct described in Example 1 can activate the Wnt signaling pathway in a tissue-specific manner in vivo, mice were treated with various constructs.

[0282] To analyze tissue-specific activation of the Wnt signaling pathway by Wnt signaling enhancer molecules, naive mice were administered a single iP dose of 10 mg / kg of αASGR1-RSPO2-EEST-EE (1R34-EEST / EE), R-spo2, or a control (anti-βgal or anti-GFP-mutRSPO) (n=5 mice per group). EEST represents substitutions located at positions 1-4 in Figure 1, and the subsequent EE represents N105E and N109E substitutions in the RSPO2 region. 48 hours after treatment, various organs and tissues were collected for analysis. Axin2 / ActB gene expression was determined and normalized to the control. Axin2 mRNA levels significantly increased in most tissues after treatment with R-spo2. However, only αASGR1-RSPO2-EEST-EE resulted in increased Axin2 mRNA in the liver (Figure 12). From left to right, the tissues shown are anti-bgal, anti-GFP-mutRSPO, αASGR1-RSPO2-EEST-EE, and RSPO2. The obtained data showed that Wnt signaling-enhancing molecules selectively activate the Wnt pathway in the liver (Figure 12).

[0283] The mRNA and protein expression of Ki67 in the liver and small intestine were determined by RT-PCR and immunofluorescence, and the protein expression of HNF4α was determined by immunofluorescence. The antigen Ki-67 is a nucleoprotein associated with proliferation and is used as a cellular marker of proliferation, while hepatocyte nuclear factor 4a (HNF4α) is an orphan nuclear receptor that plays a major role in hepatic differentiation. As shown in Figures 21 and 22, αASGR1-RSPO2-EEST-EE (EE) stimulated hepatocyte proliferation (Figure 21) but did not stimulate intestinal cell proliferation (Figure 22). In addition, the livers of animals treated with αASGR1-RSPO2-EEST-EE showed expression of Ki67 and HNF4α by immunofluorescence.

[0284] To analyze the expression of genes upregulated upon activation of the Wnt signaling pathway, naive mice were administered a single iP dose of 10 mg / kg of αASGR1-RSPO2-EEST-EE (1R34-EEST / EE), αASGR1-RSPO2-EEST-RA (1R34-EEST / RA), or αGFP-IgG (n=20 mice per group). Serum and liver samples were collected for expression analysis at 1, 4, 24, and 72 hours after protein administration (n=5 per group at each time point). mRNA expression was analyzed by qPCR, and samples were normalized to ActB. Relative multipliers were calculated by setting the mean of the anti-GFP group at 1 hour to a value of 1.

[0285] Treatment with αASGR1-RSPO2-EEST-EE or αASGR1-RSPO2-EEST-RA significantly induced the expression of hepatic Axin2, Ccnd1, and Notum compared to mice treated with αGFP-IgG-negative controls (Figure 13; from left to right at each time point: αGFP-IgG, αASGR1-RSPO2-EEST-EE, and αASGR1-RSPO2-EEST-RA; two-way ANOVA, Holm-Sidak multiple comparison with anti-GFP). * p<0.05, ** p<0.01, *** p<0.001,**** (p<0.0001). These results demonstrate that the αASGR1-RSPO2 variant activates the Wnt pathway in the liver in vivo.

[0286] In another study, mice were administered a single iP dose of 10 mg / kg of αASGR1-RSPO2-EEST-EE, αASGR1-RSPO2-EEST-RA, or αGFP-IgG (n=5 mice per group). Liver samples were collected at 1, 4, 24, and 72 hours for expression analysis and histoimmunochemical testing. Treatment with αASGR1-RSPO2-EEST-EE or αASGR1-RSPO2-EEST-RA induced the expression of the cell proliferation marker gene Mki67 compared to mice treated with an αGFP-IgG negative control (Figure 14A; from left to right at each time point: αGFP-IgG, αASGR1-RSPO2-EEST-EE, and αASGR1-RSPO2-EEST-RA; two-way ANOVA, Holm-Sidak multiple comparison with anti-GFP). * p<0.05, ** p<0.01, *** p<0.001, **** (p<0.0001). These results demonstrate that the αASGR1-RSPO2 variant can stimulate proliferation in hepatocytes. Further studies showed that this effect is dose-dependent (Figure 14B).

[0287] The dose that demonstrated achieving a transgene expression level equivalent to endogenous liver Asgr1 mRNA 7 days before treatment with the αASGR1-RSPO2 construct is 1 × 10⁶ per mouse. 11 Using genomic particles, human ASGR1 expression was induced in mouse liver by IV injection of ssAAV8-CAG-hASGR1 (data not shown).

[0288] We demonstrated the ability of the original 8M24-RA molecule (8M24-v1) and the 8M24-RA EASE variant (8M24-EASE) to induce the expression of genes regulated by the Wnt signaling pathway. Mice were administered a single iP dose of 8M24-RA (8M24-v1) or 8M24-RA EASE (8M24-EASE-RA; 1, 3, 10 or 30 mg / kg), anti-GFP (10 mg / kg), or αASGR1-RSPO2-EEST-EE (1R34-EEST / EE) in IgG2 form instead of its usual IgG1 form. Serum and liver samples were collected 24, 48, or 72 hours after treatment (n=4 at each time point). mRNA expression by qPCR was normalized to Actb. Relative multipliers were calculated by setting the mean of the anti-GFP group to 1 at each time point. As shown in Figure 29, 8M24-RA induced the expression of Wnt signaling target genes Axin2 and Ccnd1, as well as the growth marker Mki67. As shown in Figure 30, 8M-24-EASE-RA also induced the expression of Wnt signaling target genes Axin2 and Ccnd1, as well as the growth marker Mki67. Both 8M24-RA and 8M-24-EASE-RA also induced a small but significant dose-dependent increase in ALP, consistent with the involvement of ASGR in serum ALP clearance (data not shown). (Example 3) Pharmacokinetic profiles of liver-specific Wnt signaling-enhancing molecules

[0289] The pharmacokinetic profiles of Wnt signaling-enhancing molecules were investigated in mice. Mice were divided into six groups (n=25 per group) and administered a single dose of the EEST-EE construct either IV at 3, 10, 30, or 100 mg / kg, or ip at 10 or 30 mg / kg. Sparse serum samples were collected at 5 and 30 minutes (IV), 30 minutes and 1 hour (ip), and 2 hours, 6 hours, 24 hours, day 4, day 7, day 10, or day 14 (IV and ip) after protein administration at each time point (n=5 per group). Serum levels of EEST-EE were quantified by ELISA using either ASGR1 or RNF43 capture ligand. Clearance, terminal phase half-life, Cmax, and MRT are shown in the table in Figure 15. Liver samples were collected at sacrifice 30 minutes (IV), 1 hour (ip), 6 hours, 24 hours, and on day 7 or 14 (IV and ip) after protein administration (n=5 at each time point). Relative multiples were calculated by setting the mean of the anti-GFP group to 1 for each time point. As shown in Figure 15, 1R34-EEST / EE showed a nonlinear PK response to escalating doses. A comparison of AUC obtained between IV and ip administrations showed high bioavailability.

[0290] Similar studies were conducted to compare the 1R34-EEST / RA, 1R34-EEST / EE, 8M24-EASE-RA, and 8M24-EASE-EE constructs. The results are shown in Figure 31. (Example 4) Wnt signaling-enhancing molecules targeted to the liver improve liver function in a mouse model of hepatic fibrosis.

[0291] The effects of Wnt signaling enhancer molecules on liver function were investigated in two mouse models of hepatic fibrosis.

[0292] A chronic thioacetamide-induced mouse model of hepatic fibrosis was used. Six-week-old C57Bl / 6J male mice were treated with thioacetamide (TAA). Hepatic fibrosis was induced for 13 weeks by adding TAA at a concentration of 200 mg / L to drinking water. In addition, during the last 8 weeks of TAA conditioning, mice were administered TAA intraperitoneally (ip) three times weekly. TAA treatment was discontinued two days before administration of αASGR1-RSPO2 protein, and the mice were returned to purified laboratory-grade acidified drinking water. As illustrated in Figure 16, mice were administered recombinant αASGR1-RSPO2-EEST-EE (1R34-EEST / EE) or αASGR1-RSPO2-EEST-RA (1R34-EEST / RA) daily, or αGFP-IgG or Rspo2 twice weekly via intraperitoneal (ip) injection for one week.

[0293] INR was measured using Roche CoaguChek-XS Plus at the time points shown in Figure 16. At 3, 10, and / or 30 days after the start of administration, mice were anesthetized with isoflurane and blood was collected by cardiac puncture. Portions of the left hepatic lobe and duodenum were collected for analysis. Sections were prepared from liver samples fixed in formalin and embedded in paraffin, and stained with anti-Ki-67 rabbit antibody (Abcam, ab15580). Ki-67 was measured per randomly selected field of view (100x magnification using a 10x objective lens). - The number of positive nuclei was counted using Image J. Treatment with αASGR1-RSPO2-EEST-EE (1R34-EESD / EE) led to a significant decrease in INR, but treatment with αASGR1-RSPO2-EEST-RA (1R34-EEST / RA) and Rspo2 did not (Figure 17A; compared with one-way ANOVA and anti-GFP). * )p<.05, ( ** )p<.01, ( *** )p<.001, ( ****Treatment with αASGR1-RSPO2-EEST-EE or Rspo2 also led to a significant increase in axin2 and CYP2e1 mRNA expression, although treatment with αASGR1-RSPO2-EEST-RA showed a smaller but significant increase in axin2 and CYP2e1 mRNA expression (Figures 17B and 17C). * )p<.05, ( ** )p<.01, ( *** )p<.001, ( **** (p<.0001). Ki67 immunofluorescence staining also confirmed hepatocyte specificity in the TAA-induced injury model (Figure 18).

[0294] The effects of αASGR1-RSPO2-EEST-EE were also investigated in a CCl4-induced injury model. Male CCl4i.p.C57BL / 6J mouse models were injected with CCl4i.p. twice weekly for 11 weeks. The control group of mice received only olive oil iP injections (n=8). After discontinuing CCl4 treatment, the mice were divided into 10 groups (n=8), and administered αASGR1-RSPO2-EEST-EE or αASGR1-RSPO2-EEST-RA at various doses (mg / kg) daily or quarterly, or anti-GFP (10 mg / kg) or RSPO2 (4.6 mg / kg) twice weekly. Blood and liver samples were collected at sacrifice on day 7 or day 14.

[0295] As shown in Figure 19, αASGR1-RSPO2-EEST-EE significantly induced Axin2 and Mki67 mRNA levels on day 7. Larger increases in Axin2, Ccnd1, and Mki67 mRNA were observed with αASGR1-RSPO2-EEST-EE than with αASGR1-RSPO2-EEST-RA. In addition, immunofluorescence confirmed that this increase was hepatocyte-specific (Figure 20). (Example 5) Wnt signaling-enhancing molecules improve liver synthetic function and reduce fibrosis.

[0296] Six-week-old C57Bl / 6J male mice were treated with thioacetamide (TAA). Liver fibrosis was induced by adding TAA at a concentration of 200 mg / L to drinking water for 18 weeks. In addition, during the last seven weeks of TAA conditioning, mice were administered TAA intraperitoneally (ip) three times weekly, resulting in liver fibrosis. TAA treatment was discontinued two days before administration of αASGR1-RSPO2-EEST-EE (1R34-EEST / EE), and the mice were returned to purified laboratory-grade acidified drinking water. Mice were administered recombinant αASGR1-RSPO2-EEST-EE or a negative control at a dose of 10 mg / kg daily via intraperitoneal (ip) injection for 14 days.

[0297] INR was measured using Roche CoaguChek-XS Plus at the time points shown in Figure 16A. INR (internalized normalized ratio) is a measure of the rate of blood clot formation. High INR levels reflect liver disease or cirrhosis, indicating the inability to produce relevant amounts of normal protein and suboptimal coagulation. At 3, 7, and / or 14 days after the start of administration, mice were anesthetized with isoflurane and blood was collected by cardiac puncture. Treatment with αASGR1-RSPO2-EEST-EE led to a significant decrease in INR compared to controls (Figure 16B). In this mouse model of fibrosis, short-term treatment with both Rspo and αASGR1-RSPO2-EEST-EE resulted in a moderate, variable reduction in fibrosis (data not shown). (Example 6) Effects of tissue-targeted RSPO mimetic on liver function in a chronic CCl4-induced mouse model of hepatic fibrosis.

[0298] We also investigated liver fibrosis using a chronic CCl4-induced mouse model of liver fibrosis. Specifically, we compared the effects of 1R23-EEAT / EE on CCl4-induced liver fibrosis in immunodeficient mice and immunocompotent mice.

[0299] 32 six-week-old C57BL / 6J males (Jackson Laboratories) and 32 NOD.CB17-Prkdc scid / J(SCID) mice were intraperitoneally injected with CCl4 (0.5 mL / kg, twice / week) for 10 weeks. Sixteen mice from each strain were intraperitoneally injected with olive oil carrier (0.5 mL / kg). After CCl4 treatment, eight mice from each strain (CCl4-treated or untreated) were sacrificed, and blood and tissue samples were collected for baseline measurements. The remaining CCl4-treated mice were randomly assigned to treatment groups based on body weight (Table 4), and these mice were administered protein for two weeks. The treatment groups for each strain were as follows: 20 mg / kg of 1R34-EEAT / EE, n=8 (daily); 4.6 mg / kg of Fc-RSPO2-WT, n=8 (twice / week); 10 mg / kg of anti-GFP, n=8 (twice / week). A further control group of n=8, pre-injected with oil only, was also included. Blood was collected from the mice on day 7 (day 0 being the first day of protein administration). The mice were sacrificed on day 14. Total body weight and liver weight were measured, and blood and liver tissue were collected and stored for testing.

[0300] Table 4 provides a description of the treatment groups for the CCl4-induced mouse fibrosis model: immunodeficiency, NOD.CB17-Prkdc scid / J, or immunonormal, C57BL / 6J, male mice were preconditioned with CCl4 diluted with an olive oil carrier, or with olive oil alone. The mice were divided into groups A-L as indicated. The mice were then injected with the test product at the indicated dose and frequency, followed by sacrifice at baseline on day 0 or 14 days after the start of administration of the test product. [Table 4]

[0301] The liver-to-body weight ratio was significantly increased not only in the group treated with RSP02-positive controls, but also in the groups treated with RSPO mimetic and 1R34-EEAT / EE (Figure 32).

[0302] Serum alkaline phosphatase (ALP) and albumin were measured at 1 and 2 weeks after protein treatment. Mouse serum was collected by tail blood collection on day 7 and final blood collection on day 14 and analyzed using VetAxcel (Alfa-Wasserman). Data are presented in Figures 33A and 33B. Serum ALP was statistically higher at both 1 and 2 weeks, consistent with the upregulation of alkaline phosphatase protein levels due to the loss of the ASGR receptor, as described for the ASGR1-KO mouse model (see, e.g., Cell Host Microbe. 2018 Oct 10;24(4):500-513). Serum albumin levels were significantly decreased in response to RSPO2 and 1R34-EEAT / EE. This result suggests a predicted transient decrease in periportal hepatocyte function due to increased pericentral hepatocyte dilation induced by increased Wnt signaling.

[0303] Changes in liver gene expression were measured using quantitative PCR. Treatment of mice with RSP02 or 1R34-EEAT / EE led to increased Wnt-induced Axin2 gene expression in SCID mice on day 14, but not in C57BL / 6J mice. These results suggest that the activity of the test material is maintained in immunodeficient mice after two weeks, but not in immunonormal mice.

[0304] Treatment with RSPO2 and 1R34-EEAT / EE also revealed a trend of increased Mki67 and Cyclin D1 (Ccnd1) proliferation markers in the liver after 1R34-EEAT / EE treatment, and a significant trend of increased levels after RSPO2 treatment (Figure 34). Immunofluorescence staining of liver sections showed an increase in the number of Ki67-HNF4α double-positive cells in liver samples from SCID mice treated with RSPO2 and 1R34-EEAT / EE (Figure 35). Similar results were obtained in liver samples from C57BL / 6J mice (data not shown). These results suggest that RSPO2 and 1R34-EEAT / EE promote hepatocyte proliferation.

[0305] Liver tissue sections were stained with Sirius Red to measure the level of fibrosis (Figure 36A). The Sirius Red stained area was quantified using Image J (NIH) (Figure 36B). These results indicate that 1R34-EEAT / EE significantly reduced the percentage of collagen fiber area stained with Sirius Red in both immunonormal and immunodeficient mice. RSPO2 also reduced the percentage of area stained with Sirius Red, though not significantly, in SCID mice.

[0306] In summary, these data suggest that the RSPO mimetic, 1R34-EEAT / EE, has a significant effect on the rate at which mouse livers can resolve fibrosis and regenerate functional hepatocytes. (Example 7) RSPO Wnt signaling-enhancing molecules targeted to the liver activate Wnt signaling in non-human primates and associate with their targets.

[0307] Non-human female primates were treated with an intravenous bolus of 10 mg / kg of either αASGR1-RSPO2-EEST-EE (1R34-EEST / EE), αASGR1-RSPO2-EEST-RA (1R34-EEST / RA), 8M24 αASGR1-RSPO2-EASE-RA (M24-EASE / RA), 8M24-EASE-RSPO2-EASE-EE (8M24 / EASE / EE), or a vehicle control on days 1 and 15. They were then sacrificed 24 hours after the second dose, on day 16. Liver samples were obtained and subjected to blood analysis and histopathological diagnosis. AXIN2 expression in liver samples was analyzed by qPCR and normalized to ACTB expression. Relative multiples were calculated by setting the mean of the vehicle group to 1. Mean + / - SEM. One-way ANOVA, Holm-Sidak multiplex comparison with vehicle, * P<0.05.

[0308] Treatment with αASGR1-RSPO2-EEST-EE, αASGR1-RSPO2-EEST-RA, 8M24 αASGR1-RSPO2-EASE-RA, or 8M24-EASE-RSPO2-EASE-EE resulted in no unplanned deaths, abnormal clinical observations, or changes in body weight or food intake. Axin2 mRNA levels were significantly increased in the liver and were slightly higher after treatment with αASGR1-RSPO2-EEST-EE, 8M24 αASGR1-RSPO2-EASE-RA, or 8M24-EASE-RSPO2-EASE-EE than after treatment with αASGR1-RSPO2-EEST-RA (Figure 11). Regarding clinical pathology, there were no substantial changes in hematological tests, but there was a substantial transient increase in ALP. This was consistent with the binding of the molecule to ASGR1, and therefore inhibition of ALP clearance by this receptor (Figure 24).

[0309] These studies demonstrate that Wnt signaling enhancer molecules are well-tolerated and active in non-human primates. (Example 8) Crystal structure of the human ASGR1-CBD:8M24 complex

[0310] The asialoglycoprotein receptor (ASGR;ASGPR), a type C lectin primarily expressed in mammalian liver cells (hepatocytes), mediates the clearance of desialylated plasma glycoproteins with galactose or N-acetylgalactosamine at their terminus via receptor-mediated endocytosis. The ASGR assembly is considered a heterotrimer composed of two ASGR1 and one ASGR2 polypeptide, referred to as H1 and H2, respectively. Structurally, both ASGR1(H1) and ASGR2(H2) polypeptides are type II membrane proteins, possessing a short N-terminal cytoplasmic domain followed by an extracytoplasmic domain consisting of a single transmembrane helix and a helix-stalk region. They are type II membrane proteins that mediate oligomerization through a coiled-coil structure and their C-terminal carbohydrate-binding domains (CBDs). Human ASGR1 and ASGR2 share 54% sequence identity.

[0311] The crystal structure of the human ASGR1-CBD (HuASGR1-CBD) domain (residues 154-291 of Uniprot registry number P07306; https: / / www.dot.uniprot.org / uniprot / P07306) conjugated with the Fab domain of the antibody named 8M24 was determined. The sequence of the HuASGR1-CBD construct used for structural study, which contained an octahistidine motif and a biotin acceptor peptide (BAP) at its N-terminus, is as follows: HuASGR1-CBD_P07306_154-291 [ka] Expression and purification of HuASGR1-CBD for structural studies

[0312] Plasmids expressing HuASGR1-CBD were transfected in Expi293 cells (ThermoFisher USA) using FectoPro transfection agent according to the standard protocol from the manufacturer (Polyplus Transfection NY USA), typically in 1000 mL volumes. After 4 days of continuous cell growth, the culture medium was collected by centrifugation, and HuASGR1-CBD was purified from the medium by incubation with pre-equilibriumized HisComplete resin (1 mL per 1 L of culture; Roche) in 50 mM sodium dihydrogen phosphate, pH 8.0, and 300 mM NaCl. The purified HuASGR1-CBD was washed with 10 mM imidazole and eluted with 250 mM imidazole in equilibrium buffer. The eluate was concentrated to 5 mL and further refined on a HiLoad 16 / 600 Superdex 200 pg column (GE Life Sciences) pre-equilibriumized with HBS (20 mM HEPES pH 7.4 and 150 mM sodium chloride). The fraction near the major peak was further analyzed by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and Tris-HCl 4-15% gel (Bio-Rad, Hercules, CA) to confirm the contents. The sample was prepared in Laemmli sample buffer and heated at 100°C for 5 minutes. The fraction containing HuASGR1-CBD was concentrated to 1.78 mg / mL and frozen at -80°C in the presence of 10% glycerol for storage until further use. Protein concentration was determined by direct UV A280 using a NanoDrop spectrophotometer (Thermo Scientific). The relationship between absorbance and protein concentration is linear based on the Beer-Lamber equation, A=εlc, where A is the absorbance value, ε is the wavelength-dependent extinction coefficient, l is the path length in centimeters, and c is the protein concentration. The extinction coefficients of all produced proteins were estimated based on their amino acid sequences. Expression and purification of 8M24 Fab

[0313] Plasmids expressing the light and heavy chains (with hexahistidine tags at their C-terminus) of 8M24 Fab (L1H1 version corresponding to SZP19057+19056) were transfected in Expi293 cells (ThermoFisher USA) using FectoPro transfection agent according to the standard protocol from the manufacturer (Polyplus Transfection NY USA), typically in 1000 mL quantities, for expression. After 4 days of continuous cell growth, the medium was collected by centrifugation and conjugated to pre-equilibriumized Complete-His resin (2.5 mL per L of culture; Roche) in PBS, and eluted under gravity using 250 mM imidazole in PBS. The eluate containing the Fab binding factor was concentrated to approximately 5 mL and further refined on a pre-equilibriumized HiLoad 16 / 600 Superdex 200 pg column (GE Life Sciences) using HBS. The fractions near the main peak were further analyzed by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and Tris-HCl 4-15% gel (from Bio-Rad, Hercules, CA) to confirm their contents. Samples were prepared in Laemmli sample buffer and heated at 100°C for 5 minutes. The fraction containing 8M24 Fab was concentrated to approximately 7.12 mg / mL and frozen at -80°C in the presence of 10% glycerol for storage until further use. Protein concentration was determined by direct UV A280 using a NanoDrop spectrophotometer (Thermo Scientific). The relationship between absorbance and protein concentration is linear based on the Beer-Lamber equation, A=εlc; A is the absorbance value, ε is the wavelength-dependent extinction coefficient, l is the path length in centimeters, and c is the protein concentration. The extinction coefficients of all produced proteins were estimated from their amino acid sequences.

[0314] Formation, crystallization, and structural determination of the HuASGR1-CBD:8M24 complex. Purified HuASGR2-CBD and 8M24 were mixed in a molar ratio of 1.1:1 (with a slight excess of HuASGR1-CBD) and incubated overnight at 4°C with carboxypeptidases A and B in a w / w ratio of 100:1. Complex formation was confirmed by observation of a single major peak on a SuperdexS200 Increase (10 / 300 GL) column pre-equilibriumized during HBS. The fraction containing the complex was further checked by SDS-PAGE and concentrated to 20 mg / mL for crystallization screening. Crystallization screening using commercially available MCSG1, MCSG2, MCSG3, MCSG4, PACT (Molecular Dimensions USA), PEGs I and PEGs II (Qiagen USA) screenings was performed using a Mosquito (TTP LabTech) liquid handler and equilibrated at 18°C ​​inside an EchoTherm incubator (Torrey Pines Scientific USA). 96-well plate crystal screening experiments were manually and periodically monitored via a Discovery V20 stereomicroscope (Zeiss USA), and crystals were frozen for data acquisition by immersion in liquid nitrogen in the presence of various antifreeze agents (typically 15–30% v / v glycerol or ethylene glycol). X-ray diffraction datasets were collected at the Berkeley Center for Structural Biology at the Advanced Light Source (ALS), Berkeley, CA, and processed using the XDS [XDS.Kabsch W. (2010) Acta Cryst. D66:125-132] and xdsme [Legrand P. (2017) XDSME: XDS Made Easier GitHub repository, https: / / github.com / legrandp / xdsme DOI 10.5281 / zenodo.837885] programs.The structure of the HuASGR1-CBD:8M24 complex was compared to the published structure of ASGR1-CBD [PDB code: 5JPV; Efficient Liver Targeting by Polyvalent Display of a Compact Ligand for the Asialoglycoprotein Receptor. Sanhueza CA, Baksh MM, Thuma B, Roy MD, Dutta S, Preville C, Chrunyk BA, Beaumont K, Dullea R, Ammirati M, Liu S, Gebhard D, Finley JE, Salatto CT, King-Ahmad A, Stock I, Atkinson K, Reidich B, Lin W, Kumar R, Tu M, Menhaji-Klotz E, Price DA, Liras S, Finn MG, Mascitti V. (2017) J. Am. Chem. Soc. 139: 3528-3536] polyalanine model, and Surrozen At Inc., using variable and constant domains of the crystal structure previously determined for unrelated Fabs, Phaser [Phaser crystallographic software] was used.The molecular substitution method was determined using McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, and Read RJ. (2007) J Appl Crystallogr 40, 658-674], followed by Phenix [PHENIX: a comprehensive Python-based system for macromolecular structure solution. PD Adams, PV Afonine, G. Bunkoczi, VB Chen, IW Davis, N. Echols, JJ Headd, LW Hung, GJ Kapral, RW Grosse-Kunstleve, AJ McCoy, NW Moriarty, R. Oeffner, RJ Read, DC Richardson, JS Richardson, TC Terwilliger, and PH Zwart. (2010) Acta Cryst D66, 213-221; MolProbity: all-atom structure validation for macromolecular Crystallography was refined and validated using MolProbity implemented in [Cellularography. Chen VB, Arendall WB, Headd JJ, Keedy DA, Immormino RM, Kapral GJ, Murray LW, Richardson JS, and Richardson DC. (2010) Acta Cryst. D66, 12-21]. Crystallographic models were manually examined and constructed using COOT [Features and development of Coot. Emsleym P, Lohkamp B, Scott WG, and Cowtan K. (2010) Acta Cryst. D66, 486-501]. Analysis and imaging of the refined crystal structures were performed using MOE (CCG) and PyMol (Schrodinger). Structure of the HuASGR2-CBD:8M24 complex

[0315] The light and heavy chain sequences of 8M24 Fab used for structural studies are shown below. 8M24L1 Light Chain:

[0316] [ka]

[0317] [ka]

[0318] Diffraction-quality crystals (concentration = 20 mg / mL) of the HuASGR1-CBD:8M24 complex were grown under PACT-A6 crystallization conditions containing 0.1 M SPG (succinic acid, sodium dihydrogen phosphate monohydrate, glycine buffer) pH 9.0 and 25% w / v PEG 1500. The crystals were freeze-protected using 20% ​​glycerol in the well solution. The HuASGR1-CBD:8M24 complex was crystallized with one complex molecule per asymmetric unit in the P 212121 space group (a=38.91 Å, b=90.32 Å, c=167.80 Å). The structure of the HuASGR1-CBD:8M24 complex was determined at a resolution of 1.7 Å, with 17.3% and 20.5% R, respectively. cryst Factors and R free The factors were refined down to the smallest detail.

[0319] The overall structure of the HuASGR1-CBD:8M24 complex is shown in Figure 37A. Structural analysis of HuASGR1-CBD reveals its whole fold and three Ca2+ folds, which are important for the structural stability of CBD. 2+Both ions were found to be similar to their previously published structure [PDB code: 1DV8; Crystal structure of the carbohydrate recognition domain of the H1 subunit of the asialoglycoprotein receptor. Meier M, Bider MD, Malshkevich VN, Spiess M, and Burkhard P. (2012) J Mol Biol 300, 857-865]. The structure shows that the 8M24 epitope on ASGR1 is part of the native ligand binding site Ca 2+ It was also revealed that the ions are located at a distance from the ions (Figure 37B).

[0320] Using the structure of the complex, we identified an epitope on human ASGR1 for 8M24 with the following residues defining the core interaction site (5 Å cutoff): Gly163, Pro165, Val166, Asn167, Cys175, Trp177, Ser181, Lys183, Ala184, Ala186, Asp187, Asn190, Tyr191, Arg193, Leu194, Glu195, Asp196, Trp285, Thr289, Glu290, and Leu291.

[0321] In addition, the following residues on human ASGR1 were identified as immediate interaction sites (interatomic distance > 5.0 Å and ≤ 8.0 Å) with 8M24: Cys164, Trp168, Arg173, Ser174, Phe178, Ser179, Arg180, Gly182, Trp185, Ala188, Asp189, Cys192, Ala197, Gln227, Cys279, Gln280, Arg281, Cys287, and Glu288.

[0322] Using the structure of the HuASGR1-CBD:8M24 complex, the following residues of 8M24 were identified at positions less than or equal to 5.0 Å from any atom of human ASGR1: 8M24 heavy chain: Asn31, Phe52, Arg54, Ser55, Asn57, Phe59, Lys99, Arg101, Asp102, Tyr103, Gly104, Thr105, Ser106, and His107. 8M24 light chain: Tyr30, Ser31, Asn32, Phe91, Trp92, Gly93, and Phe96.

[0323] Furthermore, the structure of the HuASGR1-CBD:8M24 complex revealed that the following residues of 8G8 are the immediate interaction sites with human ASGR1, having interatomic distances >5.0 Å and ≤8.0 Å: 8M24 heavy chain: Thr28, Thr30, Tyr32, Gly33, Asn35, Glu50, Ile51, Pro53, Asp56, Thr58, Gly100, Tyr108, ​​and Phe109. 8M24 light chain: Ile2, Asn28, Ile29, Ala50, His90, and Thr94. (Example 9) Effects of RSPO mimics targeted to hepatocytes on liver function and tissue repair after acetaminophen-induced liver injury.

[0324] The mouse model of acetaminophen (APAP) hepatotoxicity is a well-established model of acute liver injury, with similar mechanisms and severity in mice and humans. We investigated the ability of 1R34-EEAT-EE to repair the hepatotoxic effects of APAP-induced liver injury.

[0325] 100 male C57BL / 6J mice (9 weeks old) were randomly assigned to 10 study groups (groups A-J) based on body weight and then fasted overnight. To induce liver injury, a single intraperitoneal (IP) dose of APAP 300 mg / kg was administered to the mice (groups B-J, n=90), while the control group (group A, n=10) received saline IP. After this, the mice were returned to their cages and were allowed to feed freely. Two hours after APAP administration, depending on the randomization group, mice in groups B-J received one of the following single IP injections: anti-GFP 10 mg / kg (negative control), N-acetylcysteine ​​(NAC) 1200 mg / kg (positive control), or 1R34-EEAT-EE 10 mg / kg. Mice in group A were followed without further vehicle injections. The mice were then tracked for up to 72 hours, and slaughter was performed 24, 48, or 72 hours after the procedure.

[0326] At each slaughter point, blood and liver were collected for clinical chemistry and immunohistopathological analysis. Quantitative polymerase chain reaction (qPCR) analysis of liver mRNA was used to measure the expression levels of Wnt target genes and major cytochrome P450 (CYP) metabolic enzymes. [Table 5]

[0327] 1R-34-EEAT-EE activated the Wnt / β-catenin signaling pathway, as indicated by increased hepatic mRNA expression of Axin2, a marker of Wnt / β-catenin activation, and induction of cyclin D1 (Ccnd1), a Wnt target gene and proliferation marker for cell cycle G1 / S phase transition (Figure 43). In addition, Notum, a Wnt target gene and a negative physiological regulator of Wnt ligands, was induced by 1R34-EEAT-EE.

[0328] Cyp1a2 and Cyp2e1 gene expression was significantly reduced in all groups after APAP-induced liver injury (Figure 43). 1R34-EEAT-EE treatment resulted in significantly higher Cyp1a2 and Cyp2e1 expression levels at 48 and 72 hours post-administration.

[0329] Immunoreactivity Ki67 at 72 hours post-treatment + Spontaneous repair, as evidenced by the presence of nuclei, was observed by immunofluorescence in the pericentral region of the liver treated with anti-GFP. The regenerative capacity of 1R34-EEAT-EE surpasses that of naturally occurring Ki67 + / HNF4α + This was demonstrated by an increase in bipositive hepatocytes (Figure 44, white squares) and a uniform distribution across all liver zones, including the periportal region, as shown by biimmunofluorescence staining for Ki-67 and CYP2F2 expressed in the periportal region (Figure 45). In contrast, Ki-67, which was not detected in HNF4α, was absent in the anti-GFP and N-acetylcysteine ​​groups. + Based on the presence of nuclei (yellow squares), a significant proportion of non-hepatocytes appeared to proliferate.

[0330] Histological analysis showed that the control group exhibited a large diffuse necrotic area within the pericentral region of the liver, while the livers treated with 1R34-EEAT-EE showed a reduction in necrosis (Figure 46).

[0331] Serum alkaline phosphatase (ALP) levels were significantly increased at 24 and 48 hours post-treatment. This is consistent with ASGR1 occupancy by 1R34-EEAT-EE and the known role of ASGR in ALP clearance (Figure 47). Plasma ammonia levels were significantly reduced by 1R34-EEAT-EE compared to anti-GFP at all measurement time points. There were no significant differences in serum AST or ALT levels between 1R34-EEAT-EE and anti-GFP at any of the measurement time points.

[0332] This study in a mouse model of APAP-induced liver injury demonstrated that 1R34-EEAT-EE mitigates APAP-induced hepatotoxicity by targeting activation of Wnt / β-catenin signaling in the liver and stimulating hepatocyte-specific regeneration. (Example 10) Effects of RSPO mimetic targeted to hepatocytes on liver function and tissue repair after chronic excessive ethanol intake-induced liver injury.

[0333] Animal models of alcoholic liver injury reproduce, to varying degrees, many of the features of AH in patients, such as fatty liver and elevated hepatic expression of inflammasome components like IL-1β. A commonly used model is the chronic overdose model, consisting of voluntary feeding using a Lieber-DeCarli liquid alcohol (EtOH)-containing diet and ethanol delivered by oral force-administration (Bertola et al. 2013). This study investigated the effects of 1R34-EEST-EE on hepatocyte enlargement and function in a model of acute alcoholic hepatitis (AAH) induced by multiple chronic overdose over a long period in aged mice with significantly impaired spontaneous regenerative capacity of the mouse liver.

[0334] Eleven-month-old C57BL / 6J female mice were continuously fed a control Lieber-DeCarli diet for five days to acclimate them to liquid diets and enteral nutrition (Figure 48). All mice were then randomized (Figure 55). Mice in the EtOH-fed group were allowed free access to a Lieber-DeCarli (LD) diet containing 5% (volume / volume) EtOH for seven weeks, while the pair-feed group received an LD control diet with isocaloric maltose dextrin instead of ethanol. From week 2 through week 7 of the feeding period, EtOH-fed and pair-feed mice received forced administration of either 20% EtOH (5.23 g / kg body weight) or isocaloric maltose dextrin twice weekly. Upon completion of the EtOH feeding period, mice were returned to the control LD liquid diet and randomly assigned to receive either 1R34-EEST-EE (30 mg / kg) or anti-GFP (10 mg / kg), administered once daily by intraperitoneal injection. Mice were then sacrificed after either 3 or 7 days of treatment. [Table 6]

[0335] Blood and tissue samples were collected at each slaughter point for clinical chemistry analysis. Activation, proliferation, and inflammatory markers of the Wnt pathway were investigated by quantitative polymerase chain reaction (qPCR) analysis of liver mRNA.

[0336] 1R34-EEST-EE activated the Wnt / β-catenin signaling pathway, as indicated by increased hepatic mRNA expression of two Wnt target genes, Axin2 and Ccnd1 (Figure 49), and induction of hepatic proliferation markers, such as Rrm2, Cdk1, Ccnb1, Cdc20, and Mki67 (Figure 50). The hepatocyte-specific regenerative activity of 1R34-EEST-EE was confirmed by double immunofluorescence staining with the proliferation marker Ki67 and the hepatocyte-specific marker HNF4A (Figure 51).

[0337] In addition, 1R34-EEST-EE significantly increased two serum biomarkers of Wnt activation, leukocyte-derived chemotaxin-2 (Lect2) and angiogenin, as measured by enzyme-linked immunosorbent assay (ELISA) (Figure 53). 1R34-EEST-EE also reduced the mRNA expression of the inflammatory markers interleukin Il1b and Il6 (Figure 54). Compared to anti-GFP (control group), ALT was slightly elevated and AST was significantly decreased in response to 1R34-EEST-EE, with significant changes observed after 3 days of treatment with 1R34-EEST-EE, resulting in a substantial decrease in the AST / ALT ratio (Figure 52). In addition, circulating ammonia was significantly reduced by 1R34-EEST-EE compared to anti-GFP on day 3 (Figure 52).

[0338] In conclusion, 1R34-EEST-EE induced liver-specific Wnt / β-catenin signaling in a model of AAH in aged mice. Furthermore, 1R34-EEST-EE stimulated hepatocyte-specific cell regeneration. These data provide proof of concept that 1R34-EEST-EE stimulates hepatocyte expansion under proliferative impairment conditions caused by aging and alcohol use. (Example 11) Biomarkers for regeneration in drug-induced liver failure

[0339] Acetaminophen (APAP) overdose has limited treatment options due to acute liver failure (ALF) or other drug-induced liver injury (DILI). While 65% of patients with APAP-induced ALF survive spontaneously, approximately 500 deaths occur annually in the United States due to APAP hepatotoxicity. For DILI, the no-transplant survival rate is approximately 25%, with an estimated 300-500 deaths in the United States. Patients who do not show promise of recovery after first-line treatments such as intravenous N-acetylcysteine ​​are placed on a liver transplant list. Due to the increasing demand and limited supply of liver transplants, reliable tests to predict liver recovery are desired.

[0340] Wnt signaling plays a central role in hepatocyte expansion during development and tissue repair. Downstream standard Wnt signaling, mediated by β-catenin stabilization, correlates with increased regeneration in ALF patients (Apte 2009, Bhushan 2014).

[0341] Here, we determined the differences in serum levels of liver injury biomarkers (alpha-fetoprotein and cholinesterase) and Wnt signaling markers (angiogenin and leukocyte-derived chemotaxin 2) between ALF patients who did not receive a liver transplant and patients who received a liver transplant or died.

[0342] Alpha-fetoprotein (AFP) is secreted by proliferating immature hepatocytes and is elevated in liver injury. In cases of ALF, spontaneous survivors had a higher day 3 to day 1 AFP ratio than patients who died or received transplants. This suggests that changes in AFP levels are prognostic (Schiot 2006).

[0343] Butyrylcholinesterase (BChE) is a nonspecific esterase produced by the liver, and its levels decrease in many cases of liver failure, including acute and chronic liver injury, inflammation, and infection.

[0344] Angiogenins are direct Wnt targets, primarily secreted by hepatocytes. Angiogenins induce angiogenesis and are involved in cell growth and survival. A correlation between angiogenins and ALF outcomes has not been reported.

[0345] Leukocyte-derived chemotaxin 2 (LECT2) is a hepatokine almost exclusively secreted by hepatocytes and is a direct Wnt target. LECT2 plays a major role in liver regeneration: specific to ALF, LECT2 levels increased as liver function recovered (Sato 2004), while low LECT2 levels in the first three days after injury correlated with a higher survival rate (Slowik 2019).

[0346] Serum samples were selected from the US Adult Acute Liver Failure Study Group Registry (NCT 00518440). Liver failure was classified into two groups based on the etiology of ALFSG:APAP or DILI / other / undetermined. Spontaneous survivors (SS) were defined as patients who recovered without transplantation and were compared to patients who received transplantation or died (LT / D). Samples were collected on days 1, 3, and 7 after enrollment from 10 APAP overdose patients and 5 DILI patients in the SS group, as well as on days 1 and 3 from 10 APAP patients and 10 DILI patients in the LT / D group (see Table 7). [Table 7]

[0347] AFP, angiogenin, and LECT2 were measured by enzyme-linked immunosorbent assay (ELISA), and BChE was measured by enzyme activity assay.

[0348] Time since study enrollment represented different clinical course times among patients. To account for this, biomarker levels were interpreted in relation to time since admission. A log-scale model of biomarker levels was constructed by performing a random-mixed-effects model with covariates including a time since admission term and a status group term indicating SS or LT / D. Unstructured correlations were assumed to account for correlations due to repeated measures over time within the same patient. Least-squares mean point estimates and 95% confidence intervals (CIs) were estimated for each status group and for the difference between two statuses.

[0349] Profiles for AFP, angiogenin, LECT2, and BChE were plotted separately for SS and LT / D against time since admission. Least squares mean point estimates and 95% confidence intervals were compared between SS and LT / D. The multiple differences for SS relative to LT / D are summarized in Table 8. [Table 8]

[0350] The difference in the multiples of point estimates for angiogenin and LECT2 between SS and LT / D was significant, but the difference in multiples for AFP and BChE was not significant.

[0351] The difference in the multiples of point estimates was compared separately between SS and LT / D for the etiology of liver failure (APAP and DILI / other). In APAP patients, there were significant differences in the multiples for both angiogenin and LECT2, but in DILI / other patients, there was only a significant difference for angiogenin (Table 9). [Table 9]

[0352] In the case of ALF, a >2.5-fold increase in circulating angiogenin and a >6-fold increase in circulating LECT2 were observed early after hospitalization in patients who recovered without liver transplantation. These results suggest that serum markers may function as indicators of regeneration prognosis and as biomarkers for Wnt signaling activation. Furthermore, since 1R34-EEST-EE was shown to significantly increase LECT2 and angiogenin in Example 10, these data suggest that treatment with 1R34-EEST is associated with increased Wnt signaling and regeneration. References Acute liver failure induced by idiosyncratic reaction to drugs: challenges in diagnosis and therapy. Authors: Tujios, S; Lee, W. Journal Title: Liver International. Publisher: Wiley. Publication Date: 01 / 2018. Volume: 38. Issue: 1. Pages: 6-14. DOI: 10.1111 / liv.13535. PMID: 28771932. Beta-catenin activation promotes liver regeneration after acetaminophen-induced injury. Authors: Apte, U; Singh, S; Zeng, G; Cieply, B; Virji, M; Wu, T; Monga, S. Journal Title: The American Journal of Pathology. Publisher: Elsevier. Publication Date: 09 / 2009. Volume: 175. Issue: 3. Pages: 1056-1065. DOI: 10.2353 / ajpath.2009.080976. PMID: 19679878. Pro-regenerative signaling after acetaminophen-induced acute liver injury in mice identified using a novel incremental dose model. Authors: Bhushan, B; Walesky, C; Manley, M; Gallagher, T; Borude, P; Edwards, G; Monga, S; Apte, U. Journal Title: The American Journal of Pathology. Publisher: Elsevier. Publication Date: 11 / 2014. Volume: 184. Issue: 11. Pages: 3013-3025. DOI: 10.1016 / j.ajpath.2014.07.019. PMID: 25193591. Alpha-fetoproitein and prognosis in acute liver failure. Authors: Schiot, F; Ostapowicz, G; Murray, N; Satyanarana, R; Zaman, A; Munoz, S; Lee, W. Journal Title: Liver Transplantation. Publisher: Wiley. Publication Date: 12 / 2006. Volume: 12. Issue: 12. Pages: 1776-1781. DOI: 10.1002 / lt.20886. PMID: 17133565. Serum LECT2 level as a prognostic indicator in acute liver failure. Authors: Sato, Y.; Watanabe, H.; Kameyama, H.; Kobayashi, T.; Yamamoto, S.; Takeishi, T.; Hirano, K.; Oya, H.; Nakatsuka, H.; Watanabe, T.; Kokai, H.; Yamagoe, S.; Suzuki, K.; Oya, K.; Kojima, K.; Hatakeyama, K. Journal Title: Transplantation Proceedings. Publisher: Elsevier. Publication Date: 10 / 2004. Volume: 36. Issue: 8. Pages: 2359-2361. DOI: 10.1016 / j.transproceed.2004.07.007. PMID: 15561249. Leukocyte cell derived chemotaxin-2 (Lect2) as a predictor of survival in adult acute liver failure. Authors: Slowik, V; Borude, P; Jaeschke, H; Woolbright, B; Lee, W; Apte, U, the Acute Liver Failure Study Group. Journal Title: Translational Gastroenterology and Hepatology. Publisher: AME Publishing Company. Publication Date: 03 / 2019. Volume: 4. Issue: 17. Pages: 2359-2361. DOI: 10.21037 / tgh.2019.03.03. PMID: 30976720.

[0353] The various embodiments described above can be combined to provide further embodiments.

[0354] The embodiments may be modified as necessary to use the contents of various patents, applications, and publications to provide further embodiments.

[0355] These and other modifications may be made to the embodiments in light of the detailed description above. In general, the terms used in the following claims should not be construed as limiting the claims to the specific embodiments disclosed herein and in the claims, but rather as including all possible embodiments along the entire scope of the equivalent for which such claims are granted. Accordingly, the claims are not limited by this disclosure.

[0356] All U.S. patents, U.S. patent application publications, U.S. patent applications, foreign patents, foreign patent applications, and non-patent publications mentioned herein and / or listed in application data sheets are incorporated herein by reference in their entirety.

Claims

1. A liver-specific Wnt ("Wingless-associated integration site" or "Wingless and Int-1" or "Wingless-Int") signal enhancing molecule, or a pharma- ceutically acceptable salt thereof, comprising a first domain that specifically binds to one or more transmembrane E3 ubiquitin ligases selected from zinc and ring finger 3 (ZNR-3) and ring finger protein 43 (RNF43), and a second domain that specifically binds to asialoglycoprotein receptor 1 (ASGR1); (a) the first domain comprises a modified R-spondin polypeptide, or a fragment or variant thereof; (b) The second domain comprises an altered antibody comprising CDRH1, CDRH2 and CDRH3 sequences and CDRL1, CDRL2 and CDRL3 sequences, or an antigen-binding fragment thereof, a molecule or a pharma- ceutically acceptable salt thereof.

2. The molecule according to claim 1, wherein said R-spondin polypeptide, or a fragment or variant thereof, comprises a furin domain 1 sequence, and optionally a wild-type or mutant furin domain 2 sequence, or a fragment or variant thereof, and said R-spondin polypeptide, or a fragment or variant thereof, has reduced binding to leucine-rich repeat-containing G protein-coupled receptors 4-6 (LGR4-6) compared to a full-length, wild-type R-spondin polypeptide.

3. The molecule of claim 1 or claim 2, wherein the R-spondin polypeptide or a fragment or variant thereof comprises amino acid substitutions at positions corresponding to amino acids 105 and 109 of human R-spondin2.

4. The amino acid substitution is (a) F105R, F105A, or F105E, and (b) F109A or F109E The molecule of claim 3 ,

5. The two amino acid substitutions are (a) F105R and F109A, (b) F105A and F109A, (c) F105E and F109A; or (d) F105E and F109E The molecule of claim 4,

6. The combination of CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, and CDRL3 sequences is as follows: (a) SYAMS (SEQ ID NO: 34), AISGSGGSTYYAESVKG (SEQ ID NO: 35), DFSSRRWYLEY (SEQ ID NO: 36), QGESLRSYYAS (SEQ ID NO: 37), YGKSNRPS (SEQ ID NO: 38), and CTSLERIGYLSYV (SEQ ID NO: 39), respectively; (b) SYAMS (SEQ ID NO:34), AISGSGGSTYYAESVKG (SEQ ID NO:35), DFSSRRWYLEY (SEQ ID NO:36), QGESLRSYYAS (SEQ ID NO:37), YGKANRPS (SEQ ID NO:40), and CTSLERIGYLSYV (SEQ ID NO:39), respectively; or (c) RISENIYSNLA (SEQ ID NO: 41), AAINLAE (SEQ ID NO: 42), QHFWGTPFT (SEQ ID NO: 43), AYGIN (SEQ ID NO: 44), EIFPRSDSTFYNEKFKG (SEQ ID NO: 45), and KGREYGTSHYFDY (SEQ ID NO: 46), respectively. The molecule according to any one of claims 1 to 5, selected from:

7. 7. The molecule of any one of claims 1 to 6, wherein the second domain comprises an antibody light chain polypeptide and an antibody heavy chain polypeptide, and the first domain is fused to the N-terminus of the antibody heavy chain polypeptide, optionally via a linker moiety.

8. The molecule of claim 7 , wherein the linker moiety is a peptidyl linker sequence.

9. The molecule of claim 8 , wherein the linker sequence comprises one or more amino acids selected from the group consisting of glycine, asparagine, serine, threonine and alanine.

10. The molecule according to any one of claims 1 to 9, comprising two antibody light chain polypeptides and two fusion polypeptides, each fusion polypeptide comprising the modified R-spondin polypeptide or a fragment or variant thereof fused to the N-terminus of the antibody heavy chain polypeptide via a linker moiety, optionally a peptidyl linker sequence, wherein the two fusion polypeptides are linked to each other, and the two antibody light chain polypeptides are each linked to a different heavy chain polypeptide of the fusion polypeptide.

11. (i) the two antibody light chain polypeptides comprise a variable region sequence having at least 95% identity to any one of SEQ ID NOs: 1, 3, 5, 7, 9, 11, 14, 17, 18, 19, 21, 23, 25 or 27, or a variable region sequence thereof; and / or (ii) the two antibody heavy chain polypeptides comprise a variable region sequence having at least 95% identity to any one of SEQ ID NOs: 2, 4, 6, 8, 10, 12, 13, 15, 16, 20, 22, 24, 26, 28, 33, or 51, or a variable region sequence in the variable region thereof; The molecule of claim 10.

12. 12. The molecule of claim 10 or claim 11, wherein each of the two fusion polypeptides comprises any one of SEQ ID NOs: 2, 4, 6, 8, 10, 12, 13, 14, 15, 16, 20, 22, 24, 26, 28, 33 or 51, or a sequence having at least 95% identity to the variable regions thereof.

13. 13. The molecule of any one of claims 10 to 12, wherein the two antibody light chain polypeptides comprise a sequence having at least 95% identity to SEQ ID NO:7 or a variable region thereof, and the two fusion polypeptides each comprise a sequence having at least 95% identity to SEQ ID NO:8 or a variable region thereof.

14. 13. The molecule of any one of claims 10 to 12, wherein the two antibody light chain polypeptides comprise a sequence having at least 95% identity to SEQ ID NO:25 or a variable region thereof, and the two fusion polypeptides each comprise a sequence having at least 95% identity to SEQ ID NO:26 or a variable region thereof.

15. 15. A nucleic acid sequence encoding an antibody light chain polypeptide or fusion polypeptide according to any one of claims 10 to 14, or encoding a polypeptide having at least 95% identity to any one of SEQ ID NOs: 1-33 or 51, or the variable regions thereof.

16. 16. The nucleic acid sequence of claim 15 which is DNA or mRNA.

17. A vector comprising the nucleic acid sequence of claim 16.

18. 18. The vector of claim 17, which is an expression vector comprising a promoter sequence operably linked to the nucleic acid sequence.

19. The vector of claim 17, which is a virus comprising a promoter sequence operably linked to the nucleic acid sequence.

20. A host cell comprising a vector according to any one of claims 17 to 19.

21. 21. A process for producing an antibody light chain polypeptide or fusion polypeptide according to any one of claims 10 to 14, comprising culturing a host cell according to claim 20 under conditions in which said polypeptide is expressed by said expression vector.

22. 22. The process of claim 21, further comprising the step of isolating the fusion polypeptide produced.

23. a) a molecule according to any one of claims 1 to 14, a nucleic acid sequence according to any one of claims 15 to 16, a vector according to any one of claims 17 to 19, or a host cell according to claim 20; and b) A Pharmaceutically Acceptable Diluent, Adjuvant or Carrier 13. A pharmaceutical composition comprising:

24. 25. A composition comprising a molecule according to any one of claims 1 to 14, a composition comprising a nucleic acid according to any one of claims 15 to 16, a composition comprising a vector according to any one of claims 17 to 19, a composition comprising a host cell according to claim 20, or a pharmaceutical composition according to claim 23 for use in a method for increasing Wnt ("Wingless associated integration site" or "Wingless and Int-1" or "Wingless-Int") signalling in liver tissue, said method comprising: a) the molecule, b) the nucleic acid; c) the vector, d) the host cell; or e) The pharmaceutical composition contacting the the molecule binds to the liver tissue and sequesters or increases the endocytosis of one or more transmembrane E3 ubiquitin ligases selected from zinc and ring finger 3 (ZNR3) and ring finger protein 43 (RNF43) in the liver tissue; composition.

25. 20. A composition comprising a molecule according to any one of claims 1 to 14, a composition comprising a nucleic acid according to any one of claims 15 to 16, a composition comprising a vector according to any one of claims 17 to 19, a composition comprising a host cell according to claim 20, or a pharmaceutical composition according to claim 23 for treating or preventing a liver disease or liver damage in a subject in need thereof, wherein the liver disease or liver damage is associated with reduced Wnt ("Wingless associated integration site" or "Wingless and Int-1" or "Wingless-Int") signaling or would benefit from increased Wnt signaling. composition.

26. The composition of claim 25, comprising a molecule described in any one of claims 1 to 14.

27. ​​The composition described in claim 25, comprising a nucleic acid described in any one of claims 15 to 16.

28. The composition described in claim 25, comprising a vector described in any one of claims 17 to 19.

29. The composition of claim 25, comprising a host cell of claim 20.

30. The composition of claim 25, which is a pharmaceutical composition of claim 23.

31. The liver disease or injury may be selected from the group consisting of acute liver failure of all causes, acute liver failure induced by drugs, acute exacerbation of chronic liver failure (ACLF), acute hepatic decompensation, ascites due to cirrhosis, hyponatremia in patients with cirrhosis, hepatorenal syndrome-acute kidney injury (HRS-AKI), hepatic encephalopathy, alcoholic liver disease, chronic liver failure of all causes, decompensated liver failure, late decompensated liver failure, cirrhosis, hepatic fibrosis of all causes, portal hypertension, chronic liver insufficiency of all causes, end stage liver disease (ESLD), non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD) (fatty liver), alcoholic hepatitis, acute alcoholic hepatitis (AAH), chronic alcoholic hepatitis, chronic excessive alcohol intake induced liver injury, alcoholic liver disease (ALD) (alcohol related liver disease (ARL) 31. The composition of any of claims 25 to 30, wherein the hepatitis C virus-induced liver disease (also referred to as Hepatitis C virus-induced liver disease (HCV), Hepatitis B virus-induced liver disease (HBV), other viral hepatitis (e.g., Hepatitis A virus-induced liver disease (HAV) and Hepatitis D virus-induced liver disease (HDV)), primary biliary cirrhosis, autoimmune hepatitis, liver surgery, liver injury, veno-occlusive disease (VOD), sinusoidal obstruction syndrome (SOS), primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), liver transplantation, "too small for graft" syndrome in liver surgery and transplantation, congenital liver diseases and disorders, liver failure due to APAP (acetaminophen) overdose, and any other liver disease or disorder resulting from genetic disease, degeneration, aging, drugs or injury.

32. 32. The composition of claim 31, wherein the liver disease or injury is selected from acute alcoholic hepatitis, acute liver failure, acute exacerbation of chronic liver failure (ACLF), acute hepatic decompensation, ascites due to cirrhosis, hyponatremia in patients with cirrhosis, hepatorenal syndrome-acute kidney injury (HRS-AKI), hepatic encephalopathy, or cirrhosis.

33. A composition according to any one of claims 25 to 32, characterized in that it is administered parenterally, orally, intramuscularly or locally, and optionally intravenously, to the liver.

34. 34. The composition of any one of claims 25 to 33, wherein the subject is a mammal, optionally a human.

35. A composition comprising a molecule according to any one of claims 1 to 14, a composition comprising a nucleic acid according to any one of claims 15 to 16, a composition comprising a vector according to any one of claims 17 to 19, a composition comprising a host cell according to claim 20, or a pharmaceutical composition according to claim 23 for use in a method for generating, culturing or maintaining liver cells, liver tissue or liver organoids, said method comprising: a) the molecule, b) the nucleic acid; c) the vector, d) the host cell; or e) The pharmaceutical composition The composition comprising the step of contacting the 36. The composition of claim 35 for maintaining viability of liver tissue ex vivo, the method comprising contacting liver tissue obtained from a donor with a composition comprising a molecule of any one of claims 1 to 14, optionally by perfusing the liver tissue ex vivo.

37. The composition described in claim 35 for maintaining the viability of liver tissue, the method comprising a step of contacting donor liver tissue in vivo with a composition comprising a molecule described in any one of claims 1 to 14.

38. The composition of claim 35 for generating or maintaining a liver organoid culture, the method comprising contacting the liver organoid culture, if necessary, by culturing the liver organoid culture in a medium comprising a molecule described in any one of claims 1 to 14.

39. 1. A polypeptide comprising any one of SEQ ID NOs: 1-28, 33 or 51, or a sequence having at least 95% identity to a variable region thereof, optionally comprising the following sets of CDRs: (a) SYAMS (SEQ ID NO:34), AISGSGGSTYYAESVKG (SEQ ID NO:35), and DFSSRRWYLEY (SEQ ID NO:36); (b) QGESLRSYYAS (SEQ ID NO:37), YGKSNRPS (SEQ ID NO:38), and CTSLERIGYLSYV (SEQ ID NO:39); (c) QGESLRSYYAS (SEQ ID NO: 37), YGKANRPS (SEQ ID NO: 40), and CTSLERIGYLSYV (SEQ ID NO: 39) (d) RISENIYSNLA (SEQ ID NO: 41), AAINLAE (SEQ ID NO: 42), and QHFWGTPFT (SEQ ID NO: 43); or (e) AYGIN (SEQ ID NO: 44), EIFPRSDSTFYNEKFKG (SEQ ID NO: 45), and KGREYGTSHYFDY (SEQ ID NO: 46) A polypeptide comprising one of:

40. 40. The polypeptide according to claim 39, which is a fusion protein comprising a modified R-spondin polypeptide or a fragment or variant thereof fused to the N-terminus of an antibody heavy chain polypeptide via a linker moiety, optionally a peptidyl linker sequence, wherein said R-spondin polypeptide or a fragment or variant thereof comprises two amino acid substitutions at positions corresponding to amino acids 105 and 109 of human R-spondin2.

41. The two amino acid substitutions are (a) F105R, F105A, or F105E, and (b) F109A or F109E 41. The polypeptide of claim 40,

42. The two amino acid substitutions are (a) F105R and F109A, (b) F105A and F109A, (c) F105E and F109A; or (d) F105E and F109E 42. The polypeptide of claim 41 ,

43. The antibody heavy chain polypeptide comprises: (a) SYAMS (SEQ ID NO: 34), AISGSGGSTYYAESVKG (SEQ ID NO: 35), DFSSRRWYLEY (SEQ ID NO: 36), respectively; or (b) RISENIYSNLA (SEQ ID NO: 41), AAINLAE (SEQ ID NO: 42), and QHFWGTPFT (SEQ ID NO: 43), respectively.

43. The polypeptide of any one of claims 40 to 42, comprising a combination of CDRH1, CDRH2, and CDRH3 sequences selected from:

44. 40. The polypeptide of claim 39, comprising a modified antibody light chain polypeptide.

45. The modified antibody light chain polypeptide comprises: (a) QGESLRSYYAS (SEQ ID NO: 37), YGKSNRPS (SEQ ID NO: 38), and CTSLERIGYLSYV (SEQ ID NO: 39), respectively; (b) QGESLRSYYAS (SEQ ID NO: 38), YGKANRPS (SEQ ID NO: 40), and CTSLERIGYLSYV (SEQ ID NO: 39), respectively; or (c) AYGIN (SEQ ID NO: 44), EIFPRSDSTFYNEKFKG (SEQ ID NO: 45), and KGREYGTSHYFDY (SEQ ID NO: 46), respectively.

45. The polypeptide of claim 44, comprising a combination of CDRL1, CDRL2, and CDRL3 sequences selected from:

46. 38. The molecule of any one of claims 1 to 14, the nucleic acid sequence of claims 15 or 16, the vector of claims 17 to 19, the host cell of claim 20, the process of claim 21 or 22, the pharmaceutical composition of claim 23, or the composition of any one of claims 24 to 38, wherein the molecule is selected from the Wnt signal enhancing molecules called EEST-EE, EEST-RA, EEAT-EE, 8M24 EASE-EE or 8M24 EASE-RA.

47. 47. The molecule, nucleic acid sequence, vector, host cell, process, pharmaceutical composition, or composition of matter of claim 46, wherein the molecule is EEST-EE.

48. 47. The molecule, nucleic acid sequence, vector, host cell, process, pharmaceutical composition, or composition of matter of claim 46, wherein the molecule is EEST-RA.

49. 47. The molecule, nucleic acid sequence, vector, host cell, process, pharmaceutical composition, or composition of matter according to claim 46, wherein the molecule is EEAT-EE.

50. 47. The molecule, nucleic acid sequence, vector, host cell, process, pharmaceutical composition, or composition of matter according to claim 46, wherein the molecule is 8M24 EASE-EE.

51. 47. The molecule, nucleic acid sequence, vector, host cell, process, pharmaceutical composition, or composition of claim 46, wherein the molecule is 8M24 EASE-RA.